Combination of STAT3 targeting oligonucleotides with PD-L1 inhibitors
Through the combination of STAT3 oligonucleotides and PD-L1 inhibitors, the multidrug resistance and immunosuppressive tumor environmental problems in cancer treatment are solved, and CD8+ T cell activation is promoted by targeting STAT3 and PD-L1 signaling pathways. , realizes tumor volume reduction and immune activation, and improves the therapeutic effect.
Patent Information
- Application Number
- CN202380027591.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-15
- Publication Date
- 2024-11-08
AI Technical Summary
Existing chemotherapy often encounters multidrug resistance problems when treating cancer. The tumor microenvironment, especially the immunosuppressive and inflammatory environment, is highly resistant to traditional therapies and lacks effective new therapies.
Using the combination of STAT3 oligonucleotide and PD-L1 inhibitor, by targeting STAT3 mRNA and PD-L1 signaling pathways, it promotes CD8+ T cell activation, induces anti-tumor memory response, reduces tumor volume, and reduces immunosuppressive gene expression .
The tumor volume is significantly reduced in the body, induce anti-tumor memory response, enhance immune activation, reduce tumor resistance to immune checkpoint therapy, and improve treatment effect.
Smart Images

Figure BDA0005042383940000741 
Figure BDA0005042383940000801 
Figure BDA0005042383940000802
Abstract
Description
References to Cross-Related Applications
[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No. 63,320,163, filed on March 15, 2022. The entire contents of this U.S. Provisional Patent Application are incorporated herein by reference. References to sequence listings
[0002] The contents of the electronic sequence listing (DICN_021_001WO_SeqList_ST26.xml; size: 4,153,073 bytes; creation date: March 8, 2023) are incorporated herein by reference in their entirety. Background Art
[0003] At present, chemotherapy is the most important cancer therapy in the world, usually combined with surgery or combined with surgery and radiotherapy, depending on the tumor type and stage (Abbas et al., AN OVERVIEW OF CANCER TREATMENT MODALITIES / INTECHOPEN, 2018). Since the discovery of several important mutations that cause carcinogenesis (e.g., epidermal cell changes (Yamaoka et al., INT. J. MOL. SCI. (2017) 18 (11): 2420)), these mutations and the proteins they represent have been widely used as targets for developing more selective drugs and drug combinations to treat cancer patients. Although these drugs are effective, multidrug resistance (MDR) is often observed in patients, which often leads to tumor recurrence, limited treatment options and poor quality of life for patients. In addition, cancer research often focuses on tumor cells, although it has been proven that the role of the tumor microenvironment and the "normal" or non-cancerous cells therein plays a key role in tumor progression, development and MDR (Klemm et al., TRENDS CELL BIOL (2015) 25 (4): 198-213). New therapies targeting different aspects of the TME that promote tumor growth are needed. Summary of the invention
[0004] The present disclosure is based in part on the discovery that the combination of STAT3 oligonucleotides and PD-L1 inhibitors provides synergistic anti-tumor efficacy against tumors in different tumor microenvironments. Specifically, as demonstrated herein, lipid-conjugated STAT3 oligonucleotides, when delivered in combination with anti-PD-L1 antibodies, reduced tumor volume in vivo in immunosuppressive and inflamed tumor models. In addition, as shown herein, the combination of STAT3 oligonucleotides and PD-L1 inhibitors induced an anti-tumor memory response, as no tumors were formed when mice were re-challenged with cancer cells. In addition, the efficacy of STAT3 oligonucleotides and PD-L1 inhibitors depends on the presence of CD8+T cells.
[0005] Thus, in some aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, thereby treating the cancer in the subject, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
[0006] In other aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
[0007] In yet other aspects, the present disclosure provides a method for treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating the disease, disorder or condition associated with activated STAT3 expression, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
[0008] In a further aspect, the present disclosure provides a kit comprising an RNAi oligonucleotide, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the oligonucleotide to a subject in need thereof who has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
[0009] In other aspects, the disclosure provides a kit comprising a PD-L1 inhibitor, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the antibody to a subject in need thereof who has received or is receiving an RNAi oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length and a sense strand of 15 to 40 nucleotides in length, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
[0010] In some or any of the foregoing or related aspects, the subject suffers from a disease, illness or condition related to the expression of activated STAT3. In some aspects, the disease, illness or condition related to the expression of activated STAT3 is cancer. In some aspects, the cancer is selected from cancer, sarcoma, melanoma, lymphoma and leukemia, prostate cancer, breast cancer, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer and glioblastoma. In some aspects, the cancer comprises an immunosuppressive tumor microenvironment. In some aspects, the immunosuppressive tumor microenvironment has low levels of CD8+T cell infiltration and high levels of MDSC. In other aspects, the cancer comprises an inflamed tumor microenvironment. In some aspects, the inflamed tumor microenvironment comprises infiltrating T cells. In some aspects, the inflamed tumor microenvironment comprises high levels of CD8+T cell infiltration and high levels of MDSC. In some aspects, the cancer includes a tumor resistant to immune checkpoint therapy. In some aspects, the cancer includes a tumor partially resistant to immune checkpoint therapy. In some aspects, the cancer comprises a tumor sensitive to immune checkpoint therapy.
[0011] In some or any of the foregoing or related aspects, the methods described herein treat spontaneous tumor metastasis.
[0012] In some or any of the foregoing or related aspects, the methods described herein reduce immunosuppressive genes and enhance immune activation genes. In some aspects, immunosuppressive genes include genes, inhibitory cytokines, inhibitory chemokines, and angiogenesis and matrix remodeling-related genes of checkpoint inhibitors, STAT3 mediation. In some aspects, immune activation genes include genes related to T cell migration, T cell activation, T cell memory and / or T cell cytotoxicity.
[0013] In some or any of the foregoing or related aspects, the PD-L1 inhibitor is an antibody. In some aspects, the antibody is an anti-PD-L1 antibody. In some aspects, the anti-PD-L1 antibody is selected from FAZ053, atezolizumab, avelumab, durvalumab, envafolimab, and BMS-936559. In some aspects, the antibody is an anti-PD-1 antibody. In some aspects, the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, and cemiplimab.
[0014] In some aspects, the PD-L1 inhibitor is a small molecule inhibitor. In some aspects, the PD-L1 inhibitor is a peptide. In some aspects, the PD-L1 inhibitor is a nucleic acid molecule. In some aspects, the nucleic acid molecule is selected from an antisense oligonucleotide, siRNA or miRNA.
[0015] In some or any of the foregoing or related aspects, the STAT3 mRNA target sequence comprises any one of SEQ ID NOs: 89-280. In some aspects, the complementary region is fully complementary to the STAT3 mRNA target sequence. In some aspects, the complementary region comprises no more than 4 mismatches with the STAT3 mRNA target sequence.
[0016] In some or any of the foregoing or related aspects, the antisense strand is 19 to 27 nucleotides in length. In some aspects, the antisense strand is 21 to 27 nucleotides in length; optionally wherein the antisense strand is 22 nucleotides in length.
[0017] In some or any of the foregoing or related aspects, the sense strand is 19 to 40 nucleotides in length, optionally wherein the sense strand is 36 nucleotides in length.
[0018] In some or any of the foregoing or related aspects, the length of the duplex region is at least 19 nucleotides. In some aspects, the length of the duplex region is at least 20 nucleotides, optionally wherein the length of the duplex region is 21 nucleotides.
[0019] In some or any of the foregoing or related aspects, the complementary region to STAT3 is at least 19 consecutive nucleotides in length. In some aspects, the complementary region to STAT3 is at least 21 consecutive nucleotides in length.
[0020] In some or any of the foregoing or related aspects, the sense strand comprises at its 3' end a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop of 3 to 5 nucleotides in length between S1 and S2. In some aspects, L is a tetraloop, optionally wherein L is 4 nucleotides in length. In some aspects, L comprises a sequence represented as GAAA.
[0021] In some or any of the foregoing or related aspects, the antisense strand comprises a 3' overhang sequence of one or more nucleotides in length, optionally wherein the 3' overhang sequence is 2 nucleotides in length, optionally wherein the 3' overhang sequence is GG.
[0022] In some or any of the foregoing or related aspects, the oligonucleotide comprises at least one modified nucleotide. In some aspects, the modified nucleotide comprises a 2'-modification. In some aspects, the 2'-modification is selected from 2'-aminoethyl, 2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl and 2'-deoxy-2'-fluoro-β-d-arabino nucleic acid modifications. In some aspects, about 10-15%, 10%, 11%, 12%, 13%, 14% or 15% of the nucleotides of the sense strand comprise a 2'-fluoro modification. In some aspects, about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the antisense strand comprise a 2'-fluoro modification. In some aspects, about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the oligonucleotide include 2'-fluoro modification. In some aspects, the sense strand includes 36 nucleotides from 5' to 3' for positions 1-36, wherein positions 8-11 include 2'-fluoro modification. In some aspects, the antisense strand includes 22 nucleotides from 3' to 5' for positions 1-22, and wherein positions 2, 3, 4, 5, 7, 10 and 14 include 2'-fluoro modification. In some aspects, the remaining nucleotides include 2'-O-methyl modification. In some aspects, all nucleotides of the oligonucleotide are modified.
[0023] In some or any of the foregoing or related aspects, the oligonucleotide comprises at least one modified internucleotide linkage. In some aspects, the at least one modified internucleotide linkage is a phosphorothioate linkage.
[0024] In some or any of the foregoing or related aspects, the 4'-carbon of the sugar of the 5'-nucleotide of the antisense strand comprises a phosphate analog. In some aspects, the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.
[0025] In some or any of the foregoing or related aspects, at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands. In some aspects, the nucleotide is conjugated to more than one targeting ligand, wherein the targeting ligands are the same or different. In some aspects, the one or more targeting ligands are selected from carbohydrates, amino sugars, cholesterol, polypeptides or lipids. In some aspects, the one or more targeting ligands are saturated or unsaturated fatty acid moieties. In some aspects, the targeting ligand is a saturated fatty acid moiety with a size range of C10 to C24 length. In some aspects, the targeting ligand is a C16 saturated fatty acid moiety. In some aspects, the targeting ligand is a C18 saturated fatty acid moiety. In some aspects, the targeting ligand is a C22 saturated fatty acid moiety. In some aspects, the targeting ligand comprises an N-acetylgalactosamine (GalNAc) moiety. In some aspects, the GalNAc moiety is a monovalent GalNAc moiety, a divalent GalNAc moiety, a trivalent GalNAc moiety or a tetravalent GalNAc moiety. In some aspects, up to 4 nucleotides of L of the stem-loop are each conjugated to a monovalent GalNAc moiety.
[0026] In some or any of the foregoing or related aspects, in some or any of the foregoing or related aspects, the sense strand comprises a sequence as shown in SEQ ID NOs: 857-946. In some aspects, the antisense strand comprises a sequence as shown in SEQ ID NOs: 947-1036.
[0027] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) are SEQ ID NOs: 69 and 70, respectively.
[0028] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 861 and 951, respectively; (b) SEQ ID NOs: 857 and 947, respectively; (c) SEQ ID NOs: 858 and 948, respectively; (d) SEQ ID NOs: 859 and 949, respectively; (e) SEQ ID NOs: 860 and 950, respectively; (f) SEQ ID NOs: 862 and 952, respectively; (g) SEQ ID NOs: 863 and 953, respectively; (h) SEQ ID NOs: 864 and 954, respectively; (i) SEQ ID NOs: 865 and 955, respectively; (j) SEQ ID NOs: 866 and 956, respectively; (k) SEQ ID NOs: 867 and 957, respectively; (1) SEQ ID NO: 868 and 958, respectively; (m) are SEQ ID NOs: 869 and 959, respectively; (n) SEQ ID NO: 870 and 960, respectively; (o) SEQ ID NOs: 871 and 961, respectively; (p) SEQ ID NOs: 872 and 962, respectively; (q) SEQ ID NOs: 873 and 963, respectively; (r) SEQ ID NOs: 874 and 964, respectively; (s) are SEQ ID NOs: 875 and 965, respectively; (t) SEQ ID NOs: 876 and 966, respectively; (u) SEQ ID NOs: 877 and 967, respectively; (v) SEQ ID NOs: 878 and 968, respectively; (w) SEQ ID NOs: 879 and 969, respectively; (x) are SEQ ID NOs: 880 and 970, respectively; (y) are SEQ ID NOs: 881 and 971, respectively; (z) SEQ ID NOs: 882 and 972, respectively; (aa) are SEQ ID NOs: 883 and 973, respectively; (bb) SEQ ID NOs: 884 and 974, respectively; (cc) SEQ ID NOs: 885 and 975, respectively; (dd) SEQ ID NOs: 886 and 976, respectively; (ee) are SEQ ID NOs: 887 and 977, respectively; (ff) are SEQ ID NOs: 888 and 978, respectively; (gg) SEQ ID NO: 940 and 1030, respectively; (hh) SEQ ID NOs: 896 and 986, respectively; and (ii) SEQ ID NO: 920 and 1010, respectively.
[0029] In some or any of the foregoing or related aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 862 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 952. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 875 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 965. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 876 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 966. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 920 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1010.
[0030] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively.
[0031] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NO: 939 and 1029, respectively.
[0032] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively.
[0033] In some or any of the foregoing or related aspects, the sense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 11, 39, 67, and 71. In some aspects, the antisense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 12, 40, 68, and 72.
[0034] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 11 and 12, respectively; (b) SEQ ID NOs: 39 and 40, respectively; (c) SEQ ID NOs: 67 and 68, respectively; and (d) are SEQ ID NOs: 71 and 72, respectively.
[0035] In some or any of the foregoing or related aspects, the sense strand comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1042, 1055, 1056, and 1100. In some aspects, the antisense strand comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1132, 1145, 1146, and 1190.
[0036] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1041 and 1131, respectively; (b) SEQ ID NOs: 1037 and 1127, respectively; (c) SEQ ID NOs: 1038 and 1128, respectively; (d) SEQ ID NOs: 1039 and 1129, respectively; (e) SEQ ID NOs: 1040 and 1130, respectively; (f) SEQ ID NOs: 1042 and 1132, respectively; (g) SEQ ID NOs: 1043 and 1133, respectively; (h) SEQ ID NOs: 1044 and 1134, respectively; (i) SEQ ID NOs: 1045 and 1135, respectively; (j) SEQ ID NOs: 1046 and 1136, respectively; (k) SEQ ID NOs: 1047 and 1137, respectively; (1) SEQ ID NO: 1048 and 1138, respectively; (m) SEQ ID NOs: 1049 and 1139, respectively; (n) SEQ ID NO: 1050 and 1140, respectively; (o) SEQ ID NOs: 1051 and 1141, respectively; (p) SEQ ID NOs: 1052 and 1142, respectively; (q) SEQ ID NOs: 1053 and 1143, respectively; (r) SEQ ID NOs: 1054 and 1144, respectively; (s) are SEQ ID NOs: 1055 and 1145, respectively; (t) SEQ ID NOs: 1056 and 1146, respectively; (u) SEQ ID NOs: 1057 and 1147, respectively; (v) SEQ ID NOs: 1058 and 1148, respectively; (w) SEQ ID NOs: 1059 and 1149, respectively; (x) are SEQ ID NOs: 1060 and 1150, respectively; (y) SEQ ID NOs: 1061 and 1151, respectively; (z) SEQ ID NOs: 1062 and 1152, respectively; (aa) are SEQ ID NOs: 1063 and 1153, respectively; (bb) SEQ ID NOs: 1064 and 1154, respectively; (cc) SEQ ID NOs: 1065 and 1155, respectively; (dd) SEQ ID NO: 1066 and 1156, respectively; (ee) SEQ ID NO: 1067 and 1157, respectively; (ff) are SEQ ID NOs: 1068 and 1158, respectively; (gg) are SEQ ID NOs: 1120 and 1210, respectively; (hh) SEQ ID NOs: 1076 and 1166, respectively; and (ii) SEQ ID NO: 1100 and 1190, respectively.
[0037] In some or any of the foregoing or related aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 1042 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1132. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 1055 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1145. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 1056 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1146. In some aspects, the sense strand comprises the nucleotide sequence of SEQ ID NO: 1100 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1190.
[0038] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1081 and 1171, respectively; (b) SEQ ID NOs: 1090 and 1180, respectively; (c) SEQ ID NOs: 1079 and 1169, respectively; (d) SEQ ID NOs: 1076 and 1166, respectively; (e) SEQ ID NOs: 1072 and 1162, respectively; (f) SEQ ID NOs: 1070 and 1160, respectively; and (g) are SEQ ID NOs: 1069 and 1159, respectively.
[0039] In some or any of the foregoing or related aspects, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1120 and 1210, respectively; (b) SEQ ID NOs: 1117 and 1207, respectively; and (c) SEQ ID NO: 1119 and 1209, respectively.
[0040] In some or any of the foregoing or related aspects, the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1095 and 1185, respectively; (b) SEQ ID NOs: 1104 and 1194, respectively; (c) SEQ ID NOs: 1093 and 1183, respectively; and (d) SEQ ID NO: 1100 and 1190, respectively.
[0041] In some aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an anti-PD-L1 antibody, the method comprising administering an RNAi oligonucleotide comprising an antisense strand and a sense strand, thereby treating the cancer in the subject, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 84, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprising the nucleotide sequence shown in SEQ ID NO: 83.
[0042] In other aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering an anti-PD-L1 antibody, thereby treating the cancer in the subject, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 84, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 83.
[0043] In yet other aspects, the present disclosure provides a method for treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating the disease, disorder or condition associated with activated STAT3 expression, wherein the subject has received or is receiving an anti-PD-L1 antibody, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 84, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 83.
[0044] In a further aspect, the present disclosure provides a kit comprising an RNAi oligonucleotide, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the oligonucleotide to a subject in need thereof who has received or is receiving an anti-PD-L1 antibody, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 84, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 83.
[0045] In other aspects, the present disclosure provides a kit comprising an anti-PD-L1 antibody, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the antibody to a subject in need thereof who has received or is receiving an RNAi oligonucleotide comprising an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 84, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 83.
[0046] In some aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an anti-PD-L1 antibody, the method comprising administering an RNAi oligonucleotide comprising an antisense strand and a sense strand, thereby treating the cancer in the subject, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 70, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 69.
[0047] In other aspects, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering an anti-PD-L1 antibody, thereby treating the cancer in the subject, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 70, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 69.
[0048] In yet other aspects, the present disclosure provides a method for treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating the disease, disorder or condition associated with activated STAT3 expression, wherein the subject has received or is receiving an anti-PD-L1 antibody, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 70, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 69.
[0049] In a further aspect, the present disclosure provides a kit comprising an RNAi oligonucleotide, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the oligonucleotide to a subject in need thereof who has received or is receiving an anti-PD-L1 antibody, wherein the oligonucleotide comprises an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 70, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 69.
[0050] In other aspects, the present disclosure provides a kit comprising an anti-PD-L1 antibody, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the antibody to a subject in need thereof who has received or is receiving an RNAi oligonucleotide, the RNAi oligonucleotide comprising an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 70, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and the sense strand comprises the nucleotide sequence shown in SEQ ID NO: 69. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1A The structures of RNAi oligonucleotide molecules with chemical modifications are provided, in which GalNAc (upper panel) or lipid (eg, C18 hydrocarbon chain) (lower panel) is conjugated to the oligonucleotide molecule to generate an oligonucleotide-ligand conjugate.
[0052] Figure 1B The structures of lipid tails suitable for conjugation to RNAi oligonucleotide molecules are provided.
[0053] Figure 2A and Figure 2B is a graph showing the remaining mouse Stat3 mRNA levels in the liver of mice treated with GalXC-STAT3-conjugates (GalNAc conjugates) targeting different regions of Stat3 mRNA. Mice were administered a single dose (3 mg / kg) ( Figure 2A ) or different doses (0.3, 1.0 or 3.0 mg / kg) to determine the dose-responsiveness ( Figure 2B ). Arrows indicate constructs selected for further studies.
[0054] Figure 3A and Figure 3B Figure 2 is a graph showing mouse Stat3 mRNA expression in G-MDSCs and M-MDSCs from Pan02 xenografts implanted in mice 3 days after treatment with GalXC-STAT3-C18 conjugate. Figure 3A) and 50mg / kg( Figure 3B ) administration.
[0055] Figure 4A and Figure 4B Figure 2 shows that after treatment of Pan02 xenograft mice with GalXC-STAT3-C18 conjugate at doses of 25 and 50 mg / kg, the mass tumor mass (TME) ( Figure 4A ) and tumor draining lymph nodes (TdLN) ( Figure 4B ) is a graph of mouse Stat3 mRNA expression in .
[0056] Figure 5A The graphs provided show the effects of GalXC-STAT3-C18-4123 on Stat3 and Pdl1 mRNA levels in G / M-MDSCs in the TME and TdLN of Pan02 xenograft mice 3 days after a 25 or 50 mg / kg dose of the conjugated oligonucleotide.
[0057] Figure 5B The graphs provided show the effects of GalXC-STAT3-C18-4123 on Stat3 and Pdl1 mRNA levels in TdLN of Pan02 xenograft mice 7 days after a 25 mg / kg dose of the conjugated oligonucleotide.
[0058] Fig. 6A and Figure 6B Figure 2 is a graph showing the in vivo effect of subcutaneous treatment with a total dose of 50 mg / kg of GalXC-STAT3-C18-4123 on tumor volume over time in immunocompetent mice bearing Pan02 murine pancreatic tumors. Fig. 6A ) or twice 25 mg / kg ( Figure 6B ) dose of conjugated oligonucleotide to treat mice.
[0059] Figure 7 The provided graph depicts the percentage (%) of human STAT3 mRNA remaining in Huh7 cells endogenously expressing human STAT3 after 24 hours of treatment with 1 nM DsiRNA targeting different regions of the STAT3 gene. 192 DsiRNAs were designed and screened. Two primer pairs were used. Expression between samples was normalized using HPRT and SFRS9 housekeeping genes (Forward 1 - SEQ ID NO: 1219, Reverse 1 - SEQ ID NO: 1220; Probe 1 - SEQ ID NO: 1221; Forward 2 - SEQ ID NO: 1222, Reverse 2 - SEQ ID NO: 1223; Probe 2 - SEQ ID NO: 1224).
[0060] Fig. 8Aand Figure 8B The graph provided depicts the percentage (%) of human STAT3 mRNA remaining in Huh7 cells endogenously expressing human STAT3 after 24 hours of treatment with 0.05 nM, 0.3 nM or 1 nM DsiRNAs targeting different regions of the STAT3 gene. Fig. 8A 48 GalNAc-conjugated STAT3 oligonucleotides were tested in the present study, and 34 of these oligonucleotides were selected for further in vivo testing ( Figure 8B ).
[0061] Fig. 9A and Fig. 9B The provided figure depicts the percentage (%) of human STAT3 mRNA remaining in the liver of mice (hydrodynamic injection model) exogenously expressing human STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 1 mg / kg of the indicated GalNAc-STAT3 oligonucleotides formulated in PBS. Three days after administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. The level of human STAT3 mRNA was determined from the liver collected 18 hours after injection. Arrows indicate the oligonucleotides selected for dose response analysis. Hs / Mf = human / monkey common sequence; Hs / Mm = human / mouse common sequence; Hs / Mf / Mm = human / monkey / mouse triple common sequence.
[0062] Fig.10 A diagram depicting the dose response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of human STAT3 mRNA remaining in the liver of mice (HDI model) expressing exogenous STAT3 was measured after treatment with human GalNAc-conjugated STAT3 oligonucleotides at two different doses (0.3 mg / kg or 1 mg / kg). The level of human STAT3 mRNA was determined in the liver collected 18 hours after injection of a plasmid encoding human STAT3. Arrows indicate oligonucleotides selected for dose response analysis. Hs / Mf = human / monkey common sequence; Hs / Mm = human / mouse common sequence.
[0063] Fig.11 The provided figure depicts the relative mouse STAT3 mRNA remaining (relative to Ppib) in the liver of mice endogenously expressing mouse STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. 3 mg / kg of the shown GalNAc-STAT3 oligonucleotides prepared in PBS were administered subcutaneously to mice. The liver was collected five days after administration and the level of mouse STAT3 mRNA was determined. Arrows indicate the top-ranked oligonucleotides and the oligonucleotides selected for dose response studies.
[0064] Fig.12 The provided figure depicts the normalized relative mouse STAT3 mRNA remaining in the liver of mice endogenously expressing mouse STAT3 (relative to Ppib) after treatment with GalNAc-conjugated STAT3 oligonucleotides. 3 mg / kg of the shown GalNAc-STAT3 oligonucleotides prepared in PBS were administered subcutaneously to mice. The liver was collected five days after administration and the level of mouse STAT3 mRNA was determined. The arrow indicates the oligonucleotide selected for the dose response study.
[0065] Fig.13A and Fig. 13B A graph depicting the dose response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of mouse STAT3 mRNA remaining in the liver of mice endogenously expressing STAT3 was measured after treatment with human GalNAc-conjugated STAT3 oligonucleotides at three doses (0.3 mg / kg, 1 mg / kg, and 3 mg / kg). The level of mouse STAT3 mRNA was determined from the liver collected after 5 days. TC = triple common (mouse / human / monkey); Hs_Mm = human / mouse.
[0066] Fig.14 The provided figure depicts the percentage (%) of human STAT3 mRNA remaining in the liver of mice (hydrodynamic injection model) that exogenously express human STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 1 mg / kg of the shown GalNAc-STAT3 oligonucleotides formulated in PBS. Three days after administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. The level of human STAT3 mRNA was determined from the liver collected 18 hours after injection. The arrow indicates the oligonucleotide selected for the dose response study.
[0067] Fig.15 A diagram depicting the dose response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of human STAT3 mRNA remaining in the liver of mice (hydrodynamic injection model) exogenously expressing human STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered three doses (0.3 mg / kg, 1 mg / kg, and 3 mg / kg) of the shown GalNAc-STAT3 oligonucleotides formulated in PBS. Three days after administration, mice were hydrodynamically injected (HDI) with DNA plasmids encoding human STAT3. The level of human STAT3 mRNA was determined from the liver collected 18 hours after injection. TC = triple common (mouse / human / monkey); Hs_Mm=human / mouse; Hs=human.
[0068] Fig.16 Provided is a diagram depicting the dose response of GalNAc-conjugated STAT3 oligonucleotides.After treatment with GalNAc-conjugated STAT3 oligonucleotides, the percentage (%) of human STAT3 mRNA remaining in the liver of mice (hydrodynamic injection model) expressing exogenous human STAT3. Two doses (0.3 mg / kg and 1 mg / kg) of GalNAc-STAT3 oligonucleotides prepared in PBS were subcutaneously administered to mice. Three days after administration, DNA plasmids encoding human STAT3 were hydrodynamically injected (HDI) into mice. The level of human STAT3 mRNA was determined from the liver collected 18 hours after injection.
[0069] Fig.17 The graph provided depicts the percentage (%) of human STAT1 mRNA remaining in Huh7 cells endogenously expressing STAT3 and STAT1 treated with GalNAc-conjugated STAT3 oligonucleotides. Cells were treated with three doses (0.05 nM, 0.3 nM and 1 nM) of oligonucleotides for 24 hours.
[0070] Fig.18A The provided figure depicts the tumor volume after GalXC-STAT3-C18 oligonucleotides are administered alone or in combination with anti-PD-L1 mAb. 25 mg / kg of GalXC-STAT3-C18-4123 were administered subcutaneously (sc) to immunocompetent mice bearing Pan02 mouse pancreatic tumors, and 10 mg / kg of anti-PD-L1 mAb were used for intraperitoneal (ip) treatment. Controls included GalXC-placebo (a HBV siRNA with the same chemical properties and lipid conjugation as GalXC-STAT3 oligonucleotides), 25 mg / kg of GalXC-STAT3-C18-4123 or 25 mg / kg of GalXC-placebo combined with 10 mg / kg of anti-PD-L1 mAb. Mice were first administered two doses at intervals of three days, and then two doses at intervals of three days after two weeks [(q3dx2)x2]. Arrows indicate the number of days of the dose.
[0071] Fig.18B The graph provided depicts tumor volume after administration of GalXC-STAT3-C18 oligonucleotide in combination with anti-PD-L1 mAb. Fig.18A Placebo-treated mice were treated subcutaneously (sc) with 25 mg / kg of GalXC-STAT3-C18-4123 and intraperitoneally (ip) with 10 mg / kg of anti-PD-L1 mAb.
[0072] Figure 19A-Figure 19CThe graphs provided depict tumor volumes after administration of GalXC-STAT3-C18 oligonucleotide alone or in combination with anti-PD-L1 mAb, or GalXC-placebo alone or in combination with anti-PD-L1 mAb, in tumors with different immunophenotypes. Fig.19A ), MC-38 (colon cancer, partially checkpoint sensitive) ( Fig.19B ) or Hepa1-6 (hepatocellular carcinoma, checkpoint sensitive) ( Fig.19C ) cells were implanted into mice. Tumor-bearing mice were given subcutaneous treatment with 25 mg / kg of GalXC-STAT3-C18-4123 and 10 mg / kg of anti-PD-L1 mAb intraperitoneally. Controls included GalXC-placebo, 25 mg / kg of GalXC-STAT3-C18-4123, or 25 mg / kg of GalXC-placebo combined with 10 mg / kg of anti-PD-L1 mAb. MC-38 and Hepa1-6 tumor-bearing mice were given two doses of 25 mg / kg three days apart, and the same treatment regimen was repeated the following week. 4T1 tumor-bearing mice were given three doses, each three days apart (q3d x 3). Arrow (5 / 5CR) = All treated mice were completely relieved.
[0073] Fig. 20 The graph provided depicts the effect of Hepa1-6 re-challenge on completely eradicated tumors. Fig.19C After complete tumor regression in all 5 mice treated with GalXC-STAT3-C18 (25 mg / kg, sc) and anti-PD-L1 mAb (10 mg / kg, ip), mice were re-challenged with Hepa1-6 cells (2e6 cells / mouse) in the contralateral flank on day 51, and tumor volumes were monitored ( Fig. 20 ). Arrow (5 / 5CR) = All mice remained tumor-free even after re-challenge.
[0074] Fig.21 The provided figure depicts the tumor volume after administration of GalXC-STAT3-C18 oligonucleotide alone or in combination with anti-PD-L1 mAb in immunocompromised mice without functional CD8+T cells. 4T1 tumor-bearing mice were subcutaneously administered GalXC-STAT3-C18-4123 (25 mg / kg, three doses each, three days apart (q3d x 3)), and anti-PD-L1 mAb (10 mg / kg, q3d x 3) was administered intraperitoneally. Controls included GalXC-placebo, 25 mg / kg of GalXC-STAT3-C18-4123, or 25 mg / kg of GalXC-placebo combined with 10 mg / kg of anti-PD-L1 mAb.
[0075] Fig. 22 The image provided shows the Fig.19A Appearance of tumors (with accompanying cell death) in mice assayed in the experiment, and perforin staining for positive cytotoxic CD8+ T cells in the tumors at the end of the study.
[0076] Fig.23 The image provided shows how Fig.19A and Fig.21 Lung tumor metastasis after treatment with GalXC-STAT3-C18-4123 oligonucleotide alone or in combination with anti-PD-L1 mAb. 4T1 tumor-bearing mice (immunocompetent or immunocompromised) were given GalXC-STAT3-C18-4123 (50 mg / kg, q3d x 3) subcutaneously and anti-PD-L1 mAb (10 mg / kg, q3d x 3) intraperitoneally. Controls included GalXC-placebo, 50 mg / kg of GalXC-STAT3-C18-4123, or 50 mg / kg of GalXC-placebo combined with 10 mg / kg of anti-PD-L1 mAb.
[0077] Fig.24 The heat map provided shows the modulation of targets involved in immune regulation observed in CT26 tumors after combination treatment with GalXC-STAT3-C18-4123 (sc, 25 mg / kg, q3d x 3) and anti-PD-L1 mAb (ip, 10 mg / kg, q3d x 3) compared to controls including GalXC-placebo, 25 mg / kg of GalXC-STAT3-C18-4123, or 25 mg / kg of GalXC-placebo plus 10 mg / kg of anti-PD-L1 mAb. DETAILED DESCRIPTION
[0078] The present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which illustrative embodiments of the present disclosure are shown. However, the present disclosure may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; on the contrary, these embodiments are provided to make the present disclosure more thorough and complete, and to fully convey the scope of the present disclosure to those skilled in the art. definition
[0079] The publications discussed throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure.
[0080] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items. In addition, the singular form and the articles "a", "an" and "the" are also intended to include the plural form, unless otherwise expressly stated. It should also be understood that the terms "include" and / or "comprise" when used in this specification refer to the presence of the features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or groups thereof. In addition, it should be understood that when an element, including a component or subsystem, is referred to and / or shown as being connected or coupled to another element, it may be directly connected or coupled to the other element, or there may be intervening elements.
[0081] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Exemplary methods and materials are described herein, but methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions.
[0082] General texts describing molecular biology techniques useful herein, including the use of vectors, promoters, and many other related topics, include Berger and Kimmel, GUIDE TO MOLECULAR CLONING TECHNIQUES, METHODS IN ENZYMOLOGY, Vol. 152, (Academic Press, Inc., San Diego, Calif.) ("Berger"); Sambrook et al., MOLECULAR CLONING--A LABORATORY MANUAL, 2nd ed., Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989 ("Sambrook") and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, FM Ausubel et al., eds., CURRENT PROTOCOLS, A JOINT VENTURE BETWEEN ENGREENE PUBLISHING ASSOCIATES, INC. AND JOHN WILEY AND SONS, INC., (Supplemented through 1999) ("Ausubel").Examples of protocols sufficient to guide the skilled artisan in performing in vitro amplification methods, including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicase amplification and other RNA polymerase-mediated techniques (e.g., NASBA), such as those used to generate homologous nucleic acids of the present disclosure, can be found in Berger, Sambrook and Ausubel, and Mullis et al., (1987) U.S. Pat. No. 4,683,202; Innis et al., eds., (1990); PCR PROTOCOLS: A GUIDE TOMETHODS AND APPLICATIONS (Academic Press Inc. San Diego, Calif.) ("Innis"); Arnheim and Levinson (October 1, 1990) Cand EN 36-47; J. NIH RES. (1991) 3:81-94; Kwoh et al., (1989) PROC. NATL. ACAD. SCI. USA 86:1173; Guatelliet et al., (1990) PROC. NAT'L. ACAD. SCI. USA 87:1874; Lomell et al., (1989) J. CLIN. CHEM 35:1826; Landegren et al., (1988) SCIENCE 241:1077-80; Van Brunt (1990) BIOTECHNOLOGY 8:291-94; Wu and Wallace (1989) GENE 4:560; Barringer et al., (1990) GENE 89:117; and Sooknanan and Malek (1995) BIOTECHNOLOGY 13:563-564. An improved method for cloning in vitro amplified nucleic acids is described in U.S. Pat. No. 5,426,039 to Wallace et al. Improved methods for amplifying large nucleic acids by PCR are summarized in Cheng et al., (1994) NATURE 369:684-85 and references cited therein, in which PCR amplicons of up to 40 kb were generated.
[0083] As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes a mixture of two or more such carriers, and so forth.
[0084] Ranges can be expressed herein as from "about" one value and / or to "about" another value. When such ranges are expressed, another embodiment includes from a value and / or to another value. Similarly, when a value is expressed as an approximation by using the antecedent "about", it should be understood that the value constitutes another embodiment. It should be further understood that the endpoints of each range are important in relation to and independently of another endpoint. It should also be understood that several values are disclosed herein, and each value is disclosed as "about" the value in addition to the value itself. For example, if the value "10" is disclosed, "about 10" is also disclosed. It should also be understood that when a value is disclosed, "less than or equal to" the value, "greater than or equal to" the value, and the possible range between the values are also disclosed, as appropriately understood by those skilled in the art. For example, if the value "10" is disclosed, "less than or equal to 10" and "greater than or equal to 10" are also disclosed. It should also be understood that throughout the application, data are provided in several different formats, and the data represent the range of any combination of endpoints and starting points and data points. For example, if a specific data point "10" and a specific data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15, and between 10 and 15 are considered disclosed. It is also understood that every unit between two specific units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0085] Throughout this specification and the appended claims, reference will be made to several terms which shall be defined to have the following meanings:
[0086] The terms "cancer" or "tumor" include, but are not limited to, solid tumors and blood-borne tumors. These terms include diseases of the skin, tissues, organs, bones, cartilage, blood, and blood vessels. These terms further encompass primary cancers and metastatic cancers.
[0087] The term "PD-1" refers to a protein found on T cells that helps control immune responses. When PD-1 binds to another protein called PD-L1, it helps prevent T cells from killing other cells, including cancer cells. Some cancer drugs called immune checkpoint inhibitors are designed to block PD-1. When this protein is prevented from acting on T cells, they can be used to kill cancer cells.
[0088] The term "STAT3" refers to signal transduction and transcription activator 3 (STAT3), which is a transcription factor encoded by the STAT3 gene (STAT3 human (Hs) NM_001369512.1 Genbank RefSeq #, or NM_139276.3) in humans. STAT3 mediates the expression of a variety of genes in response to cellular stimulation, and therefore plays a key role in many cellular processes such as cell growth and apoptosis, as well as the growth and progression of cancer.
[0089] As used herein, the term "cold tumor" or "non-inflamed tumor" refers to a tumor or tumor microenvironment in which there are minimal or no anti-tumor immune cells, such as tumor infiltrating lymphocytes (TILs), and / or contain cell subsets associated with immunosuppression, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages. Specifically, in some embodiments, cold tumors are characterized by low numbers or even absence of infiltration of anti-tumor immune cells, which may be present but remain in the surrounding matrix and are therefore unable to colonize the tumor microenvironment to provide their anti-tumor functions.
[0090] As used herein, "complementarity" refers to a structural relationship between two nucleotides (e.g., on two relative nucleic acids or on relative regions of a single nucleic acid chain) that allows the two nucleotides to form base pairs with each other. For example, the purine nucleotides of a nucleic acid complementary to the pyrimidine nucleotides of the relative nucleic acid can be base-paired together by forming hydrogen bonds with each other. In some embodiments, the complementary nucleotides can be base-paired in a Watson-Crick manner or in any other manner that allows the formation of a stable duplex. In some embodiments, two nucleic acids may have a region of multiple nucleotides that are complementary to each other to form a complementary region, as described herein.
[0091] As used herein, "species cross-reactive oligonucleotides" refer to oligonucleotides that are capable of inhibiting the expression of a target mRNA in more than one species. For example, in some embodiments, species cross-reactive oligonucleotides are capable of inhibiting the expression of a target mRNA in humans and non-human primates. Example species include, but are not limited to, humans, non-human primates, mice, and rats. In some embodiments, species cross-reactive oligonucleotides are capable of targeting and inhibiting mRNA in at least two, at least three, or at least four species.
[0092] As used herein, "deoxyribonucleotide" refers to a nucleotide that has a hydrogen instead of a hydroxyl group at the 2' position of its pentose sugar, as compared to a ribonucleotide. A modified deoxyribonucleotide is a deoxyribonucleotide with one or more modifications or substitutions of atoms other than the 2' position, including modifications or substitutions of the sugar, phosphate group, or base, or modifications or substitutions therein.
[0093] As used herein, "double-stranded RNA" or "dsRNA" refers to an RNA oligonucleotide that is substantially in the form of a duplex. In some embodiments, the complementary base pairing in the duplex region of a dsRNA oligonucleotide is formed between the antiparallel nucleotide sequences of the covalently separated nucleic acid chains. In some embodiments, the complementary base pairing in the duplex region of a dsRNA is formed between the antiparallel nucleotide sequences of the covalently connected nucleic acid chains. In some embodiments, the complementary base pairing in the duplex region of a dsRNA is formed by a single nucleic acid chain folded (e.g., by a hairpin) to provide a complementary antiparallel nucleotide sequence of base pairing together. In some embodiments, dsRNA comprises two covalently separated nucleic acid chains that completely form a duplex with each other. However, in some embodiments, dsRNA comprises two covalently separated nucleic acid chains (e.g., having an overhang at one or both ends) that partially form a duplex. In some embodiments, dsRNA comprises partially complementary antiparallel nucleotide sequences, therefore, may have one or more mispairings, which may include internal mispairings or terminal mispairings.
[0094] As used herein, "duplex" with respect to nucleic acids (eg, oligonucleotides) refers to the structure formed by complementary base pairing of two anti-parallel nucleotide sequences.
[0095] As used herein, "excipient" refers to a non-therapeutic agent that can be included in the composition, for example, to provide or contribute to a desired consistency or stabilizing effect.
[0096] As used herein, the term "hot tumor" or "inflamed tumor" refers to a tumor or tumor microenvironment in which anti-tumor immune cells, especially TILs, are present in large numbers and are therefore generally immunostimulatory.
[0097] As used herein, "loop" refers to an unpaired region of a nucleic acid (e.g., an oligonucleotide) flanked by two antiparallel regions of the nucleic acid that are sufficiently complementary to each other such that under appropriate hybridization conditions (e.g., in phosphate buffer, in a cell), the two antiparallel regions flanking the unpaired region hybridize to form a duplex (referred to as a "stem"). A loop comprising four nucleotides may be referred to as a tetraloop (tetraL). A loop comprising three nucleotides may be referred to as a triloop (triL).
[0098] As used herein, "modified internucleotide linkages" refers to internucleotide linkages having one or more chemical modifications compared to a reference internucleotide linkage comprising a phosphodiester bond. In some embodiments, the modified nucleotide is a non-naturally occurring linkage. Typically, the modified internucleotide linkage imparts one or more desired properties to the nucleic acid in which the modified internucleotide linkage is present. For example, the modified nucleotide can improve thermal stability, degradation resistance, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, etc.
[0099] As used herein, "modified nucleotides" refer to nucleotides having one or more chemical modifications compared to corresponding reference nucleotides selected from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides, adenine deoxyribonucleotides, guanine deoxyribonucleotides, cytosine deoxyribonucleotides and thymine deoxyribonucleotides. In some embodiments, modified nucleotides are non-naturally occurring nucleotides. In some embodiments, modified nucleotides have one or more chemical modifications in their sugars, nucleobases and / or phosphate groups. In some embodiments, modified nucleotides have one or more chemical moieties conjugated to corresponding reference nucleotides. Typically, modified nucleotides confer one or more desired properties to nucleic acids in which the modified nucleotides are present. For example, modified nucleotides can improve thermal stability, degradation resistance, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, etc.
[0100] As used herein, a "nicked tetraloop structure" refers to the structure of an RNAi oligonucleotide characterized by separate sense (passenger) and antisense (guide) strands, wherein the sense strand has a complementary region that is complementary to the antisense strand, and wherein at least one of the strands, typically the sense strand, has a tetraloop configured to stabilize an adjacent stem region formed within the at least one strand.
[0101] As used herein, "oligonucleotide" refers to a short nucleic acid (e.g., less than about 100 nucleotides in length). An oligonucleotide can be single-stranded (ss) or double-stranded (ds). An oligonucleotide can have or not have a duplex region. An oligonucleotide can comprise deoxyribonucleotides, ribonucleosides, or a combination of the two. In some embodiments, a double-stranded oligonucleotide comprising a ribonucleotide is referred to as a "dsRNA". As a group of non-limiting examples, an oligonucleotide can be, but is not limited to, a small interfering RNA (siRNA), a microRNA (miRNA), a short hairpin RNA (shRNA), a cleavage substrate interfering RNA (dsiRNA), an antisense oligonucleotide, a short siRNA, or a ss siRNA. In some embodiments, a double-stranded RNA (dsRNA) is an RNAi oligonucleotide.
[0102] The terms "RNAi oligonucleotide conjugate" and "oligonucleotide-ligand conjugate" are used interchangeably and refer to an oligonucleotide comprising one or more nucleotides conjugated to one or more targeting ligands.
[0103] As used herein, "overhang" refers to a terminal non-base paired nucleotide that is produced by a strand or region extending beyond the end of a complementary strand that forms a duplex with the strand or region. In some embodiments, the overhang comprises one or more unpaired nucleotides extending from the duplex region at the 5' end or 3' end of the dsRNA. In certain embodiments, the overhang is a 3' or 5' overhang on the antisense strand or sense strand of the dsRNA.
[0104] As used herein, "phosphate analogue" refers to a chemical part that simulates the electrostatic properties and / or spatial properties of a phosphate group. In some embodiments, the phosphate analogue is located at the 5' terminal nucleotide of an oligonucleotide, rather than a 5'-phosphate that is usually easily removed enzymatically. In some embodiments, the 5' phosphate analogue contains a phosphatase-resistant connection. Examples of phosphate analogues include, but are not limited to, 5'-phosphonates, such as 5'-methylenephosphonates (5'-MP) and 5'-(E)-vinylphosphonates (5'-VP). In some embodiments, an oligonucleotide has a phosphate analogue (referred to as a "4'-phosphate analogue") at the 4'-carbon position of the sugar at the 5'-terminal nucleotide. An example of a 4'-phosphate analogue is an oxymethylphosphonate, in which the oxygen atom of the oxymethyl group is bound to a sugar moiety (e.g., at its 4'-carbon) or an analog thereof. See, e.g., U.S. Provisional Patent Application No. 62 / 383,207 (filed on September 2, 2016) and U.S. Provisional Patent Application No. 62 / 393,401 (filed on September 12, 2016). Other modifications have been developed for the 5' end of oligonucleotides (see, e.g., International Patent Application No. WO2011 / 133871; U.S. Patent No. 8,927,513; and Prakash et al. (2015) NUCLEICACIDS RES. 43:2993-3011).
[0105] As used herein, "reduced expression" of a gene (e.g., STAT3) refers to a reduction in the amount or level of RNA transcripts (e.g., STAT3 mRNA) or proteins encoded by the gene in a cell, cell colony, sample or subject compared to an appropriate reference (e.g., a reference cell, cell colony, sample or subject), and / or a reduction in the amount or level of activity of the gene. For example, compared to cells not treated with dsRNA, the act of contacting a cell with an oligonucleotide herein (e.g., an oligonucleotide comprising an antisense strand having a nucleotide sequence complementary to a nucleotide sequence comprising STAT3 mRNA) can result in a reduction in the amount or level of STAT3 mRNA, protein and / or activity (e.g., via degradation of STAT3 mRNA by RNAi approaches). Similarly, and as used herein, "reduced expression" refers to an act that results in a reduction in the expression of a gene (e.g., STAT3). As used herein, "reduction of STAT3 expression" refers to a decrease in the amount or level of STAT3 mRNA, STAT3 protein and / or STAT3 activity in a cell, cell population, sample or subject compared to an appropriate reference (e.g., a reference cell, cell population, sample or subject).
[0106] As used herein, "region of complementarity" refers to a nucleotide sequence of a nucleic acid (e.g., dsRNA) that is sufficiently complementary to an antiparallel nucleotide sequence to allow the two nucleotide sequences to hybridize under appropriate hybridization conditions (e.g., in phosphate buffer, in a cell, etc.). In some embodiments, the oligonucleotides herein comprise a targeting sequence having a region of complementarity that is complementary to an mRNA target sequence.
[0107] As used herein, "ribonucleotide" refers to a nucleotide having ribose as its pentose, which contains a hydroxyl group at its 2' position. A modified ribonucleotide is a ribonucleotide having one or more modifications or substitutions of atoms other than the 2' position, including modifications or substitutions of ribose, a phosphate group, or a base, or modifications or substitutions therein.
[0108] As used herein, "RNAi oligonucleotide" refers to (a) a dsRNA having a sense (passenger) strand and an antisense (guide) strand, wherein the antisense strand or a portion of the antisense strand is used by the Argonaute 2 (Ago2) endonuclease in cleavage of a target mRNA, or (b) a single-stranded oligonucleotide having a single antisense strand, wherein the antisense strand (or a portion of the antisense strand) is used by the Ago2 endonuclease in cleavage of a target mRNA.
[0109] As used herein, a "strand" refers to a single, continuous sequence of nucleotides linked together by internucleotide bonds (eg, phosphodiester bonds or phosphorothioate bonds). In some embodiments, a strand has two free ends (eg, a 5' end and a 3' end).
[0110] As used herein, "subject" refers to any mammal, including mice, rabbits, non-human primates (NHPs) and humans. In one embodiment, the subject is a human or NHP. In addition, "individual" or "patient" can be used interchangeably with "subject".
[0111] As used herein, "synthetic" refers to nucleic acids or other molecules that are synthesized artificially (e.g., using a machine (e.g., a solid-state nucleic acid synthesizer)) or that are otherwise not derived from a natural source (e.g., a cell or organism) that normally produces the molecule.
[0112] As used herein, "targeting ligand" refers to a molecule or "part" (e.g., a carbohydrate, an amino sugar, cholesterol, a polypeptide, or a lipid) that selectively binds to a homologous molecule (e.g., a receptor) of a tissue or cell of interest, and / or can be conjugated to another substance so as to target the other substance to a tissue or cell of interest. For example, in some embodiments, a targeting ligand can be conjugated to an oligonucleotide so as to target the oligonucleotide to a specific tissue or cell of interest. In some embodiments, a targeting ligand selectively binds to a cell surface receptor. Therefore, in some embodiments, when a targeting ligand is conjugated to an oligonucleotide, the delivery of the oligonucleotide to a specific cell is promoted by selective binding to a receptor expressed on the cell surface and endocytosis of a complex comprising the oligonucleotide, the targeting ligand, and the receptor by the cell. In some embodiments, a targeting ligand is conjugated to an oligonucleotide via a linker that is cleaved after or during cellular internalization so that the oligonucleotide is released from the targeting ligand in the cell.
[0113] As used herein, "loop", "tricycle" or "tetraloop" refers to a loop that increases the stability of adjacent duplexes formed by hybridization of nucleotide flanking sequences. The increase in stability can be detected as a melting temperature (T m ) increases, the T m higher than the average expected T of adjacent stem duplexes from a set of loops of comparable length consisting of randomly selected nucleotide sequences. m For example, the loop (e.g., tetraloop or triloop) can confer a T of at least about 50°C, at least about 55°C, at least about 56°C, at least about 58°C, at least about 60°C, at least about 65°C, or at least about 75°C to a hairpin comprising a duplex of at least 2 base pairs (bp) in length in 10 mM NaHPO4. m. In some embodiments, the ring (e.g., tetraloop) can stabilize the bp in the adjacent stem duplex by stacking interactions. In addition, the interactions between nucleotides in the tetraloop include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., (1990) NATURE 346: 680-82; Heus and Pardi (1991) SCIENCE 253: 191-94). In some embodiments, the ring comprises 3 to 6 nucleotides or is composed of 3 to 6 nucleotides, and is generally 4 to 5 nucleotides. In certain embodiments, the ring comprises 3, 4, 5 or 6 nucleotides or is composed of 3, 4, 5 or 6 nucleotides, which may be modified or may not be modified (e.g., it may be conjugated with a targeting moiety or may not be conjugated with a targeting moiety). In some embodiments, the tetraloop comprises 3 to 6 nucleotides or is composed of 3 to 6 nucleotides, and is generally 4 to 5 nucleotides. In certain embodiments, the tetracycle comprises 3,4,5 or 6 nucleotides or is composed of 3,4,5 or 6 nucleotides, which may be modified or may not be modified (for example, it may be conjugated with a targeting moiety or may not be conjugated with a targeting moiety). In one embodiment, the ring composed of 4 nucleotides is a tetracycle. Any nucleotide may be used in a ring (for example, a tetracycle), and the standard IUPAC-IUB symbols of such nucleotides may be used as described in Cornish-Bowden ((1985) NUCLEIC ACIDS RES.13:3021-3030). For example, the letter "N" may be used to represent that any base may be in this position, the letter "R" may be used to represent that A (adenine) or G (guanine) may be in this position, and "B" may be used to represent that C (cytosine), G (guanine) or T (thymine) may be in this position. Examples of tetraloops include tetraloops of the UNCG family (e.g., UUCG), tetraloops of the GNRA family (e.g., GAAA), and CUUG tetraloops (Woese et al., (1990) PROC. NATL. ACAD. SCI. USA 87: 8467-71; Antao et al., (1991) NUCLEIC ACIDS RES. 19: 5901-05). Examples of DNA tetraloops include tetraloops of the d(GNNA) family (e.g., d(GTTA)), tetraloops of the d(GNRA) family, tetraloops of the d(GNAB) family, tetraloops of the d(CNNG) family, and tetraloops of the d(TNCG) family (e.g., d(TTCG)). (See, e.g., Nakano et al., (2002) BIOCHEM. 41: 4281-92; Shinji et al., (2000) NIPPON KAGAKKAI KOENYOKOSHU 78: 731). In some embodiments, the tetraring is contained within a gapped tetraring structure.
[0114] As used herein, "treatment" or "treating" refers to the act of providing medical care to a subject in need thereof, for example, by administering a therapeutic agent (e.g., an oligonucleotide herein) to the subject for improving the health and / or well-being of the subject with respect to an existing condition (e.g., a disease, a disorder), or preventing or reducing the likelihood of a condition occurring. In some embodiments, treatment involves reducing the frequency or severity of at least one sign, symptom, or contributing factor of a condition (e.g., a disease, a disorder) experienced by the subject.
[0115] As used herein, the term "tumor microenvironment" refers to the cellular environment in which any given tumor resides, including tumor stroma, surrounding blood vessels, immune cells, fibroblasts, other cells, signaling molecules, and ECM. It should be understood that the tumor microenvironment carries and / or surrounds tumor cells that interact with it. How to use Combination of STAT3 oligonucleotides with PD-L1 inhibitors
[0116] In some embodiments, the disclosure provides STAT3 oligonucleotides for use or suitable for use in treating a subject (e.g., a person suffering from a disease, disorder, or condition associated with STAT3 expression) who has received or is receiving a PD-L1 inhibitor.
[0117] In some embodiments, the methods described herein include selecting a subject suffering from or susceptible to a disease, disorder, or condition associated with STAT3 expression and / or PD-L1 expression. In some cases, the methods may include selecting an individual with markers for a disease associated with STAT3 expression and / or PD-L1 expression, such as cancer or other chronic lymphoproliferative disorders.
[0118] Likewise, and as described in detail herein, the methods may further include steps such as measuring or obtaining a baseline value for a marker of STAT3 expression and / or PD-L1 expression, and then comparing the value so obtained to one or more other baseline values or values obtained after administration of the oligonucleotide to assess the effectiveness of the treatment.
[0119] In some embodiments, the disclosure provides methods of treating a subject having, suspected of having, or at risk of having a disease, disorder, or condition with a STAT3 oligonucleotide herein, wherein the subject has received or is receiving a PD-L1 inhibitor. In some embodiments, the disclosure provides methods of treating a subject having, suspected of having, or at risk of having a disease, disorder, or condition with a PD-L1 inhibitor described herein, wherein the subject has received or is receiving a STAT3 oligonucleotide described herein.
[0120] In some aspects, the disclosure provides a method for treating a disease, disorder or condition associated with STAT3 expression or reducing its onset or progression using the STAT3 oligonucleotides herein in combination with a PD-L1 inhibitor. In other aspects, the disclosure provides a method for achieving one or more therapeutic benefits in a subject suffering from a disease, disorder or condition associated with STAT3 expression using the STAT3 oligonucleotides herein in combination with a PD-L1 inhibitor. In some embodiments of the methods herein, the subject is treated by administering a therapeutically effective amount of a STAT3 oligonucleotide herein in combination with a PD-L1 inhibitor. In some embodiments of the methods herein, the subject is treated by administering a therapeutically effective amount of a STAT3 oligonucleotide herein to a subject who has received or is receiving a PD-L1 inhibitor. In some embodiments of the methods herein, the subject is treated by administering a therapeutically effective amount of a PD-L1 inhibitor to a subject who has received or is receiving a STAT3 oligonucleotide herein. In some embodiments of the methods herein, the subject is treated by administering a therapeutically effective amount of a PD-L1 inhibitor to a subject who has received or is receiving a STAT3 oligonucleotide herein. In some embodiments, the subject is treated therapeutically. In some embodiments, the subject is treated prophylactically.
[0121] In some embodiments of the methods herein, one or more STAT3 oligonucleotides herein or a pharmaceutical composition comprising one or more STAT3 oligonucleotides is administered to a subject who has received or is receiving a PD-L1 inhibitor and has a disease, disorder or condition associated with STAT3 expression, so that STAT3 expression in the subject is reduced, thereby treating the subject. In some embodiments, the amount or level of STAT3 mRNA in the subject is reduced. In some embodiments, the amount or level of STAT3 and / or protein in the subject is reduced. In some embodiments of the methods herein, one or more STAT3 oligonucleotides herein or a pharmaceutical composition comprising one or more STAT3 oligonucleotides is administered to a subject who has received or is receiving a PD-L1 inhibitor and has a disease, disorder or condition associated with STAT3 expression, so that STAT3 expression and PD-L1 signaling in the subject are reduced, thereby treating the subject. In some embodiments, the amount or level of STAT3 mRNA and PD-L1 signaling in the subject is reduced. In some embodiments, the amount or level of STAT3 and / or protein in the subject is reduced, and PD-L1 signaling in the subject is reduced.
[0122] In some embodiments, a therapeutically effective amount of a STAT3 oligonucleotide and / or a PD-L1 inhibitor is administered to a subject. A therapeutically acceptable amount may be an amount that can therapeutically treat a disease or condition. The appropriate dosage for any subject will depend on certain factors, including the subject's size, body surface area, age, specific composition to be administered, active ingredients in the composition, time and route of administration, general health, and other drugs administered simultaneously.
[0123] In some embodiments, any of the compositions herein is administered to a subject enterally (e.g., orally, by a gastric feeding tube, by a duodenal feeding tube, via a gastrostomy, or rectally), parenterally (e.g., subcutaneous injection, intravenous injection or infusion, intraarterial injection or infusion, intraosseous infusion, intramuscular injection, intracerebral injection, intracerebroventricular injection, intrathecal), topically (e.g., epidermal, inhaled, by eye drops, or through a mucosa), or by direct injection into a target organ (e.g., the subject's liver). Typically, the oligonucleotides herein are administered intravenously or subcutaneously.
[0124] As a set of non-limiting examples, the oligonucleotides herein are generally administered quarterly (once every three months), every two months (once every two months), monthly or weekly. For example, the oligonucleotides may be administered weekly or at intervals of two weeks or three weeks. Alternatively, the oligonucleotides may be administered daily. In some embodiments, one or more loading doses of the oligonucleotides are administered to the subject, followed by one or more maintenance doses of the oligonucleotides.
[0125] In some embodiments, the PD-L1 inhibitors herein (e.g., anti-PD-L1 antibodies) are administered quarterly (once every three months), bimonthly (once every two months), monthly, or weekly. For example, the inhibitor is administered weekly or at intervals of two or three weeks. Alternatively, the inhibitor is administered daily.
[0126] In some embodiments, the oligonucleotides herein are co-administered with a PD-L1 inhibitor. In some embodiments, the oligonucleotide and the inhibitor are co-administered simultaneously, sequentially (in any order), or intermittently. For example, the oligonucleotide and the inhibitor can be co-administered simultaneously. Alternatively, the oligonucleotide can be administered and the inhibitor can be administered after any length of time (e.g., one hour, one day, one week, or one month), or vice versa.
[0127] In some embodiments, the subject to be treated is a human or non-human primate or other mammalian subject. Other exemplary subjects include domestic animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats and chickens; and animals such as mice, rats, guinea pigs and hamsters. In some embodiments, the present disclosure provides a method for treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, The subject's cancer is thereby treated.
[0128] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, and wherein the lipid moiety is conjugated to the nucleotides of the sense strand, thereby treating cancer in the subject.
[0129] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 10.
[0130] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 10, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0131] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38.
[0132] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0133] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66.
[0134] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0135] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70.
[0136] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising a sense strand and an antisense strand, thereby treating the cancer in the subject, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0137] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, The subject's cancer is thereby treated.
[0138] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, and wherein the lipid moiety is conjugated to the nucleotides of the sense strand, thereby treating cancer in the subject.
[0139] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the subject's cancer, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 10.
[0140] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 10, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0141] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the subject's cancer, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38.
[0142] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0143] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the subject's cancer, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66.
[0144] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0145] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the subject's cancer, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70.
[0146] In some embodiments, the present disclosure provides a method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0147] In some embodiments, the present disclosure provides a method of treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, The subject's cancer is thereby treated.
[0148] In some embodiments, the present disclosure provides a method of treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, and wherein the lipid moiety is conjugated to the nucleotides of the sense strand, thereby treating cancer in the subject.
[0149] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:10.
[0150] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 9 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 10, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0151] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38.
[0152] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 37 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 38, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0153] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66.
[0154] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 65 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 66, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0155] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70.
[0156] In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 69 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 70, and wherein a lipid moiety is conjugated to the nucleotides of the sense strand.
[0157] In some embodiments, the methods disclosed herein increase the expression of immune activation genes. In some embodiments, the RNAi oligonucleotides described herein are administered together with a PD-L1 inhibitor to increase the expression of immune activation genes. In some embodiments, the methods described herein increase the expression of one or more of CD8B1, IL2Rα, TNFRSF9, CCL19, CCL27a, CD40Ig, CXCR5, CD44, STAT4, GZMB, PFR1, FASL, and HMGB1.
[0158] In some embodiments, the method disclosed herein reduces the expression of immunosuppressive genes. In some embodiments, the RNAi oligonucleotides described herein are administered together with a PD-L1 inhibitor to reduce the expression of immunosuppressive genes. In some embodiments, the method described herein reduces the expression of one or more of CD274, LAG3, TIGIT, PDSD1IG2, CD163, PIK3R5, FOXP3, TGFBR2, IDO1, CD200R1, CCL22, CCL8, CCR9, IL10, IL33, CXCL3, CSF2RD, TNFRSF18, MMP9, LOX12, FGF18, and FAP. cancer
[0159] In some embodiments, the STAT3 oligonucleotide and PD-L1 inhibitor target are used to treat cancer or tumors. In some embodiments, the tumor is a primary tumor. In some embodiments, the tumor is a metastatic tumor. In some embodiments, the tumor is a refractory tumor. In some embodiments, the tumor is a stage I, II, III, or IV tumor. In some embodiments, the tumor is a solid tumor. A solid tumor refers to a condition in which the cancer forms a mass.
[0160] In some embodiments, the cancer is thyroid cancer, papillary thyroid cancer, head and neck cancer, liver cancer, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, lung cancer, carcinoma, blastoma, medulloblastoma, retinoblastoma, sarcoma, liposarcoma, synovial cell sarcoma, neuroendocrine tumor, carcinoid tumor, gastrinoma, islet cell carcinoma, mesothelioma, schwannoma, acoustic neuroma, meningioma, adenocarcinoma, lymphoid malignancy, squamous cell carcinoma, epithelial squamous cell carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal cancer, glioblastoma, cervical cancer, bladder cancer, hepatoma, metastatic breast cancer, colon cancer, rectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, liver cancer, anal cancer, penile cancer, Merkel cell carcinoma, testicular cancer, esophageal cancer, or biliary tract tumor. In some embodiments, the cancer is refractory to anti-PD1, anti-PDL1 and / or anti-CTLA4 therapy.In some embodiments, the cancer is pancreatic cancer or lung cancer. In some embodiments, the cancer comprises a tumor with an immunosuppressive tumor microenvironment. In some embodiments, the cancer is resistant to immune checkpoint therapy. In some embodiments, the cancer is partially resistant to immune checkpoint therapy. In some embodiments, the cancer is sensitive to immune checkpoint therapy.
[0161] In some embodiments, the STAT3 oligonucleotide and PD-L1 inhibitor reduce tumor volume. Tumor volume is measured using methods known to those skilled in the art. For example, the extracted tumor is measured manually using a caliper. Other methods include imaging methods such as ultrasound and MRI. In some embodiments, the oligonucleotide conjugate reduces tumor volume by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, compared to untreated tumors. Oligonucleotide inhibitors of STAT3
[0162] In some aspects, the present disclosure provides, among other things, oligonucleotides that reduce or inhibit STAT3 expression. In some embodiments, the oligonucleotides that inhibit STAT3 expression herein target STAT3 mRNA. The sequence of human STAT3 mRNA (NM_001369512.1) is shown in SEQ ID NO:85 or NM_139276.3 (SEQ ID NO:1217). STAT3 is a known target for traditional cancer therapy.
[0163] The tolerance activity of MDSC is controlled by the oncogenic transcription factor, signal transducer and activator of transcription 3 (STAT3) (Su et al., INT J. MOL SCI (2018) 19 (6): 1803). STAT3 is also known to be highly expressed in a range of cancer types and in vitro and in vivo preclinical models (Huynh et al., NAT. REV. CANCER (2019) 19: 82-96). Inhibition of STAT3 leads to selective apoptosis of tumor cells and tumor growth inhibition through regulation of downstream target genes (Wang et al., INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 15 (3): 668–79 (2019)). STAT3 is of particular interest in immuno-oncology because it has a clear contribution to the immunosuppressive tumor microenvironment. STAT3 contributes to the immunosuppressive tumor microenvironment by upregulating inhibitory receptors expressed by T cells and, through the expression of their ligands (PD-1 / PD-L1), through increased IFNγ secretion (Bu et al., JOURNAL OF DENTAL RESEARCH, 96(9):1027–34 (2017)). It has long been known that inhibition of STAT3 signaling in antigen presenting cells (APCs) leads to the priming of antigen-specific CD4+ T cells in response to otherwise tolerogenic stimuli (Cheng et al., IMMUNITY, 19:425–36 (2003)). In addition, phosphorylated STAT3 on MDSCs directly contributes to the regulation of the suppressive tumor microenvironment by regulating inhibitory components such as the amino acid arginine through transcriptional control (Vasques-Dunndel et al., J. CLIN. INVEST., 15(3):668–79 (2013)). Over the years, several approaches have been explored to therapeutically target STAT3. Although direct protein targeting is attractive, the real target is protein-protein interaction, which has been regarded as a model of "undruggable" target because historical data show that multiple classes of compounds fail to effectively inhibit its activity (Lau et al., CANCERS (2019) 11 (11): 1681, Zou et al., MOL CANCER (2020) 19: 145). In addition, the ubiquitous expression of STAT3 in several tissues has raised concerns about severe on-target toxicity (Wong et al., EXPERT OPINION ON INVESTIGATIONAL DRUGS, 26 (8): 883-87 (2017), (Kortylewski et al., CANCER IMMUNOLIMMUNOTHER (2017) 66 (8): 979-88).
[0164] In some embodiments, the appropriate determination or technology of one or more properties or characteristics of cells or cell colonies associated with STAT3 can be evaluated (for example, using STAT3 expression biomarkers), or the determination or technology of molecules (for example, STAT3 mRNA or STAT3 protein) directly indicating STAT3 expression can be evaluated. In some embodiments, the degree to which the oligonucleotides herein reduce STAT3 expression is evaluated by comparing the STAT3 expression in the cells or cell colonies contacted with the oligonucleotides with the appropriate control (for example, not contacted with the oligonucleotides or contacted with the control oligonucleotides) . In some embodiments, the appropriate control level of mRNA expression into protein after delivering RNAi molecules can be a predetermined level or value, so that the control level does not need to be measured every time. The predetermined level or value can take a variety of forms. In some embodiments, the predetermined level or value can be a single cutoff value, such as a median or mean value.
[0165] In some embodiments, the administration of the oligonucleotide herein causes the STAT3 expression in a cell or cell colony to decrease. In some embodiments, the reduction of STAT3 or STAT3 expression is about 1% or lower, about 5% or lower, about 10% or lower, about 15% or lower, about 20% or lower, about 25% or lower, about 30% or lower, about 35% or lower, about 40% or lower, about 45% or lower, about 50% or lower, about 55% or lower, about 60% or lower, about 70% or lower, about 80% or lower or about 90% or lower compared to the appropriate control level of mRNA. Appropriate control level can be the level of mRNA expression and / or protein translation in a cell or cell colony not yet contacted with the oligonucleotide herein. In some embodiments, the effect of oligonucleotide delivery to a cell is assessed according to the method herein after a limited period of time. For example, the level of mRNA in the cells can be analyzed at least about 8 hours, about 12 hours, about 18 hours, about 24 hours; or at least about 1, 2, 3, 4, 5, 6, 7 days, or even up to 14 days after the oligonucleotide has been introduced into the cells.
[0166] In some embodiments, the oligonucleotide is delivered in the form of a transgene that is engineered to express the oligonucleotide or the strands that make up the oligonucleotide (e.g., its sense strand and antisense strand) in a cell. In some embodiments, the oligonucleotide is delivered using a transgene that is engineered to express any of the oligonucleotides disclosed herein. The transgene can be delivered using a viral vector (e.g., adenovirus, retrovirus, vaccinia virus, poxvirus, adeno-associated virus, or herpes simplex virus) or a non-viral vector (e.g., plasmid or synthetic mRNA). In some embodiments, the transgene can be injected directly into the subject. STAT3 target sequence
[0167] In some embodiments, the oligonucleotide targets a target sequence comprising STAT3 mRNA. In some embodiments, the oligonucleotide or a portion, fragment or strand thereof (e.g., an antisense strand or guide strand of dsRNA) binds to or anneals with a target sequence comprising STAT3 mRNA, thereby inhibiting STAT3 expression. In some embodiments, for the purpose of inhibiting STAT3 expression in vivo, the oligonucleotide targets a STAT3 target sequence. In some embodiments, the amount or degree of the oligonucleotide targeting a STAT3 target sequence to inhibit STAT3 expression is related to the efficacy of the oligonucleotide. In some embodiments, the amount or degree of the oligonucleotide targeting a STAT3 target sequence to inhibit STAT3 expression is related to the amount or degree of the therapeutic benefit in a subject or patient treated with the oligonucleotide, suffering from a disease, illness or condition associated with STAT3 expression.
[0168] By examining the nucleotide sequences of mRNA encoding STAT3, including the nucleotide sequences of mRNA of multiple different species (e.g., humans, cynomolgus monkeys, mice and rats; see, e.g., Example 6), and as a result of in vitro and in vivo testing (see, e.g., Example 7 and Example 8), it has been found that certain nucleotide sequences of STAT3 mRNA are more susceptible to oligonucleotide-based inhibition than other sequences, and therefore can be used as target sequences for oligonucleotides herein. In some embodiments, the sense strand of the oligonucleotides (e.g., dsRNA) described herein comprises a STAT3 target sequence. In some embodiments, a portion or region of the sense strand of the dsRNA described herein comprises a STAT3 target sequence. In some embodiments, the STAT3 mRNA target sequence comprises the sequence of SEQ ID NO: 85, or consists of the sequence of SEQ ID NO: 85. In some embodiments, the STAT3 mRNA target sequence comprises the sequence of SEQ ID NO: 1217, or consists of the sequence of SEQ ID NO: 1217. In some embodiments, the STAT3 mRNA target sequence comprises the sequence of any one of SEQ ID NOs: 89-280, or consists of the sequence of any one of SEQ ID NOs: 89-280. In some embodiments, the STAT3 mRNA target sequence comprises the sequence set forth in SEQ ID NO: 108, or consists of the sequence set forth in SEQ ID NO: 108. In some embodiments, the STAT3 mRNA target sequence comprises the sequence set forth in SEQ ID NO: 140, or consists of the sequence set forth in SEQ ID NO: 140. In some embodiments, the STAT3 mRNA target sequence comprises the sequence set forth in SEQ ID NO: 141, or consists of the sequence set forth in SEQ ID NO: 141. In some embodiments, the STAT3 mRNA target sequence comprises the sequence set forth in SEQ ID NO: 147, or consists of the sequence set forth in SEQ ID NO: 147. STAT3 targeting sequence
[0169] In some embodiments, the oligonucleotides herein have a complementary region complementary to STAT3 mRNA (e.g., within the target sequence of STAT3 mRNA) for the purpose of targeting mRNA in cells and reducing or inhibiting its expression. In some embodiments, the oligonucleotides herein comprise a STAT3 targeting sequence (e.g., the antisense strand or guide strand of dsRNA) having a complementary region that binds or anneals to the STAT3 target sequence by complementary (Watson-Crick) base pairing. The targeting sequence or complementary region generally has a suitable length and base content so that the oligonucleotide (or its strand) can bind or anneal to STAT3 mRNA, thereby achieving the purpose of inhibiting its expression. In some embodiments, the length of the targeting sequence or complementary region is at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 28, at least about 29, or at least about 30 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is about 12 to about 30 (e.g., 12 to 30, 12 to 22, 15 to 25, 17 to 21, 18 to 27, 19 to 27, or 15 to 30) nucleotides. In some embodiments, the length of the targeting sequence or complementary region is about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 18 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 19 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 20 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 21 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 22 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 23 nucleotides. In some embodiments, the length of the targeting sequence or complementary region is 24 nucleotides. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequence of any one of SEQ ID NO: 89-280, and the length of the targeting sequence or complementary region is 18 nucleotides. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequence of any one of SEQ ID NO: 89-280, and the length of the targeting sequence or complementary region is 19 nucleotides. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequence of any one of SEQ ID NO: 473-664, and the length of the targeting sequence or complementary region is 20 nucleotides.In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a sequence of any one of SEQ ID NOs: 473-664, and the length of the targeting sequence or the complementary region is 21 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a sequence of any one of SEQ ID NOs: 473-664, and the length of the targeting sequence or the complementary region is 22 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a sequence of any one of SEQ ID NOs: 473-664, and the length of the targeting sequence or the complementary region is 23 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a sequence of any one of SEQ ID NOs: 473-664, and the length of the targeting sequence or the complementary region is 24 nucleotides.
[0170] In some embodiments, the oligonucleotides herein comprise a targeting sequence or a complementary region that is fully complementary to a STAT3 target sequence (e.g., an antisense strand or a guide strand of a double-stranded oligonucleotide). In some embodiments, the targeting sequence or the complementary region is partially complementary to a STAT3 target sequence. In some embodiments, the oligonucleotides comprise a targeting sequence or a complementary region that is fully complementary to a sequence of STAT3 or STAT3. In some embodiments, the oligonucleotides comprise a targeting sequence or a complementary region that is partially complementary to a sequence of STAT3 or STAT3.
[0171] In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is fully complementary to a sequence of any one of SEQ ID NOs: 89-280. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is fully complementary to a sequence shown in SEQ ID NOs: 108, 140, 141, and 147. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is partially complementary to a sequence of any one of SEQ ID NOs: 89-280. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is partially complementary to a sequence shown in SEQ ID NOs: 108, 140, 141, and 147.
[0172] In some embodiments, the oligonucleotide herein comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence constituting STAT3 mRNA, wherein the length of the continuous nucleotide sequence is about 12 to about 30 nucleotides (e.g., 12 to 30, 12 to 28, 12 to 26, 12 to 24, 12 to 20, 12 to 18, 12 to 16, 14 to 22, 16 to 20, 18 to 20 or 18 to 19 nucleotides in length). In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence constituting STAT3 mRNA, wherein the length of the continuous nucleotide sequence is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence constituting STAT3 mRNA, wherein the length of the continuous nucleotide sequence is 19 nucleotides.
[0173] In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise a targeting sequence or a complementary region complementary to a continuous nucleotide sequence of any one of SEQ ID NOs: 89-280, optionally wherein the length of the continuous nucleotide sequence is 19 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence of any one of SEQ ID NOs: 108, 140, 141, and 147, wherein the length of the continuous nucleotide sequence is 19 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence of any one of SEQ ID NOs: 473-664, wherein the length of the continuous nucleotide sequence is 20 nucleotides. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region complementary to a continuous nucleotide sequence of any one of SEQ ID NOs: 492, 524, 525, and 531, wherein the length of the continuous nucleotide sequence is 20 nucleotides.
[0174] In some embodiments, the targeting sequence or complementary region of the oligonucleotide complementary to the continuous nucleotides of STAT3 or STAT3 target sequence spans the entire length of the antisense strand. In some embodiments, the complementary region of the oligonucleotide complementary to the continuous nucleotides of STAT3 or STAT3 target sequence spans a part of the entire length of the antisense strand. In some embodiments, the oligonucleotide herein includes a complementary region (e.g., on the antisense strand of dsRNA), which is at least partially (e.g., completely) complementary to the continuous nucleotide segment of nucleotide 1-20 of the target sequence spanning STAT3 or STAT3.
[0175] In some embodiments, the targeting sequence or complementary region of the oligonucleotides (e.g., RNAi oligonucleotides) herein is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 89-280 and spans the entire length of the antisense strand. In some embodiments, the targeting sequence or complementary region of the oligonucleotide is complementary to a contiguous nucleotide sequence of SEQ ID NOs: 89-280 and spans a portion of the entire length of the antisense strand. In some embodiments, the oligonucleotides (e.g., RNAi oligonucleotides) herein comprise a complementary region (e.g., on the antisense strand of the dsRNA) that is at least partially (e.g., completely) complementary to a contiguous stretch of nucleotides 1-19 or 1-20 spanning the sequence set forth in any one of SEQ ID NOs: 473-664.
[0176] In some embodiments, the oligonucleotides herein include a targeting sequence or complementary region with one or more bp mismatches with the corresponding STAT3 target sequence. In some embodiments, the targeting sequence or complementary region may have up to about 1, up to about 2, up to about 3, up to about 4, up to about 5, etc. mismatches with the corresponding STAT3 target sequence, provided that the targeting sequence or complementary region binds to or anneals with STAT3 mRNA under appropriate hybridization conditions and / or the ability of the oligonucleotide to inhibit STAT3 expression is maintained. Alternatively, the targeting sequence or complementary region may have no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 mismatches with the corresponding STAT3 target sequence, provided that the targeting sequence or complementary region binds to or anneals with STAT3 mRNA under appropriate hybridization conditions and / or the ability of the oligonucleotide to inhibit STAT3 expression is maintained. In some embodiments, the oligonucleotide includes a targeting sequence or complementary region with 1 mismatch with the corresponding target sequence. In some embodiments, the oligonucleotide includes a targeting sequence or complementary region with 2 mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or complementary region with 3 mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or complementary region with 4 mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or complementary region with 5 mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or complementary region with more than one mismatch (e.g., 2, 3, 4, 5 or more mismatches) with the corresponding target sequence, wherein at least 2 (e.g., all) mismatches are continuously located (e.g., continuous 2, 3, 4, 5 or more mismatches), or wherein the mismatches are spread throughout the targeting sequence or complementary region. In some embodiments, the oligonucleotide comprises a targeting sequence or complementary region complementary to a continuous nucleotide sequence of any one of SEQ ID NO: 89-280, wherein the targeting sequence or complementary region may have up to about 1, up to about 2, up to about 3, up to about 4, up to about 5, etc. mismatches with the corresponding STAT3 target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 89-280, wherein the targeting sequence or the complementary region may have no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 mismatches with the corresponding STAT3 target sequence. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 108, 140, 141, and 147, wherein the targeting sequence or the complementary region may have at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, etc. mismatches with the corresponding STAT3 target sequence.In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 108, 140, 141, and 147, wherein the targeting sequence or the complementary region may have no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 mismatches with the corresponding STAT3 target sequence. Types of Oligonucleotides
[0177] A variety of oligonucleotide types and / or structures can be used to target a target sequence in the methods herein, including but not limited to RNAi oligonucleotides, antisense oligonucleotides, miRNA, etc. Any oligonucleotide type described herein or elsewhere is contemplated for use as a framework to incorporate a targeting sequence herein.
[0178] In some embodiments, the oligonucleotides herein inhibit the expression of the target sequence by adding RNA interference (RNAi) pathways upstream or downstream of the Dicer. For example, RNAi oligonucleotides have been developed, each of which has a size of about 19-25 nucleotides and has at least one 3' overhang of 1 to 5 nucleotides (see, e.g., U.S. Patent No. 8,372,968). Longer oligonucleotides have also been developed, which are processed by Dicer to generate active RNAi products (see, e.g., U.S. Patent No. 8,883,996). Further work has produced extended dsRNA, wherein at least one end of at least one chain extends beyond the duplex targeting region, including a structure in which one chain comprises a thermodynamically stable tetracyclic structure (see, e.g., U.S. Patent Nos. 8,513,207 and 8,927,705, and International Patent Application No. WO2010 / 033225). Such structures may include single-strand extensions (on one side or both sides of the molecule) and double-strand extensions.
[0179] In some embodiments, the oligonucleotides herein are added to RNAi pathways downstream of the participation of a digester (e.g., digester cutting). In some embodiments, the oligonucleotides described herein are digester substrates. In some embodiments, after endogenous digester processing, a double-stranded nucleic acid of 19-23 nucleotides in length capable of reducing target mRNA expression is produced. In some embodiments, the oligonucleotide has an overhang (e.g., 1, 2, or 3 nucleotides in length) at the 3' end of the sense strand. In some embodiments, the oligonucleotide (e.g., siRNA) comprises a guide strand of 21 nucleotides that are antisense to the target RNA and a complementary passenger strand, wherein the two strands anneal to form a 19-bp duplex and an overhang of 2 nucleotides at either or both 3' ends. Longer oligonucleotide designs can also be used, including oligonucleotides with a 23 nucleotide guide strand and a 21 nucleotide passenger strand, with a blunt end on the right side of the molecule (3' end of the passenger strand / 5' end of the guide strand) and a two nucleotide 3'-guide strand overhang on the left side of the molecule (5' end of the passenger strand / 3' end of the guide strand). In such molecules, there is a 21 bp duplex region. See, e.g., U.S. Pat. Nos. 9,012,138, 9,012,621, and 9,193,753.
[0180] In some embodiments, the oligonucleotides herein include sense strands and antisense strands in the range of about 17 to 26 (e.g., 17 to 26, 20 to 25, or 21-23) nucleotides in length. In some embodiments, the oligonucleotides herein include sense strands and antisense strands in the range of about 17 to 36 (e.g., 17 to 36, 20 to 25, or 21-23) nucleotides in length. In some embodiments, the oligonucleotides described herein include antisense strands of 19-30 nucleotides in length and sense strands of 19-50 nucleotides in length, wherein the antisense strand and the sense strand are separate strands that form an asymmetric duplex region with an overhang of 1-4 nucleotides at the 3' end of the antisense strand. In some embodiments, the oligonucleotides herein include sense strands and antisense strands in the range of about 19-22 nucleotides in length. In some embodiments, the sense strand and the antisense strand are equal in length. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, such that there is a 3'-overhang on the sense strand or the antisense strand, or on both the sense strand and the antisense strand. In some embodiments, for oligonucleotides having a sense strand and an antisense strand each having a length within the range of about 21-23 nucleotides, the length of the 3' overhang on the sense strand, the antisense strand, or both the sense strand and the antisense strand is 1 or 2 nucleotides. In some embodiments, the oligonucleotide has a guide strand of 22 nucleotides and a passenger strand of 20 nucleotides, wherein there is a flat end on the right side of the molecule (3' end of the passenger strand / 5' end of the guide strand), and there is a 3'-guide strand overhang of 2 nucleotides on the left side of the molecule (5' end of the passenger strand / 3' end of the guide strand). In such molecules, there is a 20bp duplex region.
[0181] Other oligonucleotide designs for use with the compositions and methods herein include: 16-mer siRNAs (see, e.g., NUCLEIC ACIDS IN CHEMISTRY AND BIOLOGY, Blackburn (ed.), Royal Society of Chemistry, 2006), shRNAs (e.g., having a stem of 19 bp or less; see, e.g., Moore et al. (2010) METHODS MOL. BIOL. 629: 141-58), blunt-ended siRNAs (e.g., 19 bp in length; see, e.g., Kraynack and Baker (2006) RNA 12:163-76), asymmetric siRNA (aiRNA; see, e.g., Sun et al. (2008) Nat. Biotechnol. 26:1379-82), asymmetric shorter duplex siRNA (see, e.g., Chang et al. (2009) Mol. Ther. 17:725-32), fork siRNA (see, e.g., Hohjoh (2004) FEBS Lett. 557:193-98), single-stranded siRNA (Elsner (2012) Nat. Biotechnol. 30:1063), dumbbell-shaped circular siRNA (see, e.g., Abe et al. (2007) J. Am. Chem. Soc. 129:15108-09), and small internal segmented interfering RNA (siRNA; see, e.g., Bramsen et al. (2007) Nucleic Acids Res. 35:5886-97). Other non-limiting examples of oligonucleotide structures that can be used in some embodiments to reduce or inhibit STAT3 expression are microRNA (miRNA), short hairpin RNA (shRNA), and short siRNA (see, e.g., Hamilton et al. (2002) EMBO J. 21:4671-79; see also U.S. Patent Application Publication No. 2009 / 0099115).
[0182] In addition, in some embodiments, the oligonucleotides used to reduce or inhibit the expression of the target sequence herein are single-stranded. Such structures may include, but are not limited to, single-stranded RNAi molecules. Recent efforts have demonstrated the activity of single-stranded RNAi molecules (see, e.g., Matsui et al., (2016) MOL. THER. 24: 946-55). However, in some embodiments, the oligonucleotides herein are antisense oligonucleotides (ASOs). Antisense oligonucleotides are single-stranded oligonucleotides with a core base sequence, which, when written in a 5' to 3' direction, comprises a reverse complementary sequence of the targeted segment of a specific nucleic acid and is appropriately modified (e.g., as a gapmer) to induce RNase H-mediated cutting of its target RNA in a cell, or (e.g., as a mixer) to inhibit translation of target mRNA in a cell. ASOs for use herein can be modified in any suitable manner known in the art, including, for example, as shown in U.S. Pat. No. 9,567,587 (including, for example, length, sugar moieties of nucleobases (pyrimidines, purines), and changes in heterocyclic moieties of nucleobases). In addition, ASOs have been used to reduce the expression of specific target genes for decades (see, for example, Bennett et al., (2017) ANNU. REV. PHARMACOL. 57: 81-105).
[0183] In some embodiments, the antisense oligonucleotide shares a complementary region with the target mRNA. In some embodiments, the antisense oligonucleotide has a length of 15-50 nucleotides. In some embodiments, the antisense oligonucleotide has a length of 15-25 nucleotides. In some embodiments, the antisense oligonucleotide has a length of 22 nucleotides. In some embodiments, the antisense oligonucleotide has a length of at least 15 continuous nucleotides. In some embodiments, the antisense oligonucleotide has a length of at least 19 continuous nucleotides. In some embodiments, the antisense oligonucleotide has a length of at least 20 continuous nucleotides. In some embodiments, the antisense oligonucleotide has 1, 2 or 3 nucleotides different from the target sequence. Double-stranded oligonucleotide
[0184] In some embodiments, the present disclosure provides a double-stranded dsRNA for targeting and inhibiting the expression of a target sequence (e.g., via an RNAi approach), comprising a sense strand (also referred to herein as a passenger strand) and an antisense strand (also referred to herein as a guide strand). In some embodiments, the sense strand and the antisense strand are separate strands and are not covalently linked. In some embodiments, the sense strand and the antisense strand are covalently linked. In some embodiments, the sense strand and the antisense strand form a duplex region, wherein the sense strand and the antisense strand, or portions thereof, bind to each other in a complementary manner (e.g., by Watson-Crick base pairing).
[0185] In some embodiments, the sense strand has a first region (R1) and a second region (R2), wherein R2 comprises a first subregion (S1), a loop (L) such as a tetraloop (tetraL) or a triloop (triL), and a second subregion (S2), wherein L, tetraL or triL is located between S1 and S2, and wherein S1 and S2 form a second duplex (D2). D2 may have different lengths. In some embodiments, the length of D2 is about 1-6 bp. In some embodiments, the length of D2 is 2-6, 3-6, 4-6, 5-6, 1-5, 2-5, 3-5 or 4-5 bp. In some embodiments, the length of D2 is 1, 2, 3, 4, 5 or 6 bp. In some embodiments, the length of D2 is 6 bp.
[0186] In some embodiments, R1 of the sense strand and the antisense strand form a first duplex (D1). In some embodiments, the length of D1 is at least about 15 (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21) nucleotides. In some embodiments, the length of D1 is in the range of about 12 to 30 nucleotides (e.g., 12 to 30, 12 to 27, 15 to 22, 18 to 22, 18 to 25, 18 to 27, 18 to 30, or 21 to 30 nucleotides in length). In some embodiments, the length of D1 is at least 12 nucleotides (e.g., at least 12, at least 15, at least 20, at least 25, or at least 30 nucleotides in length). In some embodiments, D1 is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length. In some embodiments, D1 is 20 nucleotides in length. In some embodiments, D1 comprising a sense strand and an antisense strand does not span the entire length of the sense strand and / or antisense strand. In some embodiments, D1 comprising a sense strand and an antisense strand spans the entire length of the sense strand or the antisense strand or both. In certain embodiments, D1 comprising a sense strand and an antisense strand spans the entire length of both the sense strand and the antisense strand.
[0187] It should be understood that in some embodiments, the sequences presented in the sequence listing may be referred to when describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides (e.g., RNA counterparts of DNA nucleotides or DNA counterparts of RNA nucleotides) and / or one or more modified nucleotides and / or one or more modified internucleotide linkages and / or one or more other modifications compared to the specified sequence, while still retaining complementary properties that are substantially identical or similar to the specified sequence.
[0188] In some embodiments, the double-stranded RNA (dsRNA) herein comprises a sense strand of 25 nucleotides and an antisense strand of 27 nucleotides, which, when subjected to the action of a cutting enzyme, produces an antisense strand that is incorporated into mature RISC. In some embodiments, the sense strand of the dsRNA is longer than 27 nucleotides (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides). In some embodiments, the sense strand of the dsRNA is longer than 27 nucleotides (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides). In some embodiments, the sense strand of the dsRNA is longer than 25 nucleotides (e.g., 26, 27, 28, 29, or 30 nucleotides).
[0189] In some embodiments, the oligonucleotide herein has a 5' end with poor thermodynamic stability compared to another 5' end. In some embodiments, an asymmetric oligonucleotide is provided, which includes a flat end at the 3' end of the sense strand and includes a 3'-overhang at the 3' end of the antisense strand. In some embodiments, the length of the 3'-overhang on the antisense strand is about 1-8 nucleotides (for example, a length of 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides). Typically, the oligonucleotide for RNAi has an overhang of two nucleotides at the 3' end of the antisense (guide) strand. However, other overhangs are also possible. In some embodiments, the overhang is a 3'-overhang comprising 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or 1, 2, 3, 4, 5 or 6 nucleotides in length. However, in some embodiments, the overhang is a 5'-overhang comprising 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or a length of 1, 2, 3, 4, 5, or 6 nucleotides.
[0190] In some embodiments, the two terminal nucleotides on the 3' end of the antisense strand are modified. In some embodiments, the two terminal nucleotides on the 3' end of the antisense strand are complementary to the target mRNA. In some embodiments, the two terminal nucleotides on the 3' end of the antisense strand are not complementary to the target mRNA. In some embodiments, the two terminal nucleotides on the 3' end of the antisense strand of the oligonucleotide herein include unpaired GG. In some embodiments, the two (2) terminal nucleotides on the 3' end of the antisense strand of the oligonucleotide herein are not complementary to the target mRNA. In some embodiments, the two terminal nucleotides on each 3' end of the oligonucleotide in the gapped tetracyclic structure are GG. In some embodiments, one or both of the two (2) terminal GG nucleotides on each 3' end of the oligonucleotide herein are not complementary to the target mRNA. Typically, one or both of the two terminal GG nucleotides on each 3' end of the oligonucleotide are not complementary to the target.
[0191] In some embodiments, there are one or more (e.g., 1, 2, 3, 4, or 5) mismatches between the sense strand and the antisense strand. If there are more than one mismatch between the sense strand and the antisense strand, they can be positioned consecutively (e.g., 2, 3, or more consecutively), or scattered throughout the complementary region. In some embodiments, the 3' end of the sense strand contains one or more mismatches. In one embodiment, two mismatches are incorporated at the 3' end of the sense strand. In some embodiments, base mismatches or segment destabilization at the 3' end of the sense strand of the oligonucleotide improves the effectiveness of synthesizing duplexes in RNAi, which may be achieved by promoting the processing of the enzyme. a. Antisense strand
[0192] In some embodiments, the dsRNA comprises an antisense strand of up to about 40 nucleotides in length (e.g., up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise an antisense strand of up to about 50 nucleotides in length (e.g., up to 50, up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotides may have an antisense strand of at least about 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 22, at least 25, at least 27, at least 30, at least 35, or at least 38 nucleotides in length). In some embodiments, an oligonucleotide may have an antisense strand ranging from about 12 to about 40 (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 22, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40) nucleotides in length. In some embodiments, the oligonucleotide comprises an antisense strand that is 15 to 30 nucleotides in length. In some embodiments, the oligonucleotides may have a length of 12, 13, 14, 15, 16, The antisense strand has 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides.
[0193] In some embodiments, the antisense strand of an oligonucleotide may be referred to as a "guide strand". For example, if the antisense strand is capable of engaging with an RNA-induced silencing complex (RISC) and binding to an Argonaute protein such as Ago2, or engaging or binding to one or more similar factors, and guiding the silencing of a target gene, it may be referred to as a guide strand. In some embodiments, the sense strand complementary to the guide strand may be referred to as a "passenger strand".
[0194] In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising a sequence as shown in any one of SEQ ID NOs: 281-472 or consisting of a sequence as shown in any one of SEQ ID NOs: 281-472. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 281-472. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 (e.g., RNAi oligonucleotides) comprise an antisense strand comprising a sequence as shown in any one of SEQ ID NOs: 665-856 or consisting of a sequence as shown in any one of SEQ ID NOs: 665-856. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 665-856. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 947-1036. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 947-1036. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 10, 38, 66, and 70. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 10, 38, 66, and 70.In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as shown in any one of SEQ ID NOs: 281-472. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 281-472. In some embodiments, an oligonucleotide for targeting STAT3 disclosed herein comprises an antisense strand comprising or consisting of a sequence as shown in any one of SEQ ID NOs: 952, 965, 966, and 1010. In some embodiments, an oligonucleotide herein comprises an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 952, 965, 966, and 1010. In some embodiments, an oligonucleotide for targeting STAT3 disclosed herein comprises an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 991, 1000, 989, 986, 982, 980, and 979. In some embodiments, an oligonucleotide herein comprises an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 991, 1000, 989, 986, 982, 980, and 979. In some embodiments, an oligonucleotide for targeting STAT3 disclosed herein comprises an antisense strand comprising or consisting of a sequence as shown in any one of SEQ ID NOs: 1030, 1027, and 1029.In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 1030, 1027, and 1029. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 1005, 1014, 1003, and 1010. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 1005, 1014, 1003, and 1010.
[0195] b. Sense strand
[0196] In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression (e.g., RNAi oligonucleotides) include a sense strand sequence as shown in any one of SEQ ID NOs: 89-280. In some embodiments, the oligonucleotides herein have a sense strand comprising at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 89-280. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression (e.g., RNAi oligonucleotides) include a sense strand sequence as shown in any one of SEQ ID NOs: 473-664. In some embodiments, the oligonucleotides herein have a sense strand comprising at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 473-664. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression comprise a sense strand sequence as set forth in any one of SEQ ID NOs: 857-946. In some embodiments, the oligonucleotides herein have a sense strand consisting of at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 857-946. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression comprise a sense strand sequence as shown in any one of SEQ ID NOs: 9, 37, 65, and 69. In some embodiments, the oligonucleotides herein have a sense strand consisting of at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 9, 37, 65, and 69. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression comprise a sense strand sequence as set forth in any one of SEQ ID NOs: 862, 875, 876, and 920.In some embodiments, the oligonucleotides herein have a sense strand comprising at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 862, 875, 876, and 920. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 mRNA and inhibiting STAT3 expression comprise a sense strand sequence as set forth in any one of SEQ ID NOs: 901, 910, 899, 896, 892, 890, and 889. In some embodiments, the oligonucleotides herein have a sense strand comprising at least about 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 901, 910, 899, 896, 892, 890, and 889. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 940, 937, and 939. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as set forth in any one of SEQ ID NOs: 940, 937, and 939. In some embodiments, the oligonucleotides disclosed herein for targeting STAT3 comprise an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 915, 924, 913, and 920. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising at least about 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) consecutive nucleotides of a sequence as shown in any one of SEQ ID NOs: 915, 924, 913, and 920.
[0197] In some embodiments, the oligonucleotide comprises a sense strand (or passenger strand) of up to about 40 nucleotides in length (e.g., up to 40, up to 36, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotide may have a sense strand of at least about 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 25, at least 27, at least 30, at least 36, or at least 38 nucleotides in length). In some embodiments, the oligonucleotides may have a sense strand ranging from about 12 to about 40 (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 21, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40) nucleotides in length. In some embodiments, the oligonucleotides herein comprise a sense strand of 15 to 50 nucleotides in length. In some embodiments, the oligonucleotides herein comprise a sense strand of 18 to 36 nucleotides in length. In some embodiments, the oligonucleotide may have a sense strand that is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length. In some embodiments, the oligonucleotide comprises a sense strand that is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the oligonucleotides herein comprise a sense strand that is 36 nucleotides in length.
[0198] In some embodiments, the oligonucleotides provided herein (e.g., RNAi oligonucleotides) include a sense strand, comprising a stem-loop structure at the 3' end of the sense strand. In some embodiments, the stem-loop is formed by intrachain base pairing. In some embodiments, the sense strand comprises a stem-loop structure at its 5' end. In some embodiments, the stem of the stem-loop comprises a duplex of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 2 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 3 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 4 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 5 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 6 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 7 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 8 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 9 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 10 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 11 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 12 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 13 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a duplex of 14 nucleotides in length.
[0199] In some embodiments, the stem-loop provides protection of the oligonucleotide from degradation (e.g., enzymatic degradation), promotes or improves targeting and / or delivery to a target cell, tissue, or organ (e.g., liver), or both. For example, in some embodiments, the ring of the stem-loop is composed of nucleotides comprising one or more modifications, which promote, improve, or increase targeting to a target, inhibition of target gene expression, and / or delivery, uptake, and / or penetration into a target cell, tissue, or organ (e.g., liver), or a combination thereof. In some embodiments, the stem-loop itself or modifications to the stem-loop do not affect or substantially do not affect the intrinsic gene expression inhibition activity of the oligonucleotide, but promote, improve, or increase the stability of the oligonucleotide (e.g., providing protection against degradation) and / or its delivery, uptake, and / or penetration into a target cell, tissue, or organ. In certain embodiments, the oligonucleotides herein comprise a sense strand comprising (e.g., at its 3' end) a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a single-stranded loop of connected nucleotides of up to about 10 nucleotides in length (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length) between S1 and S2. In some embodiments, the length of the loop (L) is 3 nucleotides (referred to herein as a "three-loop"). In some embodiments, the length of the loop (L) is 4 nucleotides (referred to herein as a "four-loop"). In some embodiments, the length of the loop (L) is 5 nucleotides. In some embodiments, the length of the loop (L) is 6 nucleotides. In some embodiments, the length of the loop (L) is 7 nucleotides. In some embodiments, the length of the loop (L) is 8 nucleotides. In some embodiments, the length of the loop (L) is 9 nucleotides. In some embodiments, the length of the loop (L) is 10 nucleotides.
[0200] In some embodiments, the oligonucleotides provided herein (e.g., RNAi oligonucleotides) comprise a targeting sequence or a complementary region that is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 89-280, and the oligonucleotide comprises a sense strand that comprises (e.g., at its 3' end) a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a single-stranded loop of up to about 10 nucleotides (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length) between S1 and S2. In some embodiments, the oligonucleotide comprises a targeting sequence or a complementary region that is complementary to a contiguous nucleotide sequence of any one of SEQ ID NOs: 89-280, and the oligonucleotide comprises a sense strand that comprises (e.g., at its 3' end) a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a single-stranded loop of 4 nucleotides in length between S1 and S2.
[0201] In some embodiments, the tetraloop comprises the sequence 5'-GAAA-3'.In some embodiments, the stem-loop comprises the sequence 5'-GCAGCCGAAAGGCUGC-3' (SEQ ID NO: 86).
[0202] In some embodiments, the sense strand comprises a stem-loop structure at its 3' end. In some embodiments, the sense strand comprises a stem-loop structure at its 5' end. In some embodiments, the stem is a duplex of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 bp in length. In some embodiments, the stem-loop provides protection of the molecule from degradation (e.g., enzymatic degradation) and promotes the targeting properties of delivery to target cells. For example, in some embodiments, the loop provides added nucleotides, which can be modified thereon without substantially affecting the gene expression inhibition activity of the oligonucleotide. In certain embodiments, oligonucleotides are provided herein, wherein the sense strand comprises (e.g., at its 3' end) a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop of up to about 10 nucleotides (e.g., 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides in length) between S1 and S2. Figure 1A Non-limiting examples of such oligonucleotides are depicted.
[0203] In some embodiments, the ring (L) of the stem-ring with structure S1-L-S2 as described herein is a tricyclic ring. In some embodiments, the tricyclic ring comprises ribonucleotides, deoxyribonucleotides, modified nucleotides, ligands (e.g., delivery ligands) and combinations thereof.
[0204] In some embodiments, the ring of the stem-loop is a tetraloop (e.g., within a gapped tetraloop structure). The tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Typically, the tetraloop has 4 to 5 nucleotides. Duplex length
[0205] In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is at least 12 (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21) nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length). In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 12, 13, 14, 15, 16, 17, 18, 19, 29, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 12 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 13 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 14 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 15 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 16 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 17 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 18 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 19 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 20 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 21 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 22 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 23 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 24 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 25 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 26 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 27 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 28 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 29 nucleotides. In some embodiments, the length of the duplex formed between the sense strand and the antisense strand is 30 nucleotides.In some embodiments, the duplex formed between the sense strand and the antisense strand does not span the entire length of the sense strand and / or the antisense strand. In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of the sense strand or the antisense strand. In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand.
[0206] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 861 and 951, respectively; (b) SEQ ID NOs: 857 and 947, respectively; (c) SEQ ID NOs: 858 and 948, respectively; (d) SEQ ID NOs: 859 and 949, respectively; (e) SEQ ID NOs: 860 and 950, respectively; (f) SEQ ID NOs: 862 and 952, respectively; (g) SEQ ID NOs: 863 and 953, respectively; (h) SEQ ID NOs: 864 and 954, respectively; (i) SEQ ID NOs: 865 and 955, respectively; (j) SEQ ID NOs: 866 and 956, respectively; (k) SEQ ID NOs: 867 and 957, respectively; (1) SEQ ID NO: 868 and 958, respectively; (m) are SEQ ID NOs: 869 and 959, respectively; (n) SEQ ID NO: 870 and 960, respectively; (o) SEQ ID NOs: 871 and 961, respectively; (p) SEQ ID NOs: 872 and 962, respectively; (q) SEQ ID NOs: 873 and 963, respectively; (r) SEQ ID NOs: 874 and 964, respectively; (s) are SEQ ID NOs: 875 and 965, respectively; (t) SEQ ID NOs: 876 and 966, respectively; (u) SEQ ID NOs: 877 and 967, respectively; (v) SEQ ID NOs: 878 and 968, respectively; (w) SEQ ID NOs: 879 and 969, respectively; (x) are SEQ ID NOs: 880 and 970, respectively; (y) are SEQ ID NOs: 881 and 971, respectively; (z) SEQ ID NOs: 882 and 972, respectively; (aa) are SEQ ID NOs: 883 and 973, respectively; (bb) SEQ ID NOs: 884 and 974, respectively; (cc) SEQ ID NOs: 885 and 975, respectively; (dd) SEQ ID NOs: 886 and 976, respectively; (ee) are SEQ ID NOs: 887 and 977, respectively; (ff) are SEQ ID NOs: 888 and 978, respectively; (gg) SEQ ID NO: 940 and 1030, respectively; (hh) SEQ ID NOs: 896 and 986, respectively; and (ii) SEQ ID NO: 920 and 1010, respectively, wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length).
[0207] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 857 and 947, respectively; (b) SEQ ID NOs: 858 and 948, respectively; (c) SEQ ID NOs: 859 and 949, respectively; (d) SEQ ID NOs: 860 and 950, respectively; (e) SEQ ID NOs: 862 and 952, respectively; (f) SEQ ID NOs: 867 and 957, respectively; (g) SEQ ID NOs: 875 and 965, respectively; and (h) SEQ ID NO: 876 and 966, respectively, wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length).
[0208] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) are SEQ ID NOs: 69 and 70, respectively. wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length).
[0209] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively. wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length).
[0210] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NO: 939 and 1029, respectively. wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length).
[0211] In some embodiments, the duplex between the sense strand and the antisense strand spans the entire length of both the sense strand and the antisense strand. In some embodiments, the sense strand and the antisense strand of the oligonucleotide comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively. wherein the length of the duplex formed between the sense strand and the antisense strand is in the range of 12-30 nucleotides (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30, or 21 to 30 nucleotides in length). Oligonucleotide ends
[0212] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) include a sense strand and an antisense strand, wherein the end of any one or both strands includes a flat end. In some embodiments, the oligonucleotides herein include a sense strand and an antisense strand, and the sense strand and the antisense strand are separate strands that form an asymmetric duplex region with an overhang at the 3' end of the antisense strand. In some embodiments, the oligonucleotides herein include a sense strand and an antisense strand, wherein the end of any one or both strands includes an overhang containing one or more nucleotides. In some embodiments, the one or more nucleotides constituting the overhang are unpaired nucleotides. In some embodiments, the oligonucleotides herein include a sense strand and an antisense strand, wherein the 3' end of the sense strand and the 5' end of the antisense strand include a flat end. In some embodiments, the oligonucleotides herein include a sense strand and an antisense strand, wherein the 5' end of the sense strand and the 3' end of the antisense strand include a flat end.
[0213] In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 3' end of any one or both strands comprises a 3'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the sense strand comprises a 3'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the antisense strand comprises a 3'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein both the sense strand and the antisense strand comprise a 3'-overhang containing one or more nucleotides.
[0214] In some embodiments, the 3'-overhang is about one (1) to twenty (20) nucleotides in length (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 nucleotides in length). In some embodiments, the 3' overhang is about one (1) to nineteen (19), one (1) to eighteen (18), one (1) to seventeen (17), one (1) to sixteen (16), one (1) to fifteen (15), one (1) to fourteen (14), one (1) to thirteen (13), one (1) to twelve (12), one (1) to eleven (11), one (1) to ten (10), one (1) to nine (9), one (1) to eight (8), one (1) to seven (7), one (1) to six (6), one (1) to five (5), one (1) to four (4), one (1) to three (3), or about one (1) to two (2) nucleotides in length. In some embodiments, the 3'-overhang is one (1) nucleotide in length. In some embodiments, the 3'-overhang is two (2) nucleotides in length. In some embodiments, the 3'-overhang is three (3) nucleotides in length. In some embodiments, the 3'-overhang is four (4) nucleotides in length. In some embodiments, the 3'-overhang is five (5) nucleotides in length. In some embodiments, the 3'-overhang is six (6) nucleotides in length. In some embodiments, the 3'-overhang is seven (7) nucleotides in length. In some embodiments, the 3'-overhang is eight (8) nucleotides in length. In some embodiments, the 3'-overhang is nine (9) nucleotides in length. In some embodiments, the 3'-overhang is ten (10) nucleotides in length. In some embodiments, the 3'-overhang is eleven (11) nucleotides in length. In some embodiments, the 3'-overhang is twelve (12) nucleotides in length. In some embodiments, the 3'-overhang is thirteen (13) nucleotides in length. In some embodiments, the 3'-overhang is fourteen (14) nucleotides in length. In some embodiments, the 3'-overhang is fifteen (15) nucleotides in length. In some embodiments, the 3'-overhang is sixteen (16) nucleotides in length. In some embodiments, the 3'-overhang is seventeen (17) nucleotides in length. In some embodiments, the 3'-overhang is eighteen (18) nucleotides in length. In some embodiments, the 3'-overhang is nineteen (19) nucleotides in length. In some embodiments, the 3'-overhang is twenty (20) nucleotides in length.
[0215] In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 5' end of any one or both strands comprises a 5'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the sense strand comprises a 5'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the antisense strand comprises a 5'-overhang containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein both the sense strand and the antisense strand comprise a 5'-overhang containing one or more nucleotides.
[0216] In some embodiments, the 5'-overhang is about one (1) to twenty (20) nucleotides in length (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 nucleotides in length). In some embodiments, the 5' overhang is about one (1) to nineteen (19), one (1) to eighteen (18), one (1) to seventeen (17), one (1) to sixteen (16), one (1) to fifteen (15), one (1) to fourteen (14), one (1) to thirteen (13), one (1) to twelve (12), one (1) to eleven (11), one (1) to ten (10), one (1) to nine (9), one (1) to eight (8), one (1) to seven (7), one (1) to six (6), one (1) to five (5), one (1) to four (4), one (1) to three (3), or about one (1) to two (2) nucleotides in length. In some embodiments, the 5'-overhang is one (1) nucleotide in length. In some embodiments, the 5'-overhang is two (2) nucleotides in length. In some embodiments, the 5'-overhang is three (3) nucleotides in length. In some embodiments, the 5'-overhang is four (4) nucleotides in length. In some embodiments, the 5'-overhang is five (5) nucleotides in length. In some embodiments, the 5'-overhang is six (6) nucleotides in length. In some embodiments, the 5'-overhang is seven (7) nucleotides in length. In some embodiments, the 5'-overhang is eight (8) nucleotides in length. In some embodiments, the 5'-overhang is nine (9) nucleotides in length. In some embodiments, the 5'-overhang is ten (10) nucleotides in length. In some embodiments, the 5'-overhang is eleven (11) nucleotides in length. In some embodiments, the 5'-overhang is twelve (12) nucleotides in length. In some embodiments, the 5'-overhang is thirteen (13) nucleotides in length. In some embodiments, the 5'-overhang is fourteen (14) nucleotides in length. In some embodiments, the 5'-overhang is fifteen (15) nucleotides in length. In some embodiments, the 5'-overhang is sixteen (16) nucleotides in length. In some embodiments, the 5'-overhang is seventeen (17) nucleotides in length. In some embodiments, the 5'-overhang is eighteen (18) nucleotides in length. In some embodiments, the 5'-overhang is nineteen (19) nucleotides in length. In some embodiments, the 5'-overhang is twenty (20) nucleotides in length.
[0217] In some embodiments, one or more (e.g., 2, 3, 4, 5 or more) nucleotides constituting the 3' end or 5' end of the sense strand and / or antisense strand are modified. For example, in some embodiments, one or both terminal nucleotides at the 3' end of the antisense strand are modified. In some embodiments, the last nucleotide at the 3' end of the antisense strand is modified so that it comprises a 2' modification, or it comprises a 2'-O-methoxyethyl. In some embodiments, the last one or two terminal nucleotides at the 3' end of the antisense strand are complementary to the target. In some embodiments, the last one or two nucleotides at the 3' end of the antisense strand are not complementary to the target.
[0218] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) comprise a sense strand and an antisense strand, wherein the 3' end of the sense strand comprises a stem-loop as described herein, and the 3' end of the antisense strand comprises a 3'-overhang as described herein. In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise a sense strand and an antisense strand forming a gapped tetraloop structure as described herein, wherein the 3' end of the sense strand comprises a stem-loop, wherein the loop is a tetraloop as described herein, and wherein the 3' end of the antisense strand comprises a 3'-overhang as described herein. In some embodiments, the 3'-overhang is two (2) nucleotides in length. In some embodiments, both (2) nucleotides constituting the 3'-overhang comprise a guanine (G) nucleobase. Typically, one or both of the nucleotides constituting the 3'-overhang of the antisense strand are not complementary to the target. Oligonucleotide modification a. Sugar modification
[0219] In some embodiments, the modified sugar (also referred to herein as a sugar analog) includes a modified deoxyribose or ribose moiety, wherein, for example, one or more modifications occur at the 2', 3', 4' and / or 5' carbon position of the sugar. In some embodiments, the modified sugar may also include non-natural alternative carbon structures, such as those found in locked nucleic acids ("LNAs"; see, e.g., Koshkin et al., (1998) TETRAHEDON 54:3607-3630), unlocked nucleic acids ("UNAs"; see, e.g., Snead et al., (2013) MOL. THER-NUCL. ACIDS 2:e103) and bridged nucleic acids ("BNAs"; see, e.g., Imanishi and Obika (2002) CHEM COMMUN. (CAMB) 21:1653-1659).
[0220] In some embodiments, the nucleotide modification in the sugar includes a 2'-modification. In some embodiments, the 2'-modification can be 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-fluoro (2'-F), 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) or 2'-deoxy-2'-fluoro-β-d-arabinose nucleic acid (2'-FANA). In some embodiments, the modification is 2'-F, 2'-OMe or 2'-MOE. In some embodiments, the modification in the sugar includes a modification of the sugar ring, which may include a modification of one or more carbons of the sugar ring. For example, the modification of the sugar of the nucleotide can include the 2'-oxygen of the sugar being connected to the 1'-carbon or 4'-carbon of the sugar, or the 2'-oxygen being connected to the 1'-carbon or 4'-carbon via an ethylene or methylene bridge. In some embodiments, the modified nucleotide has an acyclic sugar lacking a 2'-carbon to 3'-carbon bond. In some embodiments, the modified nucleotide has a thiol group, for example, at the 4' position of the sugar.
[0221] In some embodiments, the oligonucleotides described herein comprise at least about 1 modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, or more). In some embodiments, the sense strand of the oligonucleotide comprises at least about 1 modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, or more). In some embodiments, the antisense strand of the oligonucleotide comprises at least about 1 modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, or more).
[0222] In some embodiments, all nucleotides of the sense strand of the oligonucleotide are modified. In some embodiments, all nucleotides of the antisense strand of the oligonucleotide are modified. In some embodiments, all nucleotides of the oligonucleotide (i.e., both the sense strand and the antisense strand) are modified. In some embodiments, the modified nucleotides include 2'-modifications (e.g., 2'-F or 2'-OMe, 2'-MOE and 2'-deoxy-2'-fluoro-β-d-arabinose nucleic acid). In some embodiments, the modified nucleotides include 2'-modifications (e.g., 2'-F or 2'-OMe).
[0223] In some embodiments, the present disclosure provides oligonucleotides with different modification patterns.In some embodiments, the oligonucleotides herein comprise a sense strand with a modification pattern as set forth in the Examples and Sequence Listing and an antisense strand with a modification pattern as set forth in the Examples and Sequence Listing.
[0224] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) comprise an antisense strand having nucleotides modified by 2'-F. In some embodiments, the oligonucleotides herein comprise an antisense strand comprising nucleotides modified by 2'-F and 2'-OMe. In some embodiments, the oligonucleotides disclosed herein comprise a sense strand having nucleotides modified by 2'-F. In some embodiments, the oligonucleotides disclosed herein comprise a sense strand comprising nucleotides modified by 2'-F and 2'-OMe.
[0225] In some embodiments, the oligonucleotides described herein comprise a sense strand, and about 10-15%, 10%, 11%, 12%, 13%, 14%, or 15% of the nucleotides of the sense strand comprise a 2'-fluoro modification. In some embodiments, about 11% of the nucleotides of the sense strand comprise a 2-fluoro modification. In some embodiments, the oligonucleotides described herein comprise an antisense strand, and about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% of the nucleotides of the antisense strand comprise a 2'-fluoro modification. In some embodiments, about 32% of the nucleotides of the antisense strand comprise a 2'-fluoro modification. In some embodiments, about 15-25%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of the nucleotides of the oligonucleotide comprise a 2'-fluoro modification. In some embodiments, about 19% of the nucleotides in the dsRNAi oligonucleotide comprise a 2'-fluoro modification.
[0226] In some embodiments, the modified oligonucleotide comprises Figure 1A or the sense strand sequence of the modification pattern described in Example 7 and having Figure 1A or the antisense strand with the modification pattern described in Example 7. In some embodiments, for these oligonucleotides, one or more of positions 8, 9, 10, or 11 of the sense strand is modified with a 2'-F group. In other embodiments, for these oligonucleotides, the sugar moiety at each of the nucleotides at positions 1-7 and 12-20 in the sense strand is modified with 2'-OMe.
[0227] In some embodiments, the antisense strand has 3 nucleotides modified with 2'-F at the 2'-position of the sugar moiety. In some embodiments, the sugar moieties at positions 2, 5, and 14 of the antisense strand, and optionally at most 1 nucleotide at positions 3, 3, 7, and 10, are modified with 2'-F. In some embodiments, the sugar moieties at positions 2, 5, and 14 of the antisense strand, and optionally at most 3 nucleotides at positions 3, 4, 7, and 10, are modified with 2'-F. In other embodiments, the sugar moieties at each of positions 2, 5, and 14 of the antisense strand are modified with 2'-F. In other embodiments, the sugar moieties at each of positions 1, 2, 5, and 14 of the antisense strand are modified with 2'-F. In other embodiments, the sugar moieties at each of positions 2, 4, 5, and 14 of the antisense strand are modified with 2'-F. In still other embodiments, the sugar moieties at each of positions 1, 2, 3, 5, 7, and 14 of the antisense strand are modified with 2'-F. In other embodiments, the sugar moiety at each of positions 2, 3, 4, 5, 7, and 14 of the antisense strand is modified with 2'-F. In yet another embodiment, the sugar moiety at each of positions 1, 2, 3, 5, 10, and 14 of the antisense strand is modified with 2'-F. In other embodiments, the sugar moiety at each of positions 2, 3, 4, 5, 10, and 14 of the antisense strand is modified with 2'-F. In another embodiment, the sugar moiety at each of positions 2, 3, 5, 7, 10, and 14 of the antisense strand is modified with 2'-F. In yet another embodiment, the sugar moiety at each of positions 2, 3, 4, 5, 7, 10, and 14 of the antisense strand is modified with 2'-F.
[0228] In some embodiments, the oligonucleotides provided herein comprise an antisense strand in which the sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 is modified with 2'-F.
[0229] In some embodiments, the oligonucleotides provided herein comprise an antisense strand, wherein the sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 of the antisense strand is modified with 2'-OMe.
[0230] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabino nucleic acid (2'-FANA).
[0231] In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moieties at positions 8-11 of the sense strand are modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moieties at positions 3, 8, 9, 10, 12, 13, and 17 of the sense strand are modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moieties at positions 1-7 and 12-17 or 12-20 of the sense strand are modified with 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moieties at positions 1-7, 12-27, and 31-36 of the sense strand are modified with 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moiety of each nucleotide at positions 1-7 and 12-17 or 12-20 of the sense strand is modified by a modification selected from 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabino nucleic acid (2'-FANA). In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moieties at positions 1-2, 4-7, 11, 14-16 and 18-20 of the sense strand are modified by 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand, the sugar moiety of each nucleotide at positions 1-2, 4-7, 11, 14-16, and 18-20 of the sense strand being modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabino nucleic acid (2'-FANA).
[0232] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, position 22, position 23, position 24, position 25, position 26, position 27, position 28, position 29, position 30, position 31, position 32, position 33, position 34, position 35, or position 36 of the sense strand that is modified with 2'-F.
[0233] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, position 22, position 23, position 24, position 25, position 26, position 27, position 28, position 29, position 30, position 31, position 32, position 33, position 34, position 35, or position 36 of the sense strand modified with 2'-OMe.
[0234] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sense strand having a position 1, a position 2, a position 3, a position 4, a position 5, a position 6, a position 7, a position 8, a position 9, a position 10, a position 11, a position 12, a position 13, a position 14, a position 15, a position 16, a position 17, a position 18, a position 19, a position 20, a position 21, a position 22, a position 23, a position 24, a position 25, a position 26, a position 27, a position 28, a position 29, a position 30, a position 31, a position 32 The sugar moiety at position 32, position 33, position 34, position 35 or position 36 is modified with a modification selected from 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabino nucleic acid (2'-FANA). b. 5' terminal phosphate
[0235] In some embodiments, the 5'-terminal phosphate group of the oligonucleotide enhances the interaction with Ago2. However, oligonucleotides comprising 5'-phosphate groups may be easily degraded via phosphatases or other enzymes, which may limit their bioavailability in vivo. In some embodiments, oligonucleotides include 5' phosphate analogs resistant to such degradation. In some embodiments, the phosphate analogs may be oxymethylphosphonates, vinylphosphonates or malonylphosphonates. In certain embodiments, the 1' end of the oligonucleotide chain is attached to a chemical moiety ("phosphate mimic") that simulates the electrostatic properties and spatial properties of a natural 5'-phosphate group.
[0236] In some embodiments, the oligonucleotide has a phosphate analog (referred to as a "4'-phosphate analog") at the 4'-carbon position of the sugar. See, for example, International Patent Application Publication No. WO 2018 / 045317. In some embodiments, the oligonucleotide herein comprises a 4'-phosphate analog at the 5'-terminal nucleotide. In some embodiments, the phosphate analog is an oxymethylphosphonate, wherein the oxygen atom of the oxymethyl group is bound to a sugar moiety (e.g., at its 4'-carbon) or an analog thereof. In other embodiments, the 4'-phosphate analog is a thiomethylphosphonate or an aminomethylphosphonate, wherein the sulfur atom of the thiomethyl group or the nitrogen atom of the aminomethyl group is bound to the 4'-carbon of a sugar moiety or its analog. In certain embodiments, the 4'-phosphate analog is an oxymethylphosphonate. In some embodiments, the oxymethylphosphonate is represented by the formula -O-CH2-PO(OH)2 or -O-CH2-PO(OR)2, wherein R is independently selected from H, CH3, alkyl, CH2CH2CN, CH2OCOC(CH3)3, CH2OCH2CH2Si(CH3)3 or a protecting group. In certain embodiments, the alkyl is CH2CH3. More typically, R is independently selected from H, CH3 or CH2CH3.
[0237] In some embodiments, the oligonucleotides provided herein comprise an antisense strand comprising a 4'-phosphate analog at the 5'-terminal nucleotide, wherein the 5'-terminal nucleotide comprises the following structure (Formula 1): 4'-O-monomethylphosphonate-2'-O-methyluridine phosphorothioate [MePhosphonate-4O-mUs]. Chemical formula 1 c. Modified internucleotide linkages
[0238] In some embodiments, the oligonucleotide may comprise a modified internucleoside linkage. In some embodiments, phosphate modification or substitution may produce an oligonucleotide comprising at least about 1 (e.g., at least 1, at least 2, at least 3, or at least 5) modified internucleotide linkages. In some embodiments, any oligonucleotide disclosed herein comprises about 1 to about 10 (e.g., 1 to 10, 2 to 8, 4 to 6, 3 to 10, 5 to 10, 1 to 5, 1 to 3, or 1 to 2) modified internucleotide linkages. In some embodiments, any oligonucleotide disclosed herein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modified internucleotide linkages.
[0239] The modified internucleotide linkage can be a phosphorodithioate linkage, a 4'-O-methylenephosphonate linkage, a phosphorothioate linkage, a phosphotriester linkage, a thioalkylphosphonate linkage, a thioalkylphosphotriester linkage, a phosphoramidite linkage, a phosphonate linkage, or a boranophosphate linkage. In some embodiments, at least one modified internucleotide linkage of any of the oligonucleotides disclosed herein is a phosphorothioate linkage. In some embodiments, at least one modified internucleotide linkage of any of the oligonucleotides disclosed herein is a 4'-O-methylenephosphonate linkage.
[0240] In some embodiments, the oligonucleotides described herein have a phosphorothioate bond between one or more of positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 3 and 4 of the antisense strand, positions 20 and 21 of the antisense strand, and positions 21 and 22 of the antisense strand. In some embodiments, the oligonucleotides described herein have a phosphorothioate bond between each of positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 20 and 21 of the antisense strand, and positions 21 and 22 of the antisense strand. d. Base modification
[0241] In some embodiments, the oligonucleotides herein have one or more modified nucleobases. In some embodiments, the modified nucleobase (also referred to herein as a base analog) is connected at the 1' position of the nucleotide sugar portion. In certain embodiments, the modified nucleobase is a nitrogenous base. In certain embodiments, the modified nucleobase does not contain a nitrogen atom. See, e.g., U.S. Patent Application Publication No. 2008 / 0274462. In some embodiments, the modified nucleotides comprise universal bases. However, in certain embodiments, the modified nucleotides do not contain nucleobases (abasic).
[0242] In some embodiments, the universal base is a heterocyclic moiety that is located at the 1' position of the nucleotide sugar moiety in the modified nucleotide, or at an equivalent position in a nucleotide sugar moiety substitution, such that when present in a duplex, it can be placed opposite more than one type of base without substantially altering the structure of the duplex. In some embodiments, a single-stranded nucleic acid containing a universal base forms a duplex with a target nucleic acid, and the T of the duplex is 1', compared to a reference single-stranded nucleic acid (e.g., an oligonucleotide) that is fully complementary to the target nucleic acid. m However, in some embodiments, when compared to a reference single-stranded nucleic acid in which the universal base has been replaced with a base to generate a single mismatch, the single-stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid, and the T of the duplex is mHigher than the duplex formed with a nucleic acid containing the mismatched base.
[0243] Non-limiting examples of universal binding nucleotides include, but are not limited to, inosine, 1-β-D-ribofuranosyl-5-nitroindole and / or 1-β-D-ribofuranosyl-3-nitropyrrole (see U.S. Patent Application Publication No. 2007 / 0254362; Van Aerschot et al. (1995) NUCLEIC ACIDS RES. 23:4363-4370; Loakes et al. (1995) Nucleic Acids Res. 23:2361-66; and Loakes and Brown (1994) Nucleic Acids Res. 22:4039-43). e. Reversible modification
[0244] Although certain modifications may be made to protect the oligonucleotide from the effects of the in vivo environment before reaching the target cell, they may reduce the effectiveness or activity of the oligonucleotide once it reaches the cytosol of the target cell. Reversible modifications may be made so that the molecule retains the desired properties outside the cell and is then removed upon entering the cytosol of the cell. For example, reversible modifications may be removed by the action of intracellular enzymes or by chemical conditions inside the cell (e.g., by reduction of intracellular glutathione).
[0245] In some embodiments, the reversibly modified nucleotides include glutathione sensitive moieties. Generally, nucleic acid molecules have been chemically modified with cyclic disulfide moieties to cover the negative charge generated by the internucleotide diphosphate bond and improve cellular uptake and nuclease resistance. See U.S. Patent Application Publication No. 2011 / 0294869, International Patent Application Publication No. WO 2014 / 088920 and WO 2015 / 188197, and Meade et al., (2014) NAT.BIOTECHNOL.32:1256-63. This reversible modification of the internucleotide diphosphate bond is designed to be cleaved in the cell by the reducing environment (e.g., glutathione) of the cytosol. Early examples include neutralization phosphotriester modifications reported to be cleavable in the cell (see Dellinger et al., (2003) J.AM.CHEM.SOC.125:940-50).
[0246] In some embodiments, such reversible modification allows to provide protection during in vivo administration (for example, transported by the lysosome / endosome compartment of blood and / or cells), wherein the oligonucleotide will be exposed to nucleases and other harsh environmental conditions (for example, pH). When released into the cytosol of cells where the glutathione level is higher than the extracellular space, the modification is reversed, and the result is the oligonucleotide cut off. Compared with the available options using irreversible chemical modifications, using reversible glutathione sensitive parts, it is possible to introduce chemical groups with larger space into the oligonucleotide of interest. This is because these larger chemical groups will be removed in the cytosol, and therefore will not interfere with the biological activity of the oligonucleotide in the cytosol of the cell. Therefore, these larger chemical groups can be engineered to give nucleotides or oligonucleotides various advantages, such as nuclease resistance, lipophilicity, charge, thermal stability, specificity and reduced immunogenicity. In some embodiments, the structure of the glutathione sensitive part can be engineered to change its release kinetics.
[0247] In some embodiments, the glutathione sensitive part is attached to the sugar of the nucleotide. In some embodiments, the glutathione sensitive part is attached to the 2'-carbon of the sugar of the modified nucleotide. In some embodiments, the glutathione sensitive part is located at the 5'-carbon of the sugar, particularly when the modified nucleotide is the 5'-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione sensitive part is located at the 3'-carbon of the sugar, particularly when the modified nucleotide is the 3'-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione sensitive part comprises a sulfonyl group. See, for example, U.S. Provisional Patent Application No. 62 / 378,635, filed on August 23, 2016, entitled Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof. Targeting ligands
[0248] In some embodiments, it is desirable to target the STAT3 targeting oligonucleotides disclosed herein to one or more cells or one or more organs. Such a strategy can help avoid adverse effects in other organs, or avoid excessive loss of oligonucleotides to cells, tissues or organs that will not benefit from the oligonucleotides. Targeting oligonucleotides to one or more cells or one or more organs can be achieved by a variety of methods. The conjugation of oligonucleotides with tissue or cell-specific antibodies, small molecules or targeting ligands can promote the delivery of oligonucleotides to one or more target cells or tissues and change the accumulation of oligonucleotides in one or more target cells or tissues (Chernolovskaya et al., (2019) FRONT PHARMACOL.10:444). For example, the conjugation of oligonucleotides with saturated fatty acids (e.g., C22) can promote delivery to cells or tissues such as adipose tissue or immune cells, and such ligands are easier to take in than conventional oligonucleotide ligands. Therefore, in some embodiments, the oligonucleotides disclosed herein are modified to promote targeting and / or delivery to tissues, cells or organs (e.g., promoting delivery of oligonucleotides to the liver). In certain embodiments, the oligonucleotides disclosed herein are modified to promote the delivery of the oligonucleotides to cells of the immune system. In certain embodiments, the oligonucleotides disclosed herein are modified to facilitate delivery of the oligonucleotide to suppressor cells of myeloid origin. In some embodiments, the oligonucleotide comprises at least one nucleotide (e.g., 1, 2, 3, 4, 5, 6 or more nucleotides) conjugated to one or more targeting ligands.
[0249] In some embodiments, the targeting ligand comprises a carbohydrate, an amino sugar, cholesterol, a peptide, a polypeptide, a protein or a portion of a protein (e.g., an antibody or antibody fragment) or a lipid. In some embodiments, the targeting ligand is an aptamer. For example, the targeting ligand can be an RGD peptide for targeting tumor vasculature or glioma cells, a CREKA peptide for targeting tumor vasculature or stoma, transferrin, lactoferrin or an aptamer for targeting transferrin receptors expressed on CNS vasculature, or an anti-EGFR antibody for targeting EGFR on glioma cells. In certain embodiments, the targeting ligand is one or more GalNAc moieties.
[0250] In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, 2 to 4 nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, a targeting ligand is conjugated to 2 to 4 nucleotides at either end of a sense strand or antisense strand (e.g., a targeting ligand is conjugated to an overhang or extension of 2 to 4 nucleotides on a sense strand or antisense strand 5' or 3' end), such that the targeting ligand is similar to the bristles of a toothbrush, and the oligonucleotide is similar to a toothbrush. For example, an oligonucleotide may include a stem-loop at the 5' or 3' end of a sense strand, and 1, 2, 3, or 4 nucleotides of the loop of the stem may be conjugated to a targeting ligand individually. In some embodiments, the oligonucleotides provided by the present disclosure (e.g., dsRNA) include a stem-loop at the 3' end of the sense strand, wherein the loop of the stem-loop includes a tricycle or a tetracycle, and wherein the 3 or 4 nucleotides constituting the tricycle or the tetracycle are conjugated to a targeting ligand, respectively. In some embodiments, the oligonucleotides provided by the present disclosure (e.g., RNAi oligonucleotides) include a stem-loop at the 3' end of the sense strand, wherein the loop of the stem-loop includes a tetracycle, and wherein the 3 nucleotides of the tetracycle are conjugated to a targeting ligand, respectively.
[0251] GalNAc is a high affinity ligand for ASGPR, which is expressed primarily on the sinusoidal surface of hepatocytes and plays a major role in binding, internalization, and subsequent clearance of circulating glycoproteins (asialoglycoproteins) containing terminal galactose or GalNAc residues. Conjugation (indirect or direct) of the GalNAc moiety to the oligonucleotides of the present disclosure can be used to target these oligonucleotides to ASGPR expressed on cells. In some embodiments, the oligonucleotides of the present disclosure are conjugated to at least one or more GalNAc moieties, wherein the GalNAc moieties target the oligonucleotides to ASGPR expressed on human liver cells (e.g., human hepatocytes). In some embodiments, the GalNAc moiety targets the oligonucleotide to the liver.
[0252] In some embodiments, the oligonucleotides of the present disclosure are directly or indirectly conjugated to monovalent GalNAc. In some embodiments, the oligonucleotides are directly or indirectly conjugated to more than one monovalent GalNAc (i.e., conjugated to 2, 3, or 4 monovalent GalNAc moieties, and typically conjugated to 3 or 4 monovalent GalNAc moieties). In some embodiments, the oligonucleotides are conjugated to one or more divalent GalNAc, trivalent GalNAc, or tetravalent GalNAc moieties.
[0253] In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of an oligonucleotide are each conjugated to a GalNAc moiety. In some embodiments, 2 to 4 nucleotides of a tetracyclic ring are each conjugated to a single GalNAc. In some embodiments, 1 to 3 nucleotides of a tricyclic ring are each conjugated to a single GalNAc. In some embodiments, a targeting ligand is conjugated to 2 to 4 nucleotides at either end of a sense strand or antisense strand (e.g., a ligand is conjugated to an overhang or extension of 2 to 4 nucleotides on the 5' or 3' end of a sense strand or antisense strand), such that the GalNAc moiety is similar to the bristles of a toothbrush, and the oligonucleotide is similar to a toothbrush. In some embodiments, the GalNAc moiety is conjugated to the nucleotides of the sense strand. For example, 4 GalNAc moieties can be conjugated to the nucleotides in the tetracyclic rings of the sense strand, wherein each GalNAc moiety is conjugated to 1 nucleotide.
[0254] In some embodiments, the tetraloop is any combination of adenine and guanine nucleotides.
[0255] In some embodiments, the tetracycle (tetraL) has a monovalent GalNAc moiety attached to any one or more guanine nucleotides of the tetracycle via any linker described herein, as shown in the following Chemical Formula 2 (X=heteroatom):
[0256] In some embodiments, the tetraloop (tetraL) has a monovalent GalNAc attached to any one or more adenine nucleotides of the tetraloop via any linker described herein, as shown in the following Chemical Formula 3 (X=heteroatom):
[0257] In some embodiments, the oligonucleotides herein comprise a monovalent GalNAc attached to a guanine nucleotide, referred to as [ademG-GalNAc] or 2'-aminodiethoxymethanol-guanine-GalNAc, as shown in the following Chemical Formula 4:
[0258] In some embodiments, the oligonucleotides herein comprise a monovalent GalNAc attached to an adenine nucleotide, referred to as [ademA-GalNAc] or 2'-aminodiethoxymethanol-adenine-GalNAc, as shown in the following Chemical Formula 5:
[0259] An example of such conjugation is shown below for a loop comprising the nucleotide sequence GAAA from 5' to 3' (Formula 6) (L = linker, X = heteroatom), with the stem attachment point shown. For example, such a loop may be present in Figure 1A The sense strand is shown in position 27-30. In the chemical formula, Used to describe the connection point to the oligonucleotide chain (Chemical Formula 6).
[0260] The targeting ligand can be connected to the nucleotide using an appropriate method or chemistry (e.g., click chemistry). In some embodiments, the targeting ligand is conjugated to the nucleotide using a click connector. In some embodiments, the targeting ligand is conjugated to the nucleotide of any of the oligonucleotides described herein using an acetal-based connector. Acetal-based connectors are disclosed, for example, in international patent applications with publication number WO 2016 / 100401. In some embodiments, the connector is an unstable connector. However, in other embodiments, the connector is stable. An example of a ring from 5' to 3' containing the nucleotide GAAA is shown below, in which the GalNAc moiety is attached to the nucleotide of the ring using an acetal connector (Chemical Formula 7 and Chemical Formula 8). For example, such a ring can be present at positions 27-30 of any sense strand as shown in Figure 1. In the chemical formula, It is the connection point to the oligonucleotide chain (Chemical Formula 7 and Chemical Formula 8).
[0261] As mentioned, the targeting ligand can be connected to the nucleotide using various appropriate methods or chemical synthesis techniques (e.g., click chemistry). In some embodiments, the targeting ligand is conjugated to the nucleotide using a click connector. In some embodiments, the targeting ligand is conjugated to the nucleotide of any oligonucleotide described herein using an acetal-based connector. Acetal-based connectors are disclosed, for example, in the international patent application with publication number WO 2016 / 100401. In some embodiments, the connector is an unstable connector. However, in other embodiments, the connector is a stable connector.
[0262] In some embodiments, a duplex extension (e.g., up to 3, 4, 5, or 6 bp in length) is provided between the targeting ligand (e.g., a GalNAc moiety) and the dsRNA. In some embodiments, the oligonucleotides herein do not have GalNAc conjugated thereto. Structure of conjugated STAT3 targeting oligonucleotides
[0263] In some embodiments, the STAT3 targeting oligonucleotides described herein comprise a nucleotide sequence having a complementary region complementary to a STAT3 mRNA target sequence and one or more targeting ligands, wherein the nucleotide sequence comprises one or more nucleosides (nucleic acids) conjugated to one or more targeting ligands represented by Formula Ia: or a pharmaceutically acceptable salt thereof, in: B is a nucleobase or hydrogen; R 1 and R 2 are independently hydrogen, halogen, R A , -CN, -S(O)R, -S(O)2R, -Si(OR)2R, -Si(OR)R2 or -SiR3; or R on the same carbon 1 and R 2 Together with their intervening atoms they form a 3-7 membered saturated or partially unsaturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; Each R A is independently an optionally substituted group selected from C 1-6 aliphatic groups, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; Each R is independently hydrogen, a suitable protecting group or an optionally substituted group selected from C 1-6 aliphatic groups, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or Two R groups on the same atom together with their intervening atoms form a 4-7 membered saturated, partially unsaturated or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, silicon and sulfur; Each targeting ligand is selected from a lipid conjugate moiety (LC), a carbohydrate, an amino sugar or GalNAc; and wherein each LC is independently a linear or branched C containing a saturated or unsaturated 1-50 A lipid conjugate portion of a hydrocarbon chain, wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, -P(S)OR-; each -Cy- is independently an optionally substituted bivalent ring selected from phenylene, 8-10 membered bicyclic arylene, 4-7 membered saturated or partially unsaturated carbocyclylene, 4-11 membered saturated or partially unsaturated spirocarbocyclylene, 8-10 membered bicyclic saturated or partially unsaturated carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, 4-11 membered saturated or partially unsaturated spiroheterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or 8-10 membered bicyclic heteroarylene having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur; n is 1-10; L is a covalent bond or a divalent saturated or unsaturated straight or branched chain C 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, -P(S)OR-, -V 1 CR 2 W 1 -or replace; m is 1-50; X 1 、V 1 and W 1 are independently -C(R)2-, -OR, -O-, -S-, -Se- or -NR-; Y is hydrogen, a suitable hydroxy protecting group, R 3 is hydrogen, a suitable protecting group, a suitable prodrug or an optionally substituted group selected from C 1-6 aliphatic groups, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; X 2 is O, S or NR; X 3 is -O-, -S-, -BH2- or a covalent bond; Y 1 is a linker group attached to the 2'- or 3'-terminus of a nucleoside, nucleotide or oligonucleotide; Y 2is hydrogen, a suitable protecting group, a phosphoramidite analog, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide or oligonucleotide, or a linker attached to a solid support; and Z is -O-, -S-, -NR- or -CR2-.
[0264] In some embodiments, the STAT3 targeting oligonucleotide comprises one or more nucleic acids conjugated to a targeting ligand represented by Formula II-a: or a pharmaceutically acceptable salt thereof.
[0265] In some embodiments, the STAT3 targeting oligonucleotide comprises one or more nucleic acids conjugated to a targeting ligand represented by Formula II-b or II-c: or a pharmaceutically acceptable salt thereof, wherein: L 1 It is a covalent bond, a monovalent or divalent saturated or unsaturated straight chain or branched C 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, -P(S)OR- or replace; R 4 is hydrogen, R A or a suitable amine protecting group; and R 5 is adamantyl, or a saturated or unsaturated straight or branched chain C 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR- or -P(S)OR.
[0266] In some embodiments, R 5 Selected from
[0267] In some embodiments, R 5 Selected from:
[0268] In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for
[0269] In some embodiments, the STAT3 targeting oligonucleotide comprises one or more nucleic acids represented by Formula II-Ib or II-Ic conjugated to a targeting ligand: or a pharmaceutically acceptable salt thereof; wherein B is a nucleobase or hydrogen; m is 1-50; X 1 is -O- or -S-; Y is hydrogen, R 3 is hydrogen or a suitable protecting group; X 2 O or S; X 3 is -O-, -S- or a covalent bond; Y 1 is a linker group attached to the 2'- or 3'-terminus of a nucleoside, nucleotide or oligonucleotide; Y 2 is hydrogen, a phosphoramidite analog, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide or oligonucleotide, or a linker attached to a solid support; R 5 is adamantyl, or a saturated or unsaturated straight or branched chain C1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, or -P(S)OR-; and R is hydrogen, a suitable protecting group or an optionally substituted group selected from C 1-6 Aliphatic groups, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0270] In some embodiments, R 5 Selected from
[0271] In some embodiments, R 5 for
[0272] In some embodiments, R 5 for
[0273] In some embodiments, the nucleotide sequence of the STAT3 targeting oligonucleotide comprises 1-10 targeting ligands. In some embodiments, the nucleotide sequence comprises 1, 2 or 3 targeting ligands.
[0274] In some embodiments, the STAT3 targeting oligonucleotide is a double-stranded molecule. In some embodiments, the STAT3 targeting oligonucleotide is an RNAi molecule. In some embodiments, the STAT3 targeting double-stranded oligonucleotide comprises a stem loop. In some embodiments, the ligand is conjugated to any nucleotide in the stem loop. In some embodiments, the ligand is conjugated to the first nucleotide from 5' to 3' in the stem loop. In some embodiments, the ligand is conjugated to the second nucleotide from 5' to 3' in the stem loop. In some embodiments, the ligand is conjugated to the third nucleotide from 5' to 3' in the stem loop. In some embodiments, the ligand is conjugated to the fourth nucleotide from 5' to 3' in the stem loop. In some embodiments, the ligand is conjugated to one, two, three or four nucleotides in the stem loop. In some embodiments, the ligand is conjugated to three nucleotides in the stem loop.
[0275] In some embodiments, the STAT3 targeting double-stranded oligonucleotide comprises a stem loop, wherein one or more lipids are conjugated to one or more nucleotides of the stem loop. In some embodiments, the STAT3 targeting double-stranded oligonucleotide comprises a stem loop, wherein one or more C16 lipids are conjugated to one or more nucleotides of the stem loop. In some embodiments, the STAT3 targeting double-stranded oligonucleotide comprises a stem loop, wherein one or more C18 lipids are conjugated to one or more nucleotides of the stem loop.
[0276] In some embodiments, the STAT3 targeting oligonucleotide comprises a sense strand of 36 nucleotides, the positions of which are numbered 1-36 from 5' to 3'. In some embodiments, the STAT3 targeting oligonucleotide comprises a lipid conjugated to position 27 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a lipid conjugated to position 28 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a lipid conjugated to position 29 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a lipid conjugated to position 30 of the sense strand of 36 nucleotides. In some embodiments, the sense strand of 36 nucleotides forms a stem loop with a loop of positions 27-30. In some embodiments, a lipid is conjugated to more than one position of the loop (e.g., positions 27 and 28 of the sense strand of 36 nucleotides).
[0277] In some embodiments, the STAT3 targeting oligonucleotide comprises a C16 lipid conjugated to position 27 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C16 lipid conjugated to position 28 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C16 lipid conjugated to position 29 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C16 lipid conjugated to position 30 of the sense strand of 36 nucleotides. In some embodiments, the sense strand of 36 nucleotides forms a stem-loop having a loop of positions 27-30. In some embodiments, the C16 lipid is conjugated to more than one position of the loop (e.g., positions 27 and 28 of the sense strand of 36 nucleotides).
[0278] In some embodiments, the STAT3 targeting oligonucleotide comprises a C18 lipid conjugated to position 27 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C18 lipid conjugated to position 28 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C18 lipid conjugated to position 29 of the sense strand of 36 nucleotides. In some embodiments, the STAT3 targeting oligonucleotide comprises a C18 lipid conjugated to position 30 of the sense strand of 36 nucleotides. In some embodiments, the sense strand of 36 nucleotides forms a stem-loop having a loop of positions 27-30. In some embodiments, the C18 lipid is conjugated to more than one position of the loop (e.g., positions 27 and 28 of the sense strand of 36 nucleotides).
[0279] In some embodiments, the STAT3 targeting oligonucleotide comprises an antisense strand of 15 to 30 nucleotides and a sense strand of 15 to 40 nucleotides, wherein the sense strand and the antisense strand form a duplex region, wherein the antisense strand comprises a complementary region complementary to a STAT3 mRNA target sequence expressed in immune cells associated with a tumor microenvironment, wherein the sense strand comprises a stem-loop at its 3' end, the stem-loop comprising a tetraloop containing 4 nucleosides, wherein one or more of the 4 nucleosides is represented by Formula II-Ib: wherein B is selected from adenine and guanine nucleobases, and wherein R 5 In some embodiments, m is 1, X1 is O, and Y2 is an internucleotide linking group attached to the 5' end of the nucleoside. Y indicates that Y1 is a linker group attached to the 2' or 3' end of the nucleotide, X2 is O, X3 is O, and R3 is H.
[0280] In some embodiments, the hydrocarbon chain is a C8-C30 hydrocarbon chain. In some embodiments, the hydrocarbon chain is a C16 hydrocarbon chain. In some embodiments, the C16 hydrocarbon chain is In some embodiments, the hydrocarbon chain is a C18 hydrocarbon chain. In some embodiments, the C18 hydrocarbon chain is express.
[0281] In some embodiments, the oligonucleotide comprises a sense strand comprising a sequence selected from SEQ ID NO: 89-280, wherein the sense strand comprises a C18 lipid. In some embodiments, the 4 nucleosides of the tetracyclic ring are numbered 1-4 from 5' to 3', and position 1 is represented by formula II-Ib. In some embodiments, position 2 is represented by formula II-Ib. In some embodiments, position 3 is represented by formula II-Ib. In some embodiments, position 4 is represented by formula II-Ib. In some embodiments, the sense strand is 36 nucleotides, the positions of these nucleotides are numbered 1-36 from 5' to 3', wherein the stem-loop comprises nucleotides at positions 21-36, and wherein one or more nucleosides at positions 27-30 are represented by formula II-Ib. In some embodiments, the antisense strand is 22 nucleotides. Exemplary STAT3 Targeting Oligonucleotides
[0282] In some embodiments, the oligonucleotide targeting STAT3 comprises a sense strand and an antisense strand as shown in Tables 1, 2, 3, 8, 9, 10, 11, and 12, wherein the oligonucleotide comprises a stem-loop structure having a double-stranded stem of about 2-6 base pairs and a loop of 3-4 nucleotides, and wherein the sense strand and the antisense strand comprise Figure 1A Or the modification pattern shown in Example 7. In some embodiments, the oligonucleotide targeting STAT3 comprises a sense strand and an antisense strand as shown in Tables 1, 2, 3, 8, 9, 10, 11 and 12, wherein the oligonucleotide comprises a stem-loop structure having a double-stranded stem of about 2-6 base pairs and a loop of 3-4 nucleotides, wherein the sense strand and the antisense strand comprise Figure 1A In some embodiments, the oligonucleotide comprises a double-stranded stem of 6 base pairs and a stem loop of 4 nucleotides, and the stem loop comprises 1, 2, 3 or 4 GalNAc-conjugated nucleotides. In some embodiments, the GalNAc-conjugated nucleotide is a monovalent GalNAc conjugated to an adenine nucleotide, referred to as [ademA-GalNAc] or 2'-aminodiethoxymethanol-adenine-GalNAc, as shown below:
[0283] In some embodiments, the stem-loop comprises a 6 base pair double-stranded stem and a loop comprising the nucleotide sequence GAAA, wherein each adenine nucleotide is ademA-GalNAc.
[0284] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) are SEQ ID NOs: 69 and 70, respectively.
[0285] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) SEQ ID NOs: 69 and 70, respectively, The sense strand and antisense strand are modified based on the following pattern Sense strand: [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][ mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][ade mX-C#][mX][mX][mX][mX][mX][mX][mX][mX] Hybrid to Antisense strand: [MePhosphonate-4O- mXs][fXs][fX][fX][fX][mX][fX][mX][mX] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX] (Key words are provided in Table 7). In some embodiments, C# is C16 or C18.
[0286] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The sense strand and antisense strand are modified based on the following pattern Sense strand: [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][ mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][ade mX-C#][mX][mX][mX][mX][mX][mX][mX][mX] Hybrid to Antisense strand: [MePhosphonate-4O- mXs][fXs][fX][fX][fX][mX][fX][mX][mX] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX] (Key words are provided in Table 7). In some embodiments, C# is C16 or C18.
[0287] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The sense strand and antisense strand are modified based on the following pattern Sense strand: [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][ mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][ade mX-C#][mX][mX][mX][mX][mX][mX][mX][mX] Hybrid to Antisense strand: [MePhosphonate-4O- mXs][fXs][fXs][fX][fX][mX][fX][mX][mX] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX] (Key words are provided in Table 7). In some embodiments, C# is C16 or C18.
[0288] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 11 and 12, respectively; (b) SEQ ID NOs: 39 and 40, respectively; (c) SEQ ID NOs: 67 and 68, respectively; and (d) are SEQ ID NOs: 71 and 72, respectively.
[0289] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sequence shown in SEQ ID NO: 81. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sequence shown in SEQ ID NO: 82. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sequence shown in SEQ ID NO: 83. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sequence shown in SEQ ID NO: 84.
[0290] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand, and the sense strand and the antisense strand have the nucleotide sequences shown in SEQ ID NOs: 87 and 68, respectively. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand, and the sense strand and the antisense strand have the nucleotide sequences shown in SEQ ID NOs: 88 and 71, respectively.
[0291] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 89-280. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 857-946. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 857-888. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 889-912. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 913-934. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 935-946.
[0292] In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 947-1036. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 947-978. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 979-1002. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1003-1024. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1025-1036.
[0293] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 857-946 and an antisense strand selected from SEQ ID NOs: 947-1036. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 857-888 and an antisense strand selected from SEQ ID NOs: 947-978. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 889-912 and an antisense strand selected from SEQ ID NOs: 979-1002. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 913-934 and an antisense strand selected from SEQ ID NOs: 1003-1024. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 935-946 and an antisense strand selected from SEQ ID NOs: 1025-1036.
[0294] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1037-1126. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1037-1068. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1069-1092. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1093-1114. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1115-1126.
[0295] In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1127-1216. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1127-1158. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1159-1182. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1183-1204. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA comprise an antisense strand sequence selected from SEQ ID NOs: 1205-1216.
[0296] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NO: 1037-1126 and an antisense strand selected from SEQ ID NO: 1127-1216. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NO: 1037-1068 and an antisense strand selected from SEQ ID NO: 1127-1182. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NO: 1069-1092 and an antisense strand selected from SEQ ID NO: 1159-1182. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NO: 1093-1114 and an antisense strand selected from SEQ ID NO: 1183-1204. In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence selected from SEQ ID NOs: 1115-1126 and an antisense strand selected from SEQ ID NOs: 1205-1216.
[0297] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 857 and 947, respectively; (b) SEQ ID NOs: 858 and 948, respectively; (c) SEQ ID NOs: 859 and 949, respectively; (d) SEQ ID NOs: 860 and 950, respectively; (e) SEQ ID NOs: 862 and 952, respectively; (f) SEQ ID NOs: 867 and 957, respectively; (g) SEQ ID NOs: 875 and 965, respectively; and (h) are SEQ ID NOs: 876 and 966, respectively.
[0298] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively.
[0299] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NO: 939 and 1029, respectively.
[0300] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively.
[0301] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively.
[0302] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:862 and the antisense strand comprises the sequence of SEQ ID NO:952.
[0303] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:875 and the antisense strand comprises the sequence of SEQ ID NO:965.
[0304] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:876 and the antisense strand comprises the sequence of SEQ ID NO:966.
[0305] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:920 and the antisense strand comprises the sequence of SEQ ID NO:1010.
[0306] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1037 and 1127, respectively; (b) SEQ ID NOs: 1038 and 1128, respectively; (c) SEQ ID NOs: 1039 and 1129, respectively; (d) SEQ ID NOs: 1040 and 1130, respectively; (e) SEQ ID NOs: 1042 and 1132, respectively; (f) SEQ ID NOs: 1047 and 1137, respectively; (g) SEQ ID NOs: 1055 and 1145, respectively; and (h) are SEQ ID NOs: 1056 and 1146, respectively.
[0307] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1081 and 1171, respectively; (b) SEQ ID NOs: 1090 and 1180, respectively; (c) SEQ ID NOs: 1079 and 1169, respectively; (d) SEQ ID NOs: 1076 and 1166, respectively; (e) SEQ ID NOs: 1072 and 1162, respectively; (f) SEQ ID NOs: 1070 and 1160, respectively; and (g) are SEQ ID NOs: 1069 and 1159, respectively.
[0308] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1120 and 1210, respectively; (b) SEQ ID NOs: 1117 and 1207, respectively; and (c) SEQ ID NO: 1119 and 1209, respectively.
[0309] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1095 and 1185, respectively; (b) SEQ ID NOs: 1104 and 1194, respectively; (c) SEQ ID NOs: 1093 and 1183, respectively; and (d) SEQ ID NO: 1100 and 1190, respectively.
[0310] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1042 and 1132, respectively; (b) SEQ ID NOs: 1055 and 1145, respectively; (c) SEQ ID NOs: 1056 and 1146, respectively; and (d) SEQ ID NO: 1100 and 1190, respectively.
[0311] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:1042 and the antisense strand comprises the sequence of SEQ ID NO:1132.
[0312] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:1055 and the antisense strand comprises the sequence of SEQ ID NO:1145.
[0313] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:1056 and the antisense strand comprises the sequence of SEQ ID NO:1146.
[0314] In some embodiments, the sense strand comprises the sequence of SEQ ID NO:1100 and the antisense strand comprises the sequence of SEQ ID NO:1190.
[0315] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand comprising a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO: 1042 and 4, respectively; (b) SEQ ID NOs: 1055 and 5, respectively; (c) SEQ ID NOs: 1056 and 6, respectively; and (d) are SEQ ID NOs: 1100 and 7, respectively.
[0316] In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression include minimal off-target effects. For example, in some embodiments, the oligonucleotides described herein reduce STAT3 expression without reducing STAT1 expression, or reduce STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO: 862, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 952, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO: 1042, the antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 1132, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 875, the antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 965, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 1055, the antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 1145, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression.
[0317] In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression are species cross-reactive oligonucleotides. In some embodiments, the oligonucleotides described herein can reduce the expression of STAT3 mRNA of at least two different species. In some embodiments, the oligonucleotides described herein can reduce the expression of STAT3 mRNA of at least two different species, but do not cross-react with non-STAT3 mRNA (e.g., STAT1). In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression are cross-reactive between at least two species. In some embodiments, the oligonucleotides for reducing the expression of STAT3 cross-react with human, non-human primate and mouse STAT3 mRNA. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA cross-react with human and mouse STAT3 mRNA. In some embodiments, the oligonucleotides for reducing the expression of STAT3 mRNA cross-react with human and non-human primate STAT3 mRNA.
[0318] In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.
[0319] In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50% to at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 80%, at least 85%, at least 90%, or at least 95%.
[0320] In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50% to at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 80%, at least 85%, at least 90%, or at least 95%.
[0321] In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50% to at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA reduce STAT3 mRNA in humans and mice (i.e., the oligonucleotides are species cross-reactive oligonucleotides) by at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA comprise a sense strand and an antisense strand selected from the following: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0322] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0323] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, wherein the oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0324] In some embodiments, an oligonucleotide for reducing expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide reduces STAT3 mRNA in humans and non-human primates (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0325] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 875 and the antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide reduces human STAT3 mRNA.
[0326] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 876 and the antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide reduces human STAT3 mRNA.
[0327] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 920 and the antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide reduces human STAT3 mRNA.
[0328] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 857 and 947, respectively; (b) SEQ ID NOs: 858 and 948, respectively; (c) SEQ ID NOs: 859 and 949, respectively; (d) SEQ ID NOs: 860 and 950, respectively; (e) SEQ ID NOs: 862 and 952, respectively; (f) SEQ ID NOs: 867 and 957, respectively; (g) SEQ ID NOs: 875 and 965, respectively; and (h) SEQ ID NO: 876 and 966, respectively, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0329] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0330] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0331] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0332] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0333] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 862 and the antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0334] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 875 and the antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0335] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0336] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.
[0337] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 857 and 947, respectively; (b) SEQ ID NOs: 858 and 948, respectively; (c) SEQ ID NOs: 859 and 949, respectively; (d) SEQ ID NOs: 860 and 950, respectively; (e) SEQ ID NOs: 862 and 952, respectively; (f) SEQ ID NOs: 867 and 957, respectively; (g) SEQ ID NOs: 875 and 965, respectively; and (h) SEQ ID NO: 876 and 966, respectively, Wherein the oligonucleotide is conjugated to a lipid.
[0338] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, Wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0339] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, Wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0340] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, Wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0341] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, Wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0342] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0343] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0344] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0345] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a lipid on the sense strand.
[0346] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 857 and 947, respectively; (b) SEQ ID NOs: 858 and 948, respectively; (c) SEQ ID NOs: 859 and 949, respectively; (d) SEQ ID NOs: 860 and 950, respectively; (e) SEQ ID NOs: 862 and 952, respectively; (f) SEQ ID NOs: 867 and 957, respectively; (g) SEQ ID NOs: 875 and 965, respectively; and (h) SEQ ID NO: 876 and 966, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0347] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0348] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0349] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0350] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 862 and 952, respectively; (b) SEQ ID NOs: 875 and 965, respectively; (c) SEQ ID NOs: 876 and 966, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0351] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0352] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0353] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0354] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.
[0355] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide reduces STAT3 mRNA in human, non-human primate and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0356] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide reduces STAT3 mRNA in human and mouse by at least 75% (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0357] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide reduces human STAT3 mRNA by at least 75%.
[0358] In some embodiments, an oligonucleotide for reducing expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide reduces STAT3 mRNA in humans and non-human primates (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0359] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 875 and the antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.
[0360] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 876 and the antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.
[0361] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO: 920 and the antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.
[0362] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces STAT3 mRNA in humans, non-human primates, and mice (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0363] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces STAT3 mRNA in human and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0364] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a lipid on the sense strand and reduces human STAT3 mRNA.
[0365] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotide is a species cross-reactive oligonucleotide).
[0366] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces human STAT3 mRNA.
[0367] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces human STAT3 mRNA.
[0368] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a lipid on the sense strand, and reduces human STAT3 mRNA.
[0369] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces STAT3 mRNA in humans, non-human primates, and mice (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0370] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces STAT3 mRNA in human and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide).
[0371] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces human STAT3 mRNA.
[0372] In some embodiments, an oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand, and reduces STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotide is a species cross-reactive oligonucleotide).
[0373] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand, and reduces human STAT3 mRNA.
[0374] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand, and reduces human STAT3 mRNA.
[0375] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand, and reduces human STAT3 mRNA.
[0376] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces STAT3 mRNA in human, non-human primate, and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0377] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces STAT3 mRNA in human and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0378] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0379] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0380] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0381] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0382] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0383] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces STAT3 mRNA in human, non-human primate, and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0384] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NOs: 939 and 1029, respectively, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces STAT3 mRNA in human and mouse (ie, the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0385] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand and an antisense strand selected from: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) SEQ ID NO: 920 and 1010, respectively, The oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0386] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 862 and an antisense strand sequence of SEQ ID NO: 952, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces STAT3 mRNA in humans and non-human primates (i.e., the oligonucleotide is a species cross-reactive oligonucleotide) by at least 75%.
[0387] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 875 and an antisense strand sequence of SEQ ID NO: 965, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0388] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 876 and an antisense strand sequence of SEQ ID NO: 966, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces human STAT3 mRNA by at least 75%.
[0389] In some embodiments, the oligonucleotide for reducing the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO: 920 and an antisense strand sequence of SEQ ID NO: 1010, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand and reduces human STAT3 mRNA by at least 75%. preparation
[0390] A variety of preparations have been developed to promote the use of oligonucleotides. For example, oligonucleotides can be delivered to a subject or a cellular environment using a preparation that minimizes degradation, promotes delivery and / or uptake, or provides another beneficial property for the oligonucleotides in the preparation. In some embodiments, the oligonucleotides are formulated in a buffer solution such as phosphate buffered saline, liposomes, micellar structures, and shells.
[0391] Oligonucleotide preparations with cationic lipids can be used to promote the transfection of oligonucleotides into cells. For example, cationic lipids such as lipofectin, cationic glycerol derivatives and polycationic molecules (e.g., polylysine) can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.) or FuGene 6 (Roche), all of which can be used according to the manufacturer's instructions.
[0392] Thus, in some embodiments, the formulation comprises lipid nanoparticles. In some embodiments, the excipient comprises a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere or a nanoparticle, or can be otherwise formulated for administration to a cell, a tissue, an organ or a body of a subject in need thereof (see, e.g., Remington: THE SCIENCE AND PRACTICE OF PHARMACY, 22nd ed., Pharmaceutical Press, 2013).
[0393] In some embodiments, the formulations herein include adjuvants. In some embodiments, the adjuvants provide improved stability, improved absorption, improved solubility, and / or therapeutic enhancement to the active ingredient conferred by the composition. In some embodiments, the adjuvant is a buffer (e.g., sodium citrate, sodium phosphate, tris alkali, or sodium hydroxide) or a vehicle (e.g., a buffer solution, vaseline, dimethyl sulfoxide, or mineral oil). In some embodiments, the oligonucleotides are lyophilized to extend their shelf life and then made into a solution before use (e.g., administration to a subject). Therefore, the adjuvant in the composition comprising any of the oligonucleotides described herein can be a lyoprotectant (e.g., mannitol, lactose, polyethylene glycol, or polyvinyl pyrrolidone) or a collapse temperature regulator (e.g., dextran, Ficoll TM or gelatin).
[0394] In some embodiments, the pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral (e.g., intravenous, intramuscular, intraperitoneal, intradermal, subcutaneous), oral (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration.
[0395] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (when water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and suitable mixtures thereof. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols such as mannitol, sorbitol, sodium chloride. Sterile injection solutions can be prepared as follows: the desired amount of oligonucleotides and one or a combination of the ingredients listed above are introduced into a selected solvent as required, followed by filtration sterilization.
[0396] In some embodiments, the composition may contain at least about 0.1% or more of the therapeutic agent, although the percentage of active ingredient may be between about 1% and about 80% or more of the weight or volume of the total composition. Those skilled in the art of preparing such pharmaceutical formulations will consider factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, and other pharmacological considerations, and therefore, a variety of dosages and treatment regimens may be desirable.
[0397] While several embodiments relate to liver-targeted delivery of any of the oligonucleotides herein, targeting of other tissues is also contemplated. Programmed death ligand 1 (PD-L1) inhibitors
[0398] In some embodiments, the present disclosure provides a PD-L1 inhibitor used in combination with an oligonucleotide described herein. In some embodiments, the PD-L1 inhibitor is a small molecule, a peptide, a protein, an antibody, or a nucleic acid molecule, such as siRNA, miRNA, or antisense RNA. In some embodiments, the PD-L1 inhibitor inhibits the association of PD-L1 and PD-1. In some embodiments, the PD-L1 inhibitor is specific for PD-L1.
[0399] In some embodiments, the PD-L1 inhibitor is an anti-PD-L1 antibody. In some embodiments, the PD-L1 inhibitor is specific for PD-1. In some embodiments, the PD-L1 inhibitor is an anti-PD-1 antibody. In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody is an antibody fragment. In some embodiments, the PD-L1 inhibitor is a small molecule.
[0400] In some embodiments, the anti-PD-L1 antibody is atezolizumab. Atezolizumab (MPDL3280A) is a fully humanized, engineered IgG1 monoclonal antibody against PD-L1. In some embodiments, the anti-PD-L1 antibody is avelumab. Avelumab (MSB0010718C) is a fully humanized, engineered IgG1 monoclonal antibody against PD-L1. In some embodiments, the anti-PD-L1 antibody is envolizumab. In some embodiments, the anti-PD-L1 antibody is durvalumab. Durvalumab (MEDI4736) is a human monoclonal antibody against PD-L1. In some embodiments, the anti-PD-L1 antibody is TSR-042. TSR-042 refers to an engineered chimeric antibody against the PD-1 / PD-L1 pathway. In some embodiments, the anti-PD-L1 antibody is KD-033. KD-033 refers to a bifunctional anti-PD-L1 / IL-15 fusion protein in which the anti-PD-L1 antibody binds to the cytokine IL-15 through the sushi domain of the IL-15 receptor attached at the tail. In some embodiments, the anti-PD-L1 antibody is STI-1014. STI-1014 refers to an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is KY-1003. KY-1003 is a monoclonal antibody against PD-L1. In some embodiments, the anti-PD-L1 antibody is YW243.55.S70. Antibody YW243.55.S70 is an anti-PDL1 described in U.S. Pat. No. 9,920,123, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-L1 antibody is MDX-1106. MDX-1106, also known as MDX-1106-04, ONO-4538 or BMS-936558, is an anti-PD1 antibody described in U.S. Pat. No. 8,008,449, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-L1 antibody is Merck 3745. Merck 3745, also known as MK-3475 or SCH-900475, is an anti-PD1 antibody described in U.S. Pat. No. 8,168,757, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-L1 antibody is CT-011. CT-011, also known as hBAT or hBAT-1, is an anti-PD1 antibody described in U.S. Pat. No. 8,747,847, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-L1 antibody is AMP-224. AMP-224, also known as B7-DClg, is a PDL2-Fc fusion soluble receptor described in U.S. Publication No. 2011 / 0223188 and U.S. Publication No. 2013 / 0017199, the contents of which are incorporated herein in their entireties.
[0401] In some embodiments, the anti-PD-L1 antibody is any anti-PD-L1 antibody known in the art, including but not limited to the anti-PD-L1 antibodies disclosed in Akinleye & Rasool "Immune checkpoint inhibitors of PD-L1 as cancer therapeutics" J. of Hematology & Oncology. 12 (92): 2019. In some embodiments, the anti-PD-L1 antibody is BMS-936559. BMS-936559 (MDX-1105) is a fully human IgG4 monoclonal antibody against PD-L1 and is described in U.S. Pat. No. 7,943,743, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-L1 antibody is CK-301. In some embodiments, the anti-PD-L1 antibody is CS-1001. In some embodiments, the anti-PD-L1 antibody is SHR-1316. In some embodiments, the anti-PD-L1 antibody is BG-A333. In some embodiments, the anti-PD-L1 antibody is an antibody disclosed in International Publication No. WO 2021 / 231741, the contents of which are incorporated herein in their entirety.
[0402] In some embodiments, the anti-PD-1 antibody is nivolumab. Nivolumab (BMS-936558) is an IgG4 monoclonal antibody described in U.S. Pat. No. 8,008,449, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-1 antibody is pembrolizumab. Pembrolizumab is an IgG4 monoclonal antibody described in U.S. Pat. No. 8,354,509, the contents of which are incorporated herein in their entirety. In some embodiments, the anti-PD-1 antibody is cemiplizumab. Cemiplizumab (REGN2810) is an IgG4 monoclonal antibody described in U.S. Pat. No. 9,987,500, the contents of which are incorporated herein in their entirety.
[0403] In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 30nM to about 100nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 30nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 40nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 50nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 60nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 70nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 80nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 90nM. In some embodiments, the anti-PD-L1 antibodies described herein bind to PD-L1 with an affinity of about 100 nM.
[0404] In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 30nM to about 100nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 30nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 40nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 50nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 60nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 70nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 80nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 90nM. In some embodiments, the anti-PD-1 antibodies described herein bind to PD-1 with an affinity of about 100 nM.
[0405] In some embodiments, the antibody is generated using display technology. Display technology for generating antibody polypeptides includes any display technology (e.g., display library screening technology). In some embodiments, synthetic antibodies are designed, selected, or optimized by screening target antigens using display technology (e.g., phage display technology). Phage display libraries can contain millions to billions of phage vectors, each of which expresses a unique antibody fragment on its viral coat. Such libraries can provide a rich and diverse resource for selecting potentially hundreds of antibody fragments with different affinity levels for one or more antigens of interest (McCafferty et al., 1990. Nature. 348: 552-4; Edwards, BM et al., 2003. JMB. 334: 103-18; Schofield, D. et al., 2007. Genome Biol. 8, R254; and Pershad, K. et al., 2010. Protein Engineering Design and Selection. 23: 279-88; the contents of each of which are incorporated herein by reference in their entirety). Typically, the antibody fragments present in such libraries include scFv antibody fragments, which comprise a V H and V L Fusion protein of antibody domain. In some cases, scFv may contain the same sequence, except for the unique sequence of the variable loop encoding CDR. In some cases, scFv is expressed as a fusion protein connected to a viral coat protein (e.g., the N-terminus of a viral pellet protein). The VL chain can be expressed alone for assembly with the VH chain in the periplasm, after which the complex is incorporated into the viral coat. The precipitated library members can be sequenced from the bound phage to obtain the cDNA encoding the desired scFv. Antibody variable domains or CDRs from such sequences can be directly incorporated into the antibody sequence for the production of recombinant antibodies, or mutated by in vitro affinity maturation and used for further optimization.
[0406] In some embodiments, yeast surface display technology is used to generate the sequence of the polypeptide to be encoded in the viral genome. In some embodiments, recombinant antibodies are developed by displaying the antibody fragment of interest as a fusion on the surface of yeast, where the protein interacts with proteins and small molecules in solution. ScFvs with affinity for the desired receptor can be isolated from the yeast surface using magnetic separation and flow cytometry. Several cycles of yeast surface display and separation can be performed to obtain scFvs with desired properties through directed evolution.
[0407] Methods for determining the affinity of an antibody for its antigen are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows real-time biospecific interactions to be analyzed by detecting changes in protein concentration within a biosensor matrix, for example using a BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further description, see Jonsson, U. et al., (1993) Ann. Biol. Clin. 51: 19-26; Jonsson, U., i (1991) Biotechniques 11: 620-627; Johnsson, B. et al., (1995) J. Mol. Recognit. 8: 125-131; and Johnsson, B. et al., (1991) Anal. Biochem. 198: 268-277.
[0408] In some embodiments, the PD-L1 inhibitor is an siRNA molecule. In some embodiments, the PD-L1 inhibitor is ALN-PDL. In some embodiments, the PD-L1 inhibitor is a PD-L1 inhibitor described in U.S. Pat. No. 10,889,813, U.S. Pat. No. 10,745,704, U.S. Pat. No. 2021 / 0277403, U.S. Pat. No. 2006 / 0276422A1, US2021 / 0277403, WO2019 / 000149 International Publication or WO2019 / 000149 International Publication, the contents of which are incorporated herein as a whole. In some embodiments, the PD-L1 inhibitor is an siRNA molecule described in Barati, M. et al., A review of PD-1 / PD-L1 siRNA delivery systems in immune T cells and cancer cells, International Immunopharmacology, 2022, vol. 111. In some embodiments, the siRNA molecules used to inhibit PD-L1 are siRNA molecules generated using methods known to those skilled in the art.
[0409] In some embodiments, the PD-L1 inhibitor is an antisense oligonucleotide. In some embodiments, the PD-L1 inhibitor is an antisense oligonucleotide described in U.S. Patent No. 10,745,480, U.S. Patent No. 10,982,215, U.S. Publication No. 2021 / 0269797A1, or U.S. Publication No. US20220220485A1, the contents of which are incorporated herein in their entirety. In some embodiments, the antisense oligonucleotide used to inhibit PD-L1 is an antisense oligonucleotide generated using methods known to those skilled in the art.
[0410] In some embodiments, the PD-L1 inhibitor is a small molecule. In some embodiments, the small molecule is CA-170. CA-170 is a small molecule antagonist of PD-L1 and VISTA. In some embodiments, the small molecule is CA-327. CA-327 refers to a small molecule antagonist of PD-L1 and TIM3. In some embodiments, the small molecule is BMS-1001. In some embodiments, the small molecule is BMS-1166. In some embodiments, the small molecule is BMS-8. In some embodiments, the small molecule is BMS-37. In some embodiments, the small molecule is BMS-202. In some embodiments, the small molecule is BMS-200. In some embodiments, the small molecule is Incyte-001. In some embodiments, the small molecule is Incyte-011. In some embodiments, the small molecule is INCB086550. In some embodiments, the small molecule is LH1306. In some embodiments, the small molecule is LH1307. In some embodiments, the small molecule is ARB-272572. In some embodiments, the PD-L1 inhibitor is a small molecule described in Sasikumar, P. et al., Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development, Front. Immunol. 2022, 13: 752065. In some embodiments, the PD-L1 inhibitor is a small molecule described in U.S. Pat. No. 11,130,740, U.S. Pat. No. 10,590,105, International Publication No. WO2019 / 076343, U.S. Pat. No. 11,555,029, or U.S. Publication No. 2018 / 0305315, the contents of which are incorporated herein in their entirety. In some embodiments, the small molecule is a small molecule described in Wu, Q. et al., Small molecule inhibitors targeting the PD-1 / PD-L1 signaling pathway, Acta Pharmacologica Sinica. 2021, 42: 1-9.In some embodiments, the small molecule is a small molecule described in Wang, Y. et al., A Small Molecule Antagonist of PD-1 / PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy, Front. Immuno. 2021. Vol. 12. In some embodiments, the small molecule inhibitor is a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a hydrate or a solvent of a small molecule described herein. In some embodiments, the small molecule used to inhibit PD-L1 is a small molecule generated using a method known to those skilled in the art.
[0411] In some embodiments, the PD-L1 inhibitor is a peptide. In some embodiments, the PD-L1 inhibitor is a peptide inhibitor described in U.S. Pat. No. 9,422,339 or U.S. Pat. No. 9,850,283, the contents of which are incorporated herein as a whole. In some embodiments, the PD-L1 inhibitor is a peptide inhibitor described in Yin, H. et al., Rational Design of Potent Peptide Inhibitors of the PD-1: PD-L1 Interaction for Cancer Immunotherapy, J.Am.Chem.Soc.2021, 143: 44, 18536-18547. In some embodiments, the PD-L1 inhibitor is a peptide inhibitor described in Lin, X. et al., Progress in PD-1 / PD-L1 pathway inhibitors: From biomacromolecules to small molecules, Euro.J.Med.Chem.2020, vol.186. In some embodiments, the inhibitor peptide for inhibiting PD-L1 is a peptide generated using a method known to those skilled in the art.
[0412] Those skilled in the art know how to determine whether a compound is a PD1 and / or PDL1 inhibitor by testing the compound in an appropriate assay. The binding of an inhibitor to PD1 and / or PDL1 and / or PDL2 can be measured, for example, by ELISA-type assays known in the art. Bioassays for measuring the biological effects of PD1 and / or PDL1 and / or PDL2 inhibition are well known to those skilled in the art. Reagent test kit
[0413] In some embodiments, the present disclosure provides a kit comprising a STAT3 oligonucleotide herein, and instructions for administering the STAT3 oligonucleotide to a subject who has received or is receiving a PD-L1 inhibitor. In some embodiments, the kit comprises the oligonucleotide herein, one or more controls, and various buffers, reagents, enzymes, and other standard components known in the art in a suitable container. In some embodiments, the container comprises at least one vial, well, test tube, flask, bottle, syringe, or other container device, in which the oligonucleotide is placed, and in some cases, appropriately aliquoted. In some embodiments in which additional components are provided, the kit comprises an additional container for placing the component. The kit may also include a device for accommodating the oligonucleotide, and any other reagents that are strictly limited for commercial sale. Such a container may include an injection-molded or blow-molded plastic container in which the desired vial is retained. These containers and / or kits may include labels with instructions for use and / or warnings.
[0414] In some embodiments, the kit comprises an oligonucleotide herein, and a pharmaceutically acceptable carrier, or a pharmaceutical composition comprising the oligonucleotide, and instructions for treating a disease, disorder, or condition associated with STAT3 expression in a subject in need thereof, or delaying its progression, wherein the subject has received or is receiving a PD-L1 inhibitor. In some embodiments, the kit comprises an oligonucleotide herein, and a pharmaceutically acceptable carrier, or a pharmaceutical composition comprising the oligonucleotide, and instructions for treating cancer in a subject in need thereof, or delaying cancer progression, wherein the subject has received or is receiving a PD-L1 inhibitor.
[0415] In some embodiments, the kit comprises a PD-L1 inhibitor, and a pharmaceutically acceptable carrier, or a pharmaceutical composition comprising the oligonucleotide, and instructions for treating a disease, disorder, or condition in a subject in need thereof, or delaying its progression, wherein the subject has received or is receiving a STAT3 oligonucleotide as described herein. In some embodiments, the kit comprises a PD-L1 inhibitor, and a pharmaceutically acceptable carrier, or a pharmaceutical composition comprising the oligonucleotide, and instructions for treating a cancer in a subject in need thereof, or delaying its progression, wherein the subject has received or is receiving a STAT3 oligonucleotide as described herein. Example
[0416] Although the disclosure has been described with reference to the specific embodiments set forth in the following examples, it will be appreciated by those skilled in the art that various changes may be made without departing from the spirit and scope of the disclosure, and equivalents may be substituted. In addition, the following examples are provided by way of example, and are not intended to limit the scope of the disclosure in any way. In addition, modifications may be made to adapt the composition, process, one or more process steps of the situation, material, substance to the purpose, spirit and scope of the disclosure. All of these modifications are intended to be within the scope of the disclosure. Standard techniques well known in the art or the technology specifically described below have been used. abbreviation Ac:Acetyl AcOH: acetic acid ACN: Acetonitrile Ad:Adamantyl AIBN: 2,2'-azobisisobutyronitrile Anhyd: Anhydrous Aq: water based B2Pin2: Bis(pinacol)diboron-4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl BH3: Borane Bn: benzyl Boc: tert-butyloxycarbonyl Boc2O: di-tert-butyl dicarbonate BPO: Benzoyl peroxide BuOH: n-Butanol CDI: Carbonyldiimidazole COD: Cyclooctadiene d: day DABCO: 1,4-diazobicyclo[2.2.2]octane DAST: Diethylaminosulfur trifluoride dba: dibenzylideneacetone DBU: 1,8-diazobicyclo[5.4.0]undec-7-ene DCE: 1,2-dichloroethane DCM: dichloromethane DEA: Diethylamine DHP: Dihydropyran DIBAL-H: Diisobutylaluminum hydride DIPA: Diisopropylamine DIPEA or DIEA: N,N-diisopropylethylamine DMA: N,N-dimethylacetamide DME: 1,2-dimethoxyethane; DMAP: 4-dimethylaminopyridine DMF: N,N-dimethylformamide DMP: Dess-Martin Oxidant DMSO-dimethyl sulfoxide DMTr: 4,4'-dimethoxytrityl DPPA: diphenylphosphoryl azide dppf: 1,1'-bis(diphenylphosphino)ferrocene EDC or EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ee: enantiomeric excess ESI: Electrospray ionization EA: Ethyl acetate EtOAc: Ethyl acetate EtOH: ethanol FA: Formic acid h or hr: hours HATU: N,N,N',N'-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate HCl: hydrochloric acid HPLC: High Performance Liquid Chromatography HOAc: acetic acid IBX: 2-Iodoacylbenzoic acid IPA: Isopropyl alcohol KHMDS: Potassium hexamethyldisilazide K2CO3: Potassium carbonate LAH: Lithium Aluminum Hydride LDA: lithium diisopropylamide L-DBTA: Dibenzoyl-L-tartaric acid m-CPBA: meta-chloroperbenzoic acid M: molar concentration MeCN: Acetonitrile MeOH: Methanol Me2S: dimethyl sulfide MeONa: Sodium methoxide Mel: Methyl iodide min: minutes mL: milliliters mM: millimolar concentration mmol: millimole MPa: Megapascal MOMCl: methyl chloromethyl ether MsCl: Methanesulfonyl chloride MTBE: Methyl tert-butyl ether nBuLi: n-butyllithium NaNO2: Sodium Nitrite NaOH: Sodium hydroxide Na2SO4: Sodium sulfate NBS: N-bromosuccinimide NCS: N-chlorosuccinimide NFSI: N-Fluorobenzenesulfonimide NMO: N-methylmorpholine N-oxide NMP: N-methylpyrrolidine NMR: Nuclear Magnetic Resonance ℃: Celsius Pd / C: Palladium on Carbon Pd(OAc)2: Palladium acetate PBS: Phosphate buffered saline PE: Petroleum ether POCl3: Phosphorus oxychloride PPh3: triphenylphosphine PyBOP: (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate Rel: relative RT or rt: room temperature s or sec: seconds sat: saturated SEMCl: chloromethyl-2-trimethylsilylethyl ether SFC: Supercritical Fluid Chromatography SOCl2: Sulfur dichloride tBuOK: Potassium tert-butoxide TBAB: Tetrabutylammonium bromide TBAF: Tetrabutylammonium fluoride TBAI: Tetrabutylammonium iodide TEA: triethylamine Tf: trifluoromethanesulfonate TfAA, TFMSA or Tf2O: trifluoromethanesulfonic anhydride TFA: trifluoroacetic acid TIBSCl: 2,4,6-Triisopropylbenzenesulfonyl chloride TIPS: triisopropylsilyl THF: Tetrahydrofuran THP: Tetrahydropyran TLC: Thin layer chromatography TMEDA: Tetramethylethylenediamine pTSA: p-Toluenesulfonic acid UPLC: Ultra-Performance Liquid Chromatography wt: weight Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene Example 1: Preparation of double-stranded RNAi oligonucleotides General Synthesis Methods
[0417] The following examples are intended to illustrate the present disclosure and should not be construed as limiting it. Temperatures are given in degrees Celsius (° C.). If not otherwise mentioned, all evaporations are carried out under reduced pressure, preferably between about 15 mmHg and 100 mmHg (=20-133 mbar). The structures of the final products, intermediates and starting materials are confirmed by standard analytical methods, such as microanalysis and spectral characteristics, such as MS, IR, NMR. The abbreviations used are conventional abbreviations in the art.
[0418] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts used to synthesize the nucleic acids or analogs thereof disclosed herein are commercially available or can be produced by organic synthesis methods known to those of ordinary skill in the art (METHODS OF ORGANIC SYNTHESIS, Thieme, Vol. 21 (Houben-Weyl 4th Edition. 1952)). In addition, the nucleic acids or analogs thereof disclosed herein can be produced by organic synthesis methods known to those of ordinary skill in the art, as shown in the following examples.
[0419] Unless otherwise stated, all reactions were performed under nitrogen or argon.
[0420] Proton NMR ( 1 H NMR) was performed in deuterated solvents. In certain nucleic acids or analogs thereof disclosed herein, one or more 1 The H shift overlaps with residual proteo-solvent signals; these signals are not reported in the experiments presented below.
[0421] As described in the examples below, in certain exemplary embodiments, nucleic acids or their analogs are prepared according to the following general procedures. It should be understood that although the general methods describe the synthesis of certain nucleic acids or their analogs disclosed herein, the following general methods and other methods known to those of ordinary skill in the art can be applied to all nucleic acids or their analogs and subclasses and species of each of these nucleic acids or their analogs, as described herein. Example 1a: Synthesis of 2-(2-((((6aR,8R,9R,9aR)-8-(6-6-benzamido-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopentacyclopenta
[0422] A solution of compound 1-1 (25.00 g, 67.38 mmol) in 20 mL DMF was treated with pyridine (11 mL, 134.67 mmol) and tetraisopropyldisiloxane dichloride (22.63...
Claims
1. A method for treating cancer in a subject who has received or is receiving a PD-L1 inhibitor, the method comprising administering an RNAi oligonucleotide comprising an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, thereby treating the cancer in the subject, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 consecutive nucleotides in length.
2. A method of treating cancer in a subject who has received or is receiving an RNAi oligonucleotide, the method comprising administering a PD-L1 inhibitor, thereby treating the cancer in the subject, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 consecutive nucleotides in length.
3. A method for treating a disease, disorder or condition associated with activated STAT3 expression, comprising administering an RNAi oligonucleotide to a subject in need thereof, thereby treating cancer in the subject, wherein the subject has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 consecutive nucleotides in length.
4. The method of claim 3, wherein the disease, disorder or condition associated with activated STAT3 expression is cancer.
5. The method of any one of claims 1-2 and 4, wherein the cancer is selected from carcinoma, sarcoma, melanoma, lymphoma and leukemia, prostate cancer, breast cancer, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer and glioblastoma.
6. The method of any one of claims 1-2 and 4-5, wherein the cancer comprises an immunosuppressive tumor microenvironment.
7. The method of any one of claims 1-2 and 4-5, wherein the cancer comprises an inflamed tumor microenvironment.
8. The method of claim 7, wherein the inflamed tumor microenvironment comprises infiltrating T cells.
9. The method of any one of claims 1-8, wherein the PD-L1 inhibitor is an antibody.
10. The method of claim 9, wherein the antibody is an anti-PD-L1 antibody.
11. The method of claim 10, wherein the anti-PD-L1 antibody is selected from FAZ053, atezolizumab, avelumab, durvalumab, envolimab, and BMS-936559.
12. The method of claim 9, wherein the antibody is an anti-PD-1 antibody.
13. The method of claim 12, wherein the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, and cemiplimab.
14. The method of any one of claims 1-8, wherein the PD-L1 inhibitor is a small molecule inhibitor.
15. The method of any one of claims 1-8, wherein the PD-L1 inhibitor is a peptide.
16. The method of any one of claims 1-8, wherein the PD-L1 inhibitor is a nucleic acid molecule.
17. The method of claim 16, wherein the nucleic acid molecule is selected from antisense oligonucleotides, siRNA or miRNA.
18. The method according to any one of claims 1-17, wherein the STAT3 mRNA target sequence comprises any one of SEQ ID NOs: 89-280.
19. The method according to any one of claims 1 to 18, wherein the complementary region is fully complementary to the STAT3 mRNA target sequence.
20. The method of any one of claims 1-18, wherein the region of complementarity contains no more than 4 mismatches to the STAT3 mRNA target sequence.
21. The method of any one of claims 1-20, wherein the antisense strand is 19 to 27 nucleotides in length.
22. The method of any one of claims 1-21, wherein the antisense strand is 21 to 27 nucleotides in length, optionally wherein the antisense strand is 22 nucleotides in length.
23. The method of any one of claims 1-22, wherein the sense strand is 19 to 40 nucleotides in length, optionally wherein the sense strand is 36 nucleotides in length.
24. The method of any one of claims 1-23, wherein the duplex region is at least 19 nucleotides in length.
25. The method of any one of claims 1-24, wherein the duplex region is at least 20 nucleotides in length, optionally wherein the duplex region is 21 nucleotides in length.
26. The method of any one of claims 1-25, wherein the complementary region to STAT3 is at least 19 consecutive nucleotides in length.
27. The method of any one of claims 1-26, wherein the complementary region to STAT3 is at least 21 consecutive nucleotides in length.
28. The method of any one of claims 1-27, wherein the sense strand comprises at its 3' end a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop of 3 to 5 nucleotides in length between S1 and S2.
29. The method of claim 28, wherein L is a tetracyclic ring, optionally wherein L is 4 nucleotides in length.
30. The method of claim 28 or 29, wherein L comprises the sequence denoted GAAA.
31. The method of any one of claims 1-30, wherein the antisense strand comprises a 3' overhang sequence of one or more nucleotides in length, optionally wherein the 3' overhang sequence is 2 nucleotides in length, optionally wherein the 3' overhang sequence is GG.
32. The method of any one of claims 1-31, wherein the oligonucleotide comprises at least one modified nucleotide.
33. The method of claim 32, wherein the modified nucleotide comprises a 2'-modification.
34. The method of claim 33, wherein the 2'-modification is a modification selected from the group consisting of 2'-aminoethyl, 2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl, and 2'-deoxy-2'-fluoro-β-d-arabinose nucleic acid.
35. The method of any one of claims 33-34, wherein about 10-15%, 10%, 11%, 12%, 13%, 14% or 15% of the nucleotides of the sense strand comprise a 2'-fluoro modification.
36. The method of any one of claims 33-35, wherein about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the antisense strand comprise a 2'-fluoro modification.
37. The method of any one of claims 33-36, wherein about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the oligonucleotide comprise a 2'-fluoro modification.
38. The method of any one of claims 33-37, wherein the sense strand comprises 36 nucleotides from 5' to 3' positions 1-36, wherein positions 8-11 comprise a 2'-fluoro modification.
39. The method of any one of claims 33-38, wherein the antisense strand comprises 22 nucleotides from 3' to 5' positions 1-22, and wherein positions 2, 3, 4, 5, 7, 10 and 14 comprise a 2'-fluoro modification.
40. The method of any one of claims 33-39, wherein the remaining nucleotides comprise a 2'-O-methyl modification.
41. The method of any one of claims 33-40, wherein all nucleotides of the oligonucleotide are modified.
42. The method of any one of claims 1-41, wherein the oligonucleotide comprises at least one modified internucleotide linkage.
43. The method of claim 42, wherein the at least one modified internucleotide linkage is a phosphorothioate linkage.
44. The method of any one of claims 1-43, wherein the 4'-carbon of the sugar of the 5'-nucleotide of the antisense strand comprises a phosphate analog.
45. The method of claim 44, wherein the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.
46. The method of claim 44, wherein the phosphate analog is an oxymethylphosphonate.
47. The method of any one of claims 1-46, wherein at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands.
48. The method of claim 47, wherein the nucleotide is conjugated to more than one targeting ligand, wherein the targeting ligands are the same or different.
49. The method of claim 47 or 48, wherein the one or more targeting ligands are selected from a carbohydrate, an amino sugar, cholesterol, a polypeptide or a lipid.
50. The method of claim 47 or 48, wherein the one or more targeting ligands are saturated or unsaturated fatty acid moieties.
51. The method of claim 47 or 48, wherein the targeting ligand is a saturated fatty acid moiety ranging in size from C10 to C24 in length.
52. The method of claim 51, wherein the targeting ligand is a C16 saturated fatty acid moiety.
53. The method of claim 51, wherein the targeting ligand is a C18 saturated fatty acid moiety.
54. The method of claim 51, wherein the targeting ligand is a C22 saturated fatty acid moiety.
55. The method of claim 47 or 48, wherein the targeting ligand comprises an N-acetylgalactosamine (GalNAc) moiety.
56. The method of claim 55, wherein the GalNAc moiety is a monovalent GalNAc moiety, a divalent GalNAc moiety, a trivalent GalNAc moiety, or a tetravalent GalNAc moiety.
57. The method of any one of claims 28-48, wherein up to 4 nucleotides of L of the stem-loop are each conjugated to a monovalent GalNAc moiety.
58. The method of any one of claims 1-57, wherein the sense strand comprises a sequence as shown in SEQ ID NOs: 857-946.
59. The method of any one of claims 1-58, wherein the antisense strand comprises a sequence as shown in SEQ ID NOs: 947-1036.
60. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) are SEQ ID NOs: 69 and 70, respectively.
61. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 861 and 951, respectively; (b) SEQ ID NOs: 857 and 947, respectively; (c) SEQ ID NOs: 858 and 948, respectively; (d) SEQ ID NOs: 859 and 949, respectively; (e) SEQ ID NOs: 860 and 950, respectively; (f) SEQ ID NOs: 862 and 952, respectively; (g) SEQ ID NOs: 863 and 953, respectively; (h) SEQ ID NOs: 864 and 954, respectively; (i) SEQ ID NOs: 865 and 955, respectively; (j) SEQ ID NOs: 866 and 956, respectively; (k) SEQ ID NOs: 867 and 957, respectively; (1) SEQ ID NO: 868 and 958, respectively; (m) are SEQ ID NOs: 869 and 959, respectively; (n) SEQ ID NO: 870 and 960, respectively; (o) SEQ ID NOs: 871 and 961, respectively; (p) SEQ ID NOs: 872 and 962, respectively; (q) SEQ ID NOs: 873 and 963, respectively; (r) SEQ ID NOs: 874 and 964, respectively; (s) are SEQ ID NOs: 875 and 965, respectively; (t) SEQ ID NOs: 876 and 966, respectively; (u) SEQ ID NOs: 877 and 967, respectively; (v) SEQ ID NOs: 878 and 968, respectively; (w) SEQ ID NOs: 879 and 969, respectively; (x) are SEQ ID NOs: 880 and 970, respectively; (y) are SEQ ID NOs: 881 and 971, respectively; (z) SEQ ID NOs: 882 and 972, respectively; (aa) are SEQ ID NOs: 883 and 973, respectively; (bb) SEQ ID NOs: 884 and 974, respectively; (cc) SEQ ID NOs: 885 and 975, respectively; (dd) SEQ ID NOs: 886 and 976, respectively; (ee) are SEQ ID NOs: 887 and 977, respectively; (ff) are SEQ ID NOs: 888 and 978, respectively; (gg) SEQ ID NO: 940 and 1030, respectively; (hh) SEQ ID NOs: 896 and 986, respectively; and (ii) SEQ ID NO: 920 and 1010, respectively.
62. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 862 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
952.
63. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 875 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
965.
64. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 876 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
966.
65. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:920 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:1010.
66. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively.
67. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NO: 939 and 1029, respectively.
68. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively.
69. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 11, 39, 67, and 71.
70. The method of any one of claims 1-57, wherein the antisense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 12, 40, 68, and 72.
71. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 11 and 12, respectively; (b) SEQ ID NOs: 39 and 40, respectively; (c) SEQ ID NOs: 67 and 68, respectively; and (d) are SEQ ID NOs: 71 and 72, respectively.
72. The method of any one of claims 1-57, wherein the sense strand comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1042, 1055, 1056, and 1100.
73. The method of any one of claims 1-57 and 72, wherein the antisense strand comprises a nucleotide sequence selected from SEQ ID NO: 1132, 1145, 1146 and 1190.
74. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1041 and 1131, respectively; (b) SEQ ID NOs: 1037 and 1127, respectively; (c) SEQ ID NOs: 1038 and 1128, respectively; (d) SEQ ID NOs: 1039 and 1129, respectively; (e) SEQ ID NOs: 1040 and 1130, respectively; (f) SEQ ID NOs: 1042 and 1132, respectively; (g) SEQ ID NOs: 1043 and 1133, respectively; (h) SEQ ID NOs: 1044 and 1134, respectively; (i) SEQ ID NOs: 1045 and 1135, respectively; (j) SEQ ID NOs: 1046 and 1136, respectively; (k) SEQ ID NOs: 1047 and 1137, respectively; (1) SEQ ID NO: 1048 and 1138, respectively; (m) SEQ ID NOs: 1049 and 1139, respectively; (n) SEQ ID NO: 1050 and 1140, respectively; (o) SEQ ID NOs: 1051 and 1141, respectively; (p) SEQ ID NOs: 1052 and 1142, respectively; (q) SEQ ID NOs: 1053 and 1143, respectively; (r) SEQ ID NOs: 1054 and 1144, respectively; (s) are SEQ ID NOs: 1055 and 1145, respectively; (t) SEQ ID NOs: 1056 and 1146, respectively; (u) SEQ ID NOs: 1057 and 1147, respectively; (v) SEQ ID NOs: 1058 and 1148, respectively; (w) SEQ ID NOs: 1059 and 1149, respectively; (x) are SEQ ID NOs: 1060 and 1150, respectively; (y) SEQ ID NOs: 1061 and 1151, respectively; (z) SEQ ID NOs: 1062 and 1152, respectively; (aa) are SEQ ID NOs: 1063 and 1153, respectively; (bb) SEQ ID NOs: 1064 and 1154, respectively; (cc) SEQ ID NOs: 1065 and 1155, respectively; (dd) SEQ ID NO: 1066 and 1156, respectively; (ee) SEQ ID NO: 1067 and 1157, respectively; (ff) are SEQ ID NOs: 1068 and 1158, respectively; (gg) are SEQ ID NOs: 1120 and 1210, respectively; (hh) SEQ ID NOs: 1076 and 1166, respectively; and (ii) SEQ ID NO: 1100 and 1190, respectively.
75. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1042 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1132.
76. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1055 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1145.
77. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1056 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1146.
78. The method of any one of claims 1-57, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1100 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1190.
79. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1081 and 1171, respectively; (b) SEQ ID NOs: 1090 and 1180, respectively; (c) SEQ ID NOs: 1079 and 1169, respectively; (d) SEQ ID NOs: 1076 and 1166, respectively; (e) SEQ ID NOs: 1072 and 1162, respectively; (f) SEQ ID NOs: 1070 and 1160, respectively; and (g) are SEQ ID NOs: 1069 and 1159, respectively.
80. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1120 and 1210, respectively; (b) SEQ ID NOs: 1117 and 1207, respectively; and (c) SEQ ID NO: 1119 and 1209, respectively.
81. The method of any one of claims 1-57, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1095 and 1185, respectively; (b) SEQ ID NOs: 1104 and 1194, respectively; (c) SEQ ID NOs: 1093 and 1183, respectively; and (d) SEQ ID NO: 1100 and 1190, respectively.
82. A kit comprising an RNAi oligonucleotide, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the oligonucleotide to a subject in need thereof who has received or is receiving a PD-L1 inhibitor, wherein the oligonucleotide comprises an antisense strand having a length of 15 to 30 nucleotides and a sense strand having a length of 15 to 40 nucleotides, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 contiguous nucleotides in length.
83. A kit comprising a PD-L1 inhibitor, an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the antibody to a subject in need thereof who has received or is receiving an RNAi oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length and a sense strand of 15 to 40 nucleotides in length, wherein the antisense strand and the sense strand form a duplex region, wherein the antisense strand comprises a complementary region that is complementary to a STAT3 mRNA target sequence, and wherein the complementary region is at least 15 consecutive nucleotides in length.
84. The kit of claim 82 or 83, wherein the subject suffers from a disease, disorder or condition associated with activated STAT3 expression.
85. The kit of any one of claims 82-84, wherein the subject has cancer.
86. The kit of claim 85, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, melanoma, lymphoma and leukemia, prostate cancer, breast cancer, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer and glioblastoma.
87. The kit of any one of claims 82-86, wherein the cancer comprises an immunosuppressive tumor microenvironment.
88. The kit of any one of claims 82-86, wherein the cancer comprises an inflamed tumor microenvironment.
89. The kit of claim 88, wherein the inflamed tumor microenvironment comprises infiltrating T cells.
90. The kit of any one of claims 82-89, wherein the PD-L1 inhibitor is an antibody.
91. The kit of claim 90, wherein the antibody is an anti-PD-L1 antibody.
92. The kit of claim 91, wherein the anti-PD-L1 antibody is selected from FAZ053, atezolizumab, avelumab, durvalumab, envolimab, and BMS-936559.
93. The kit of claim 90, wherein the antibody is an anti-PD-1 antibody.
94. The kit of claim 93, wherein the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, and cimiprilimab.
95. The kit of any one of claims 82-89, wherein the PD-L1 inhibitor is a small molecule inhibitor.
96. The kit of any one of claims 82-89, wherein the PD-L1 inhibitor is a peptide.
97. The kit of any one of claims 82-89, wherein the PD-L1 inhibitor is a nucleic acid molecule.
98. The kit according to any one of claims 82-89, wherein the nucleic acid molecule is selected from an antisense oligonucleotide, siRNA or miRNA.
99. The kit of any one of claims 82-94, wherein the STAT3 mRNA target sequence comprises any one of SEQ ID NOs: 89-280.
100. The kit according to any one of claims 82-99, wherein the complementary region is completely complementary to the STAT3 mRNA target sequence.
101. The kit of any one of claims 82-99, wherein the region of complementarity contains no more than 4 mismatches to the STAT3 mRNA target sequence.
102. The kit of any one of claims 82-101, wherein the antisense strand is 19 to 27 nucleotides in length.
103. The kit of any one of claims 82-102, wherein the antisense strand is 21 to 27 nucleotides in length, optionally wherein the antisense strand is 22 nucleotides in length.
104. The kit of any one of claims 82-103, wherein the sense strand is 19 to 40 nucleotides in length, optionally wherein the sense strand is 36 nucleotides in length.
105. The kit of any one of claims 82-104, wherein the duplex region is at least 19 nucleotides in length.
106. The kit of any one of claims 82-105, wherein the duplex region is at least 20 nucleotides in length, optionally wherein the duplex region is 21 nucleotides in length.
107. The kit according to any one of claims 82-106, wherein the complementary region to STAT3 is at least 19 consecutive nucleotides in length.
108. The kit according to any one of claims 82-107, wherein the complementary region to STAT3 is at least 21 consecutive nucleotides in length.
109. The kit of any one of claims 82-108, wherein the sense strand comprises at its 3' end a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop of 3 to 5 nucleotides in length between S1 and S2.
110. The kit of claim 109, wherein L is a tetracyclic ring, optionally wherein L is 4 nucleotides in length.
111. A kit according to claim 109 or 110, wherein L comprises a sequence represented as GAAA.
112. The kit of any one of claims 82-111, wherein the antisense strand comprises a 3' overhang sequence of one or more nucleotides in length, optionally wherein the 3' overhang sequence is 2 nucleotides in length, optionally wherein the 3' overhang sequence is GG.
113. The kit of any one of claims 82-112, wherein the oligonucleotide comprises at least one modified nucleotide.
114. The kit of claim 113, wherein the modified nucleotide comprises a 2'-modification.
115. The kit of claim 114, wherein the 2'-modification is a modification selected from the group consisting of 2'-aminoethyl, 2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl and 2'-deoxy-2'-fluoro-β-d-arabinose nucleic acid.
116. The kit of any one of claims 114-115, wherein about 10-15%, 10%, 11%, 12%, 13%, 14% or 15% of the nucleotides of the sense strand comprise a 2'-fluoro modification.
117. The kit of any one of claims 114-116, wherein about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the antisense strand comprise a 2'-fluoro modification.
118. The kit of any one of claims 114-117, wherein about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% of the nucleotides of the oligonucleotides comprise a 2'-fluoro modification.
119. The kit of any one of claims 114-118, wherein the sense strand comprises 36 nucleotides from 5' to 3' positions 1-36, wherein positions 8-11 comprise a 2'-fluoro modification.
120. The kit of any one of claims 114-119, wherein the antisense strand comprises 22 nucleotides from 3' to 5' being positions 1-22, and wherein positions 2, 3, 4, 5, 7, 10 and 14 comprise a 2'-fluoro modification.
121. The kit of any one of claims 114-120, wherein the remaining nucleotides comprise a 2'-O-methyl modification.
122. The kit according to any one of claims 114-121, wherein all nucleotides of the oligonucleotide are modified.
123. The kit of any one of claims 82-122, wherein the oligonucleotide comprises at least one modified internucleotide linkage.
124. The kit of claim 123, wherein the at least one modified internucleotide linkage is a phosphorothioate linkage.
125. The kit of any one of claims 82-124, wherein the 4'-carbon of the sugar of the 5'-nucleotide of the antisense strand comprises a phosphate analog.
126. The kit of claim 125, wherein the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.
127. The kit of any one of claims 82-126, wherein at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands.
128. A kit according to claim 127, wherein the nucleotide is conjugated to more than one targeting ligand, wherein the targeting ligands are the same or different.
129. The kit of claim 127 or 128, wherein the one or more targeting ligands are selected from a carbohydrate, an amino sugar, cholesterol, a polypeptide or a lipid.
130. The kit of claim 127 or 128, wherein the one or more targeting ligands are saturated or unsaturated fatty acid moieties.
131. The kit of claim 127 or 128, wherein the targeting ligand is a saturated fatty acid moiety ranging in size from C10 to C24 in length.
132. The kit of claim 131, wherein the targeting ligand is a C16 saturated fatty acid moiety.
133. The kit of claim 131, wherein the targeting ligand is a C18 saturated fatty acid moiety.
134. The kit of claim 131, wherein the targeting ligand is a C22 saturated fatty acid moiety.
135. The kit of claim 127 or 128, wherein the targeting ligand comprises an N-acetylgalactosamine (GalNAc) moiety.
136. The kit of claim 135, wherein the GalNAc moiety is a monovalent GalNAc moiety, a divalent GalNAc moiety, a trivalent GalNAc moiety, or a tetravalent GalNAc moiety.
137. A kit according to any one of claims 109-129, wherein up to 4 nucleotides of L of the stem-loop are each conjugated to a monovalent GalNAc moiety.
138. The kit of any one of claims 82-137, wherein the sense strand comprises a sequence as shown in SEQ ID NOs: 857-946.
139. The kit of any one of claims 82-138, wherein the antisense strand comprises a sequence as shown in SEQ ID NOs:947-1036.
140. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 9 and 10, respectively; (b) SEQ ID NOs: 37 and 38, respectively; (c) SEQ ID NOs: 65 and 66, respectively; and (d) are SEQ ID NOs: 69 and 70, respectively.
141. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 861 and 951, respectively; (b) SEQ ID NOs: 857 and 947, respectively; (c) SEQ ID NOs: 858 and 948, respectively; (d) SEQ ID NOs: 859 and 949, respectively; (e) SEQ ID NOs: 860 and 950, respectively; (f) SEQ ID NOs: 862 and 952, respectively; (g) SEQ ID NOs: 863 and 953, respectively; (h) SEQ ID NOs: 864 and 954, respectively; (i) SEQ ID NOs: 865 and 955, respectively; (j) SEQ ID NOs: 866 and 956, respectively; (k) SEQ ID NOs: 867 and 957, respectively; (1) SEQ ID NO: 868 and 958, respectively; (m) are SEQ ID NOs: 869 and 959, respectively; (n) SEQ ID NO: 870 and 960, respectively; (o) SEQ ID NOs: 871 and 961, respectively; (p) SEQ ID NOs: 872 and 962, respectively; (q) SEQ ID NOs: 873 and 963, respectively; (r) SEQ ID NOs: 874 and 964, respectively; (s) are SEQ ID NOs: 875 and 965, respectively; (t) SEQ ID NOs: 876 and 966, respectively; (u) SEQ ID NOs: 877 and 967, respectively; (v) SEQ ID NOs: 878 and 968, respectively; (w) SEQ ID NOs: 879 and 969, respectively; (x) are SEQ ID NOs: 880 and 970, respectively; (y) are SEQ ID NOs: 881 and 971, respectively; (z) SEQ ID NOs: 882 and 972, respectively; (aa) are SEQ ID NOs: 883 and 973, respectively; (bb) SEQ ID NOs: 884 and 974, respectively; (cc) SEQ ID NOs: 885 and 975, respectively; (dd) SEQ ID NOs: 886 and 976, respectively; (ee) are SEQ ID NOs: 887 and 977, respectively; (ff) are SEQ ID NOs: 888 and 978, respectively; (gg) SEQ ID NO: 940 and 1030, respectively; (hh) SEQ ID NOs: 896 and 986, respectively; and (ii) SEQ ID NO: 920 and 1010, respectively.
142. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 862 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
952.
143. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 875 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
965.
144. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 876 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:
966.
145. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:920 and the antisense strand comprises the nucleotide sequence of SEQ ID NO:1010.
146. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 901 and 991, respectively; (b) SEQ ID NO:910 and 1000, respectively; (c) SEQ ID NOs: 899 and 989, respectively; (d) SEQ ID NOs: 896 and 986, respectively; (e) SEQ ID NOs: 892 and 982, respectively; (f) SEQ ID NOs: 890 and 980, respectively; and (g) SEQ ID NO: 889 and 979, respectively.
147. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 940 and 1030, respectively; (b) SEQ ID NOs: 937 and 1027, respectively; and (c) SEQ ID NO: 939 and 1029, respectively.
148. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:915 and 1005, respectively; (b) SEQ ID NOs: 924 and 1014, respectively; (c) SEQ ID NOs: 913 and 1003, respectively; and (d) are SEQ ID NOs: 920 and 1010, respectively.
149. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 11, 39, 67, and 71.
150. The kit of any one of claims 82-137, wherein the antisense strand comprises the nucleotide sequence of any one of SEQ ID NOs: 12, 40, 68, and 72.
151. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 11 and 12, respectively; (b) SEQ ID NOs: 39 and 40, respectively; (c) SEQ ID NOs: 67 and 68, respectively; and (d) are SEQ ID NOs: 71 and 72, respectively.
152. The kit of any one of claims 82-137, wherein the sense strand comprises a nucleotide sequence selected from SEQ ID NOs: 1042, 1055, 1056, and 1100.
153. A kit according to any one of claims 82-137 and 152, wherein the antisense strand comprises a nucleotide sequence selected from SEQ ID NO: 1132, 1145, 1146 and 1190.
154. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1041 and 1131, respectively; (b) SEQ ID NOs: 1037 and 1127, respectively; (c) SEQ ID NOs: 1038 and 1128, respectively; (d) SEQ ID NOs: 1039 and 1129, respectively; (e) SEQ ID NOs: 1040 and 1130, respectively; (f) SEQ ID NOs: 1042 and 1132, respectively; (g) SEQ ID NOs: 1043 and 1133, respectively; (h) SEQ ID NOs: 1044 and 1134, respectively; (i) SEQ ID NOs: 1045 and 1135, respectively; (j) SEQ ID NOs: 1046 and 1136, respectively; (k) SEQ ID NOs: 1047 and 1137, respectively; (1) SEQ ID NO: 1048 and 1138, respectively; (m) SEQ ID NOs: 1049 and 1139, respectively; (n) SEQ ID NO: 1050 and 1140, respectively; (o) SEQ ID NOs: 1051 and 1141, respectively; (p) SEQ ID NOs: 1052 and 1142, respectively; (q) SEQ ID NOs: 1053 and 1143, respectively; (r) SEQ ID NOs: 1054 and 1144, respectively; (s) are SEQ ID NOs: 1055 and 1145, respectively; (t) SEQ ID NOs: 1056 and 1146, respectively; (u) SEQ ID NOs: 1057 and 1147, respectively; (v) SEQ ID NOs: 1058 and 1148, respectively; (w) SEQ ID NOs: 1059 and 1149, respectively; (x) are SEQ ID NOs: 1060 and 1150, respectively; (y) SEQ ID NOs: 1061 and 1151, respectively; (z) SEQ ID NOs: 1062 and 1152, respectively; (aa) are SEQ ID NOs: 1063 and 1153, respectively; (bb) SEQ ID NOs: 1064 and 1154, respectively; (cc) SEQ ID NOs: 1065 and 1155, respectively; (dd) SEQ ID NO: 1066 and 1156, respectively; (ee) SEQ ID NO: 1067 and 1157, respectively; (ff) are SEQ ID NOs: 1068 and 1158, respectively; (gg) are SEQ ID NOs: 1120 and 1210, respectively; (hh) SEQ ID NOs: 1076 and 1166, respectively; and (ii) SEQ ID NO: 1100 and 1190, respectively.
155. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1042 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1132.
156. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1055 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1145.
157. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1056 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1146.
158. The kit of any one of claims 82-137, wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 1100 and the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1190.
159. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1081 and 1171, respectively; (b) SEQ ID NOs: 1090 and 1180, respectively; (c) SEQ ID NOs: 1079 and 1169, respectively; (d) SEQ ID NOs: 1076 and 1166, respectively; (e) SEQ ID NOs: 1072 and 1162, respectively; (f) SEQ ID NOs: 1070 and 1160, respectively; and (g) are SEQ ID NOs: 1069 and 1159, respectively.
160. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1120 and 1210, respectively; (b) SEQ ID NOs: 1117 and 1207, respectively; and (c) SEQ ID NO: 1119 and 1209, respectively.
161. The kit of any one of claims 82-137, wherein the sense strand and the antisense strand comprise a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 1095 and 1185, respectively; (b) SEQ ID NOs: 1104 and 1194, respectively; (c) SEQ ID NOs: 1093 and 1183, respectively; and (d) SEQ ID NO: 1100 and 1190, respectively.
